










The handle http://hdl.handle.net/1887/60913 holds various files of this Leiden University 
dissertation. 
 
Author: Kiderlen, M. 
Title: Patterns of care and prognosis of older women with breast cancer 












Patterns of care and prognosis of 
older women with breast cancer
Mandy Kiderlen
Colofon
Cover design, Lay-out and printing: Optima Grafische Communicatie, Rotterdam 
Artwork Cover: Pink |  Repetition series | 60-60 cm | Acrylics on canvas | 
Barbara Houwers 2016 | www.barbarahouwers.com 
ISBN: 978-94-6361-048-3
The research described in this thesis was financially supported by the Dutch 
Cancer Society
Printing of this thesis was financially supported by Chipsoft B.V., Uitgeverij Jaap, 
Pfizer B.V., Elekta B.V..
Patterns of care and prognosis of older 
women with breast cancer
Proefschrift
ter verkrijging van de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties












Prof. Dr. H. Putter
Prof. Dr. J.E.A. Portielje
Prof. Dr. V.T.H.B.M. Smit
Prof. Dr. S. Siesling (Twente University)
Dr. A.N. Scholten (NKI-AVL)
Table of ConTenTs
Introduction
Chapter 1 General introduction 7
Part 1: International patterns of care for older women with breast 
cancer
Chapter 2 Surgical treatment of early stage breast cancer in elderly:  
an international comparison
15
Chapter 3 Treatment strategies and survival of older breast cancer 
patients - an international comparison between the Netherlands 
and Ireland
31
Chapter 4 Variations in compliance to quality indicators by age for 41,871 
breast cancer patients across Europe: a European Society of 
Breast Cancer Specialists database analysis
49
Part 2: The impact of comorbidity and comedication on prognosis of 
older women with breast cancer
Chapter 5 Impact of comorbidity on outcome of older breast cancer 
patients: a FOCUS cohort study
69
Chapter 6 Diabetes in relation to breast cancer relapse and all-cause 
mortality in elderly breast cancer patients: a FOCUS study 
analysis
85
Chapter 7 Impact of co-medication on breast cancer prognosis – a Tamoxi-
fen Exemestane Adjuvant Multinational (TEAM) side study
101
Part 3: Modelling prognosis of older women with breast cancer
Chapter 8 External validity of a trial comprised of elderly patients with 
hormone receptor-positive breast cancer
117
Chapter 9 Performing survival analyses in the presence of competing 
risks: a clinical example in older breast cancer patients
135
Discussion
Chapter 10 General discussion and future perspectives 151
appendices
Nederlandse samenvatting 163








Breast cancer is the most frequently diagnosed malignancy among women world-
wide, especially in developed countries.1
The ageing population results in an absolute increase in older women diagnosed 
with breast cancer.2 This specific population is underrepresented in the available 
evidence about the treatment of cancer.3,4 Therefore, there is no solid evidence on 
how to treat older women with breast cancer. Exactly this group is such a complex 
patient group, for several reasons. When we consider chronological age, we have 
to deal with a very heterogeneous population. For young breast cancer patients, in 
most of the cases, we can assume that breast cancer is the only disease to be treated 
at that moment. However, older women have a higher chance to already have 
been diagnosed with other diseases, like cardiovascular diseases and diabetes.5 
On the other hand, there is also a large group of older women who are very fit 
and furthermore healthy, who we can consider as biologically young. There are a 
few studies performed considering other diseases in relation to the treatment and 
prognosis of breast cancer.6-9
Another reason of the complexity of the population of older women with breast 
cancer is one of the most important consequences of comorbidity: death from an-
other cause than breast cancer. In an undefined number of cases, comorbidity has 
a greater impact on the life expectancy than breast cancer itself. For instance, when 
we consider a patient suffering from advanced stage cardiac failure and a new 
diagnosis of early stage breast cancer. It is imaginable that in this specific patient, 
the comorbid disease has a higher chance to result in early death, than the breast 
cancer. When a study is performed with the aim to investigate breast cancer spe-
cific prognosis, in this case the cardiac failure can blur the results, because there is 
a considerable chance that this patient will die of cardiac problems, before a breast 
cancer recurrence would have occurred. This issue is called competing mortality, 
and in current literature, this issue is underexposed. 
Due to the underrepresentation of older patients in most of the breast cancer 
studies, it is questionable if the results of the most important breast cancer trials 
can be extrapolated to the older population. It would be very valuable to repeat 
important therapeutic studies among older women. However, this would be a very 
time consuming and difficult mission to undertake. Therefore, novel study designs 
using population based data sources would be very efficient to solve this problem. 
One of the most important challenges to handle in population based, retrospec-
tive, studies is the issue of confounding by indication.10 This type of bias arises when 
outcomes of different therapies are directly compared in a retrospective database. 
In these studies, in contrast to clinical trials, different therapies are used, or not 
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used, on an individual basis. The reason of choosing for a specific therapy can be 
related to the outcome. For instance, we consider the patient with advanced stage 
cardiac failure again. When she is diagnosed with (early stage) breast cancer, the 
cardiac failure is probably a contraindication for surgery, so she does not undergo 
breast surgery. Also, she has a relatively short life expectancy. But when she dies 
(from cardiac failure), there is no causal relationship between the omission of 
breast surgery and death. However, it is not impossible to draw conclusions on 
prognosis from population based studies. For example, the instrumental variable 
might provide a solution. A variable that is related to the treatment choice, but not 
directly to the outcome.10  When there are considerable international differences 
between treatment strategies, country can be a good instrumental variable, when 
health care systems are similar and when there are no reasons to assume general 
life expectancy of the populations differ. 
In this thesis, the aim is to investigate international patterns of care for older 
women with breast cancer, and also the impact of these differences on prognosis. 
Furthermore, we had the objective to assess the impact of different specific co-
morbid diseases, but also the use of non-cancer drugs on breast cancer prognosis. 
Finally, we aim to develop a new predictive model, specifically for older women 
with breast cancer, in which as well patient-related as tumour-related factors are 
included. The model could be used in clinical decision making in the treatment of 
breast cancer in older women.
DaTa soURCes
This thesis is part of the FOCUS project: Female breast cancer in the elderly: Op-
timizing Clinical guidelines USing clinico-pathological and molecular data. This 
program was initiated after receiving a program grant from the Dutch Cancer So-
ciety in 2007. For this project,  the largest, most detailed population-based database 
of older women with breast cancer was built. This database consists of all 3,672 
consecutive breast cancer patients, aged 65 years or older at the time of diagnosis, 
diagnosed between 1997 and 2004 in the South West region of The Netherlands. 
In addition to the standard data included in the cancer registry, very detailed 
information was gathered about the tumour, treatment, but also on the occurrence 
of a recurrence during follow-up. Also, patient-related information was registered, 
including comorbidity and social economic status. Probably most innovative of 
the database was the additional gathering of tumour tissues of a very large part 
of the included patients, which resulted in the linkage of detailed clinical data to 
validated pathological information from our own laboratory.
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A considerable part of this thesis is established with data from the FOCUS data-
base. Also, data from the Tamoxifen Exemestane Adjuvant Multinational (TEAM) 
study were used. This is a large randomized clinical trial among breast cancer 
patients investigating different adjuvant endocrine therapy regimens. This trial is 
special because of the broad inclusion criteria, without upper age limit. Therefore, 
relatively much older women were included in this study. Furthermore, we used 
data from national cancer registries from several countries. For one study we had 
the opportunity to use the database of the European Society of Breast Cancer 
Specialists (EUSOMA), which consists of more than 40.000 breast cancer patients 
across six different European countries.
oUTlIne
Part 1 of this thesis describes patterns of care across different countries.  In chapter 
2, treatment and survival of older women with breast cancer is crudely compared 
between several European countries and the US. Chapter 3 highlights two coun-
tries from the former chapter, Ireland and The Netherlands.  In this chapter a more 
detailed comparison of treatment and survival is described. The European Society 
of Breast Cancer Specialists (EUSOMA) defined a set of quality indicators for the 
management of breast cancer. In chapter 4, compliance to these indicators is as-
sessed according to age.
In Part 2, the impact of non-cancer related factors are studied to find out if there 
is an impact on the cancer specific prognosis. Especially in older patients, there is 
a substantial chance of the presence of any comorbidities at the time of diagnosing 
breast cancer. It is hypothesized that there could be a interaction between the exis-
tence of specific diseases and the prognosis of breast cancer. Therefore, in chapter 
5 a study assessing the impact of comorbidity on the prognosis of older breast 
cancer patients is described. In chapter 6, one specific comorbidity, diabetes, is 
explored to find out if there is an association between having this disease and the 
prognosis of breast cancer patients. Concerning the co-existence of diabetes at the 
time of breast cancer diagnosis, it has been hypothesized that the use of metformin 
could have a positive effect on the prognosis of breast cancer. Also, other drugs, 
that have not been registered as anti-cancer medication, have been suggested to 
have a probable impact on cancer-prognosis. In chapter 7, the impact of the use of 
three commonly used non-cancer medications on the cancer-specific prognosis is 
assessed among the patients included in the TEAM trial.
Part 3 consists of studies in which the prognosis of older patients is assessed. 
Chapter 8 assesses the external validation of the results of a clinical trial for older 
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women with breast cancer. In this chapter a study is described in which the older 
patients included in the TEAM study, a large international multicenter trial, are 
compared to older breast cancer patient from the general population.
Older women with a diagnosis of breast cancer, do have a significant risk to die 
from another reason than breast cancer. In chapter 10, we show a clinical example 
of the use of competing risk analyses in older women with breast cancer, to high-
light the importance of taking into account the risk of dying from another cause 
than breast cancer, when assessing a disease specific endpoint. 
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absTRaCT
Introduction. Over 40% of breast cancer patients are diagnosed above the age of 
65. Treatment of these elderly patients will probably vary over countries. The aim 
of this study was to make an international comparison (several European countries 
and the US) of surgical and radiation treatment for elderly women with early-stage 
breast cancer. Survival comparisons were also made.
Methods. Data were obtained from national or regional population-based regis-
tries in the Netherlands, Switzerland, Ireland, Belgium, Germany and Portugal. 
For the US patients were selected from the Surveillance, Epidemiology, and End 
Results (SEER) database. Early-stage breast cancer patients aged ≥65 diagnosed 
between 1995 and 2005 were included. An international comparison was made for 
breast and axillary surgery, radiotherapy after breast conserving surgery (BCS), 
and relative or cause-specific survival. 
Results. Overall, 204.885 patients were included. The proportion of patients not 
receiving any surgery increased with age in many countries; however differences 
between countries were large. In most countries more than half of all elderly pa-
tients received breast conserving surgery (BCS), with the highest percentage in 
Switzerland. The proportion of elderly patients that received radiotherapy after 
BCS decreased with age in all countries. Moreover, in all countries the proportion 
of patients who do not receive axillary surgery increased with age. No large differ-
ences in survival between countries were recorded.  
Conclusion. International comparisons of surgical treatment for elderly women 
with early stage breast cancer are scarce. This study showed large international 
differences in treatment of elderly early-stage breast cancer patients, with the most 
striking result the large proportion of elderly who did not undergo surgery at 
all. Despite large treatment differences, survival does not seem to be affected in a 
major way.
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InTRoDUCTIon
Breast cancer is the most frequently diagnosed cancer worldwide, accounting for 
23% of all new cancer cases in women and 14% of all female cancer deaths in 20081. 
A high incidence of breast cancer is observed in women aged 65 years and older, 
comprising over 40% of all breast cancer patients in developed countries.2 Given 
the aging population and constantly improving screening and diagnostic tools, the 
number of elderly patients with breast cancer is expected to grow in the coming 
decades.3 
Clinical trials indicate that the choice of mastectomy versus breast conserving 
surgery (BCS) followed by radiotherapy (RT) for early stage breast cancer does 
not affect overall mortality or breast cancer mortality.4,5 However, patients who 
receive BCS+RT have a small but significant increase in local recurrences. Elderly 
patients have been under-represented in breast cancer treatment trials, based on 
their age, comorbid diseases and logistic barriers.2,6 Consequently it is questionable 
if trial results can be generalized to patients of all ages. Despite guideline recom-
mendations, several observational studies from different countries show that with 
increasing age, treatment of early stage breast cancer more often consists of mas-
tectomy; moreover, omission of RT after BCS increases with increasing age.3,7-11 In 
addition, older breast cancer patients are more likely than younger patients to not 
undergo breast surgery, even though mortality caused by breast surgery is shown 
to be low among elderly.12 
The different treatment approaches to elderly breast cancer patients could have 
consequences. Several observational studies showed worse overall, breast cancer 
specific and disease-free survival for ‘undertreated’ elderly patients (not treated 
according to guidelines).13,14 An international study comparing breast surgery 
among countries for patients participating in the Tamoxifen Exemestane Adjuvant 
Multinational (TEAM) trial showed large differences in surgical treatment ap-
proach to early-stage breast cancer in postmenopausal women.15 The EUROCARE 
group recently published a population-based study on the surgical treatment of 
early stage breast cancer (T1N0M0) across Europe. They found considerable dif-
ferences in the use of BCS followed by RT. Of all surgically treated patients across 
the participating countries, 55% received BCS+RT, with a range from 9% in Estonia 
to 78% in France.11 However, none of these studies specifically compared treat-
ment of the elderly patient with breast cancer. The aim of this study is to make an 
international comparison of breast and axillary surgery, and radiotherapy after 
breast conserving surgery in elderly patients with early-stage breast cancer, and its 




Women aged 65 and older, who were diagnosed with early-stage breast cancer 
(T0-2, N0-1, M0) and recorded in population-based cancer registries in the Neth-
erlands, Ireland, Switzerland, Belgium, Germany, Portugal, and the U.S were 
included.  From the population-based database of the Netherlands Cancer Regis-
try, women diagnosed between 1995 and 2005 were selected. For the US, patients 
diagnosed between 1998 and 2007 were selected from the Surveillance, Epidemi-
ology, and End Results (SEER) database covering 28% of the US population. In 
Switzerland, patients diagnosed between 2003 and 2005 were identified from seven 
population-based cancer registries (Geneva, Valais, Ticino, St Gallen-Appenzell, 
Grisons-Glarus, Basel city and countryside and Zurich) covering 47% of the Swiss 
population. In Ireland, patients were selected from the national cancer registry 
between 1999 and 2007. In Belgium, patients diagnosed between 2001 and 2006 
were selected from the national cancer registry. German patients diagnosed be-
tween 1995 and 2008 in the Munich region were selected. Finally, patients from the 
Portugal South regional cancer registry (ROR-Sul) were selected between 2006 and 
2008. Patients with a diagnosis of breast cancer on death certificate or at autopsy 
only or with unknown treatment were excluded. 
statistics
Calculations of treatment percentages and survival were performed for each 
country and aggregated into tables for the comparison between countries. Patients 
were categorized in six age groups (65-69, 70-74, 75-79, 80-84, 85-89 and ≥90) for 
the treatment analyses. Tumor stage was defined by combined TNM stage16 (cat-
egorized as stage I, IIA, IIB), with clinical stage used when pathological stage was 
missing. Stage I includes T1N0 tumors, stage IIA T1N1 or T2N0 tumors and stage 
IIB contains T2N1 tumors (also T3N0 tumors but these were excluded from this 
study). Breast surgery was categorized as mastectomy, breast conserving surgery, 
or no surgery. Patients who received BCS first, but later received mastectomy, 
for any reason, were positioned in the mastectomy group. Receipt of radiation in 
addition to BCS was also assessed. Axillary surgery (either sentinel node biopsy 
or axillary lymph node sampling or dissection) was documented (yes/no). Descrip-
tive statistics were used, as only aggregated tables were compared, to assess the 
proportion of patients receiving each treatment; where possible percentages were 
compared using the chi-square test. A p value of <0.05 was considered statistically 
significant.  
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Relative survival was calculated by the Ederer II method as the ratio of the survival 
observed among the cancer patients to the survival that would have been expected 
based on the corresponding (age, sex and year of diagnosis) general population. 
National life tables for each country were used to estimate expected survival. In all 
countries and regions, vital status was established either directly from the patient’s 
medical record or through linkage with the municipal or national population regis-
tries. The SEER database links with the National Death index, which also provided 
causes of death, and disease specific survival was calculated for patients treated in 
the US. Survival of Irish patients was mainly based on linkage to national mortality 
data, sometime supplemented with clinical information on date of death. For the 
survival analysis age was categorized as 65-74, 75-84 and ≥85. 
ResUlTs
Overall, 204.885 patients were included in the study. Characteristics of the popula-
tions are shown in Table 1. Age distribution was similar (p=0.9).across participating 
countries. Stage distribution among European countries was comparable (p=0.5), 
however, US patients more frequently had stage I disease (p=0.06). Grade distribu-
tion was significantly different between the countries (p<0.001). 
breast surgery
Figure 1 shows the proportions of patients who did not receive breast surgery in the 
several countries by age. The proportion of women not undergoing breast surgery 
varies among countries (p<0.001) from 0.5% (MCR Germany) to 13.4% (Ireland). 
Overall, the proportion of patients who did not receive surgery increased with age. 
In the lowest age categories (65-69 and 70-74), proportions of patients without breast 
surgery were small (<5%) in all countries (difference between countries were small 
but significant p<0.001). As age increases, larger differences in the omission of breast 
surgery become apparent (again p<0.001). In the US and Germany, in particular, 
relatively few patients did not undergo breast surgery. However, in Ireland and The 
Netherlands more than half of patients aged 90 years and older had no breast surgery. 
Figure 2 shows the proportion of patients that received BCS (of all operated 
patients) in the countries by age. In most countries more than half of the included 
patients underwent BCS, except for The Netherlands, Ireland and Portugal. The 
use of breast conserving procedures was highest in Switzerland (70%). In all coun-
tries, except for the US and Ireland, the proportion of BCS decreased with age. In 
the US the proportion of BCS was relatively stable with age and in Ireland the use 
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Axillary surgery
Figure 4 shows proportions of all included patients who did
not receive axillary surgery. The national cancer registry of
Belgium could not provide this information and in the US,
data on axillary staging were missing for 9.8% of patients.
In all countries, the percentage of patients who did not
undergo axillary surgery increased with age. However,
there was major variation among countries (P\ 0.001),
from 1.4% (MCR Germany) to 22.6% (Ireland) overall.
Survival
Figure 5 shows the 5-year survival after diagnosis by age
and s age. F r all ages combined, there were no jor
differences in survival between countries, with the highest
relative survival for Ireland (99%). Among stage I
*Less than 50 patients in the selection  
%
*Less than 50 patients in the selection  
Breast Cancer Res Treat (2012) 132:675–682
figure 2: Overall and age-specific percentage of patients that received breast conserving surgery (of 
all patients that received surgery), by country
Radiotherapy after breast conserving surgery
Figure 3 shows the proportion of patients treated with BCS who received adjuvant 
RT. This proportion decreased substantially with age in all countries (p<0.001), and 
also varied markedly between countries (p=0.0005). The larges  overall proportion 
of BCS followed by RT was observed in Belgium (85%) nd the lowest in Portugal 
(59%) although the sample size was small for the latter.  




Figure 4 shows proportions of all included patients who did not receive axillary 
surgery. The national cancer registry of Belgium could not provide this informa-
tion and in the US, data on axillary staging were missing for 9.8% of patients. In 
all countries, the percentage of patients who did not undergo axillary surgery in-
creased with age. However, there was major variation among countries (p<0.001), 
from 1.4% (MCR Germany) to 22.6% (Ireland) overall. 
figure 4: Overall and age-specific percentages of patients that received no axillary surgery, by coun-
try 
survival
Figure 5 shows the 5-year survival after diagnosis by age and stage. For all ages 
combined, there were no major differences in survival between countries, with the 
highest relative survival for Ireland (99%). Among stage I patients, survival was 
similar between countries in all age categories. For stage II, patients aged 65-74 
years had a similar survival in all countries, but there were differences for patients 
aged 75-84 and patients aged ≥ 85, where survival was higher for patients in Ger-
many (MCR) and Ireland.
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figure 5: Relative survival (5-years) for Stage I and II disease, by age and country * Disease-specific 
survival for US
DIsCUssIon
Major findings of the present study were the large differences in locoregional treat-
ment across countries, especially in the proportion of elderly breast cancer patients 
receiving no breast surgery at all. However, despite substantial differences in 
breast cancer treatment, survival among countries was comparable. International 
comparisons of surgical treatment for elderly women with early-stage breast can-
cer are scarce. In the present study we were able to make a comparison between 
several European countries and the US. 
breast surgery
The international differences in the percentage of elderly early-stage breast cancer 
patients who did not undergo breast surgery are striking. Whereas, for example, in 
Ireland the percentage of patients aged ≥90 who did not have surgery was 67%, in 
the US only 8.8% had no surgery and in Germany all patients in this age category 
received breast surgery. The findings in the US are consistent with a recently pub-
lished study from the US in which 98% of all T1 or T2 breast cancer patients aged 
≥65 years received at least some surgery.17 International studies comparing the 
percentage of breast cancer patients who do not receive surgery are scarce. Most 
observational studies of survival excluded patients who did not have any surgical 
treatment, but the few retrospective studies that did include non-surgically treated 
patients showed poor overall and lower breast cancer specific survival for these 
patients.13,17-19 Many descriptive studies from different countries have also showed 
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less extensive surgical treatment for elderly women with early-stage breast cancer 
compared with younger patients2,3,7,11,12 
Radiotherapy
An overview of clinical trial data has shown that BCS should be followed by radio-
therapy to achieve results comparable with mastectomy in terms of recurrence and 
survival.4 In some elderly women BCS without radiation may be used to minimize 
potential treatment-related complications. However, the value of RT after BCS in 
elderly breast cancer patients is still subject of debate, since some studies suggest 
that radiation may be safely omitted for low-risk tumors in women over age 70.20,21 
The current study shows that the proportion of women who received RT after BCS 
decreased with age. This trend was found in all participating countries, although 
specific proportions vary. Notable are the high percentages of elderly patients that 
received RT after BCS in Switzerland (79%) and Germany (MCR 80%). Possibly, for 
Switzerland, high accessibility of health services could partly explain this finding. 
For the selected German region (Munich), a previous study demonstrated that this 
specific region has a higher percentage of BCS for early-stage breast cancer than 
five other regions in Germany, so this region may not be completely representative 
for the whole country.22 Also interesting are the differences in breast surgery be-
tween the Netherlands and Ireland (both national databases). Both countries have 
a high proportion of patients that receive no breast surgery although it is higher in 
Ireland. The proportion of BCS decreases with age in the Netherlands but increases 
in Ireland; the proportion of adjuvant RT decreases with age in both countries. 
This remarkable difference in locoregional therapy did not influence survival  in 
any way. Information concerning loco-regional recurrences, not routinely collected 
by most cancer registries, could add some information to these comparisons and 
should be collected when possible in the future. 
axillary surgery
In all participating countries the proportion of women in whom axillary surgery 
was not performed increased with age, a finding consistent with another observa-
tional study.23 The largest proportion was found in Ireland, directly followed by 
the US, Portugal and the Netherlands. Germany stands out on this topic; only 1.4% 
of the elderly breast cancer patients did not undergo any form of axillary surgery. 
Axillary staging is part of some guidelines, and these findings suggest that guide-
line adherence decreased with increasing age. However, several randomized and 
non-randomized studies showed very low rates of axillary recurrences and com-
parable disease-free and overall survival between clinical node-negative elderly 
breast cancer patients with and without axillary surgery.24,25 
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strengths and limitations
One of the strengths of this comparison is the large number of patients and the 
population-based datasets that included all elderly patients. This facilitated com-
parison of treatment strategies in countries with similar health systems by using 
country as an instrumental variable.  
A limitation of this study is that systemic treatment information was not available 
for all countries. However, available data indicate that rates of hormonal therapy 
(HT) were high: for example, among non-surgically treated patients, the propor-
tion receiving HT was 85% in the Netherlands and 69% in Ireland. However, it is 
questionable if HT can replace surgery in elderly patients. Trials in which women 
aged ≥70 were randomized to have surgery or HT do not show significant better 
overall survival for surgery compared to HT alone, although risk of recurrence is 
significantly larger when operable breast cancer in elderly is treated by tamoxifen 
alone.26,27 Another limitation of this study might be that information concerning the 
extent of “clear margins” after BCS was not available.
Another limitation of the study could be differences in data collection between 
the participating registries and the absence of national data for several countries 
(only The Netherlands, Belgium and Ireland are national cancer registries). In 
countries with regional data, the regions may not be perfectly representative of the 
whole country. Also the small number of patients included for Portugal may not 
be representative and in some categories, numbers were insufficient to draw con-
clusions about treatment. Finally, the years of available data were not completely 
overlapping, and thus changes in treatment patterns over time could influence our 
findings. 
ConClUsIons 
Despite the remarkable large differences in locoregional treatment of early breast 
cancer, the current study showed minimal differences in survival at five years 
between older breast cancer patients from seven Western countries. These find-
ings raise the question whether more or less aggressive treatment of early stage 
breast cancer in elderly makes a difference. Future research should be focused on 
the best therapy for elderly women with respect to survival and quality of life. It 
may well be that the much criticized “less aggressive therapy” for elderly breast 
cancer patients does not harm patients with early stage disease, particularly 
women with comorbid illness that may otherwise limit their life expectancy. To 
properly investigate this, randomized controlled trials , specifically aimed at the 
elderly, is considered to give the best evidence. RCT’s however, are costly and time 
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consuming en will not yield practice changing results within years from the start 
of such a trial. Furthermore, older patients are underrepresented  in trials and no 
direct comparison of different approaches to the local regional treatment of early 
breast cancer in older women is available. International comparison of specific 
treatment protocols could serve as a good alternative to select ‘best practices’  and 
improve the risk/ benefit ratio in the treatment of older breast cancer patients. This 
comparative effectiveness research can bridge the knowledge gap specifically in 
older cancer patient, who are by nature, heterogeneous in patient characteristics 
and treatment patterns.28
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absTRaCT
objectives. Forty percent of breast cancers occur among older patients. Unfortu-
nately, there is a lack of evidence for treatment guidelines for older breast cancer 
patients. The aim of this study is to compare treatment strategy and relative survival 
for operable breast cancer in the elderly between The Netherlands and Ireland.
Material and Methods. From the Dutch and Irish national cancer registries, 
women aged ≥65 years with non-metastatic breast cancer were included (2001-
2009). Proportions of patients receiving guideline-adherent locoregional treatment, 
endocrine therapy, and chemotherapy were calculated and compared between the 
countries by stage. Secondly, 5-year relative survival was calculated by stage and 
compared between countries.
Results. Overall, 41,055 patients from The Netherlands and 5,826 patients from 
Ireland were included. Overall, more patients received guideline-adherent locore-
gional treatment in The Netherlands, overall  (80% vs. 68%, adjusted p<0.001), 
stage I (83% vs. 65%, p<0.001), stage II (80% vs. 74%, p<0.001) and stage III (74% vs. 
57%, P<0.001) disease. On the other hand, more systemic treatment was provided 
in Ireland, where endocrine therapy was prescribed to 92% of hormone receptor-
positive patients, compared to 59% in The Netherlands. In The Netherlands, only 
6% received chemotherapy, as compared 24% in Ireland. But relative survival was 
poorer in Ireland (5 years relative survival 89% vs. 83%), especially in stage II (87% 
vs. 85%) and stage III (61% vs. 58%) patients.
Conclusion. Treatment for older breast cancer patients differed significantly on 
all treatment modalities between The Netherlands and Ireland. More locoregional 
treatment was provided in The Netherlands, and more systemic therapy was pro-
vided in Ireland. Relative survival for Irish patients was worse than for their Dutch 
counterparts. This finding should be a strong recommendation to study breast 
cancer treatment and survival internationally, with the ultimate goal to equalize 
the survival rates for breast cancer patients across Europe.
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InTRoDUCTIon
Currently, about 40 per cent of all new breast cancer cases in developed countries 
occur among women aged 65 and older.1 Life expectancy is increasing, diagnostic 
tools become more sensitive and screening programs are more widely used and ex-
panded. Consequently, the proportion of elderly breast cancer patients is expected 
to increase in the near future.2
Proper treatment for older breast cancer patients is difficult to define. Older 
women are frequently excluded from clinical treatment trials because of their age, 
comorbidity or logistical barriers.3 Moreover, the elderly who are included in trials 
are probably not representative for the general older population.4 Consequently, 
an evidence-based treatment strategy for older women with breast cancer is lack-
ing. The only guidance for clinicians is from treatment guidelines which have 
been validated in younger and healthier women.5 Extrapolation from trials might 
not be valid since breast cancer biology differs in some respects in older patients, 
treatment tolerance varies, and there are substantial competing risks of mortality.2,6 
Consequently, clinicians have to decide what is best for their patient: treatment 
according to the guidelines, or patient-tailored deviation from the guidelines.
In the last decade it has become more accepted to use observational data, pref-
erably population-based , to assess treatment effects in older cancer patients.7 
However, no strong conclusions can be drawn from these studies as bias due to 
confounding by indication is likely to be present, since specific (unknown) patient 
and tumor-related factors influence receipt of particular treatments.8 
A recent observational study comparing locoregional treatment between six 
European countries and the US found that treatment strategy in The Netherlands 
and Ireland differed considerably on various items among older women with early 
stage breast cancer, indicating that older patients with early stage breast cancer 
in Ireland seemed to be slightly undertreated, compared with The Netherlands. 
However, relative survival was not demonstrably different.9
The aim of the present study is to compare treatment strategy and relative 
survival for operable (non-metastatic) breast cancer in the elderly between The 
Netherlands and Ireland in more detail.
MaTeRIal anD MeThoDs
Data 
From the Netherlands and Irish cancer registry, all female patients aged 65 years 
and older diagnosed between 2001 and 2009 with invasive, non-metastasized 
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breast cancer were selected. Patients with a diagnosis of breast cancer on death 
certificate or at autopsy only, and other patients with a survival time of zero days, 
were excluded. If a patient had a second primary tumor during follow-up, only the 
first primary breast tumor was considered for analyses.
Tumor stage was defined by TNM stage10, with clinical T and N used when 
pathological information was lacking. Patients with missing T category were 
excluded. When nodal and distant metastatic status were unspecified (NX and 
MX), status was assumed to be N0 and M0, respectively. Stage data were originally 
coded using 6th-edition TNM rules10 in the Netherlands and 5th-edition TNM 
rules11 in Ireland. Micrometastases (≤0.2 cm) in regional nodes, classified as N1a in 
5th-edition TNM were recoded to N0 for 21 Irish cases to conform to 6th-edition 
TNM rules. For surgical treatment, only the most extensive surgery registered was 
used for analysis. Axillary surgery was coded as yes or no. 
Primary outcome was treatment strategy by stage. Treatments of interest were 
type of surgery (none, BCS or mastectomy), radiotherapy (RT; yes or no), axillary 
surgery (yes or no), locoregional guideline adherence (details below), endocrine 
therapy (yes or no) and chemotherapy (yes or no). Secondary outcome measure 
was 5-year relative survival in each country.
In both the Dutch and Irish breast cancer guidelines, primary surgical treatment 
with mastectomy or BCS followed by radiotherapy (RT) is recommended for non-
metastasized breast cancer. In addition, it is recommended to assess axillary nodal 
status by performing a sentinel node procedure or axillary lymph node dissection 
(Appendix S1).12-14 Therefore, locoregional treatment was considered guideline-
adherent when a patient had BCS and RT or mastectomy with or without RT, in 
all cases followed by any axillary surgical procedure. In addition the receipt of 
systemic therapy (adjuvant endocrine therapy and chemotherapy) was analyzed. 
Routine cancer registry data on endocrine therapy in Ireland were known to be 
incomplete (National Cancer Registry of Ireland, unpublished data), because of 
difficulties associated with outpatient prescription of the drugs involved. Endo-
crine therapy data for Irish patients were therefore supplemented by linkage to 
a national database of drug prescription, which covers publicly funded ‘medical 
card’ patients including most patients aged 65 years and over. Additional endocrine 
therapy was identified by this linkage for 21% of patients. Linkage was not possible 
for about 15% of Irish patients, and for this group, ‘missing’ endocrine therapy 
was imputed (4% of all patients). The imputation assumed that the proportion 
of ‘linked’ patients receiving endocrine therapy by stage (I, II and III), hormone 
receptor status (any positive vs. none positive) and broad age-group (65-74 and 
75+) also applied to unlinked patients, and these ‘extra’ treatments were assigned 
randomly within each stage-by-age group.
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Data from both the Netherlands Cancer Registry and the National Cancer Reg-
istry of Ireland are fully anonymized prior to being made available to researchers, 
so data cannot be traced back to the individual patient. Therefore, no informed 
consent was required from the included patients and there was no need for ap-
proval of an ethical committee.
Mortality follow-up was available to December 31st 2011 by linkage of cancer 
registry with national mortality data. 
statistical analyses
Analyses were performed in IBM SPSS Statistics 20 and Stata SE 12. Treatment 
strategies were analyzed grouped by tumor stage (I to III). Differences in treatment 
between countries were tested by a Poisson regression model, adjusted for age 
(continuous), histological subtype, tumor grade, ER and PR status. 
Relative survival was calculated by the Ederer II method15 as the ratio of the 
survival observed among the cancer patients to the expected survival based on the 
corresponding general population (by age, sex, and year of diagnosis), using the 
‘strs’ command in Stata. National life tables for each country were used to estimate 
expected survival. Results were presented as percentage relative survival after five 
years, and Relative Excess Risks (RER) derived from relative survival modeling, 
with The Netherlands as reference category.16
ResUlTs
Overall, 41,055 patients from The Netherlands and 5,826 patients from Ireland were 
included. Patient and tumor characteristics are shown in Table 1. Median age for 
patients in The Netherlands was 74 years (range 65-102), and in Ireland 74.2 (range 
65-99). Fewer early stage tumors, and more with advanced stage were observed in 
Ireland (P<0.001). Recorded grade distribution differed significantly, with a higher 
proportion of higher grades in Ireland than in The Netherlands (P<0.001).
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Table 1 – Patient and tumor characteristics.
  Country  
  The Netherlands Ireland  
  (N=41055) (N=5826) P
  N % N %
Age (years) 65-74 22,036 53.7 3,126 53.7 0.989
 75 or older 19,019 46.3 2,700 46.3  
Year of diagnosis 2001 4,432 10.8 584 10.0 0.333
 2002 4,256 10.4 582 10.0  
 2003 4,339 10.6 601 10.3  
 2004 4,439 10.8 624 10.7  
 2005 4,425 10.8 614 10.5  
 2006 4,519 11.0 664 11.4  
 2007 4,870 11.9 695 11.9  
 2008 4,914 12.0 718 12.3  
 2009 4,861 11.8 744 12.8  
Stage I 17,790 43.3 1,658 28.5 <0.001
 II 18,023 43.9 3,140 53.9  
 III 5,242 12.8 1,028 17.6  
Grade 1 8,137 19.8 542 9.3 <0.001
 2 16,314 39.7 2,803 48.1  
 3 9,018 22.0 1,720 29.5  
 missing 7,586 18.5 761 13.1  
Morphology ductal 28,463 69.3 3,861 66.3 <0.001
 lobular 5,488 13.4 789 13.5  
 mixed/other 7,104 17.3 1,176 20.2  
ER negative 3,209 7.8 930 16.0 <0.001*
 positive 19,785 48.2 4,074 69.9  
 missing 18,061 44.0 822 14.1  
PR negative 7,350 17.9 1,545 26.5 <0.001*
 positive 14,740 35.9 2,694 46.2  
 missing 18,965 46.2 1,587 27.2  
*missings excluded
Hormone receptor status showed smaller differences, with slightly smaller propor-
tions of estrogen and progesterone receptor positive tumors among Irish patients 
(81% and 64%, respectively, excluding missing or unknown values) compared with 
those from the Netherlands (86% and 67%) (P <0.001). The proportion of missing 
values was much lower in Ireland, mainly because Dutch data were not complete 
for the years 2001-2005 rather than to differences in proportions of patients tested. 
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locoregional treatment
Figure 1A shows the proportions of patients receiving guideline-adherent locore-
gional treatment by country, grouped by stage. In The Netherlands guideline-
adherent treatment was performed in 80%, with little variation between stages, 
whereas these proportions in Ireland ranged from 57% (stage III) to 74% (stage II). 
Among patients who did not receive guideline-adherent locoregional treatment, 
65% (The Netherlands) and 68% (Ireland), had no locoregional treatment at all, 6% 
(The Netherlands) and 13% (Ireland) had only BCS (without RT or axillary sur-
gery), and 29% (The Netherlands) and 20% (Ireland) had adequate local treatment, 
but no axillary surgery.  Adjusted RRs for having guideline-adherent locoregional 
therapy in Ireland relative to The Netherlands were 0.79 (95% CI 0.76-0.81), 0.87 



































figure 1a. Locoregional guideline-adherence by stage
Looking more specifically at locoregional treatment (Table 2), overall, more pa-
tients in Ireland had no breast surgery at all (19% vs. 12% in The Netherlands), also 
stratified by  stage (P<0.001 in all stages). 
In The Netherlands, 82% underwent any axillary surgical procedure, as compared 
to 74% in Ireland. Also, in all three stage groups, fewer patients in The Netherlands 
than in Ireland did not undergo axillary surgery (P<0.001).
Regarding radiotherapy (RT), among all patients, more patients received RT 
in Ireland than in The Netherlands, overall and after mastectomy (P<0.001). For 
mastectomy patients, the difference was only seen in stage I (18% of patients had 
post-mastectomy RT in Ireland vs. 3% in The Netherlands) and stage II (42% vs. 
14%) (P<0.001). In stage III patients, the difference in the receipt of RT attenuated 
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and no difference was observed in post-mastectomy RT.  However, in all stages 
significantly fewer patients in Ireland received RT after BCS (79% vs. 94% in The 
Netherlands, overall, P<0.001). (Table 2).
Table 2. Treatment by stage
Country
The Netherlands Ireland
N % N % P
All stages
Definitive surgery
None 4,971 12.1 1,121 19.2 <0.001
BCS 16,079 39.2 2,185 37.5
Mastectomy 20,008 48.7 2,520 43.3
any axillary surgery 33,637 81.9 4323 74.2 <0.001
Radiotherapy
All 19,407 47.3 2,940 50.5 <0.001
After BCS 15,050 93.6 1,728 79.1 <0.001
After Mastectomy 4,102 20.5 1,092 43.3 <0.001
Chemotherapy 2,638 6.4 138 23.8 <0.001
endocrine therapy  for eR+
not imputed 11,570 58.5 2,834 88.6 <0.001
imputed (IRL) 11,570 58.5 3,609 92.4 <0.001
Stage I
Definitive surgery
None 1,341 7.5 258 15.6 <0.001
BCS 10,244 57.6 928 56.0
Mastectomy 6,205 34.9 472 28.5
any axillary surgery 15,090 84.8 1,212 73.1 <0.001
Radiotherapy
All 9,928 55.8 832 50.2 <0.001
After BCS 9,693 94.6 733 79.0 <0.001
After Mastectomy 209 3.4 86 18.2 <0.001
Chemotherapy 321 1.8 176 10.6 <0.001
endocrine therapy  for eR+
not imputed 2,507 27.4 834 87.7 <0.001
imputed (IRL) 2,507 27.4 1,066 91.4 <0.001
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Table 2. Treatment by stage (continued)
Country
The Netherlands Ireland
N % N % P
Stage II
Definitive surgery
None 2,438 13.5 489 15.6 <0.001
BCS 5,226 29.0 1,135 36.1
Mastectomy 10,359 57.5 1,516 48.3
any axillary surgery 14,665 81.4 2,486 79.2 0.004
Radiotherapy
All 6,287 34.9 1,572 50.1 <0.001
After BCS 4,803 91.9 905 79.7 <0.001
After Mastectomy 1,443 13.9 632 41.7 <0.001
Chemotherapy 1,233 6.8 868 27.6 <0.001
endocrine therapy  for eR+
not imputed 6,890 83.6 1,573 89.6 <0.001
imputed (IRL) 6,890 83.6 2,000 93.8 <0.001
Stage III
Definitive surgery
None 1,192 22.7 374 36.4 <0.001
BCS 606 11.6 122 11.9
Mastectomy 3,444 65.7 532 51.8
any axillary surgery 3,882 74.1 626 60.9 <0.001
Radiotherapy
All 3,192 60.9 536 52.1 <0.001
After BCS 554 91.4 90 73.8 <0.001
After Mastectomy 2,450 71.1 374 70.3 0.682
Chemotherapy 1,084 20.7 343 33.4 <0.001
endocrine therapy  for eR+
not imputed 2,173 91.1 427 86.7 0.002
imputed (IRL) 2,173 91.1 543 89.3 0.188
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endocrine therapy
The overall proportion of estrogen receptor positive patients receiving endocrine 
therapy differed between the countries - 59% in The Netherlands vs. 92% in Ireland 
(P<0.001) for all stages combined. Patients with stage I disease were more than three 
times as likely to get endocrine therapy in Ireland (91% vs. 27%; P<0.001). The dif-
ference was smaller in stage II patients, 94% in Ireland vs. 84% in The Netherlands 
(P<0.001), and 89% vs. 91% respectively in stage III patients (P=0.188) (Figure 1B; 
Table 2). Adjusted RRs for having endocrine therapy in Ireland were 2.91 (95% CI 
2.77-3.05), 1.11 (1.09-1.12) and 0.99 (0.96-1.02) respectively for stage I, II and III ER-
positive patients. Among patients who did not receive any locoregional treatment 




































figure 1b. Endocrine therapy for estrogen receptor positive patients by stage
Chemotherapy
Overall, 6% of patients The Netherlands and 24% of patients in Ireland received 
chemotherapy, and there was a higher proportion of Irish patients that received 
chemotherapy in all three stages (P<0.001) (Figure 1C; Table 2). Adjusted RRs for 
having chemotherapy in Ireland were 4.55 (95% CI 3.81-5.43), 3.35 (3.11-3.62) and 
1.44 (1.31-1.58), respectively for patients with stage I, II and III.
Relative survival
Median follow-up time was 4.5 years for The Netherlands and 4.3 years for Ireland. 
During the total follow-up period, 14,771 (36.0%) patients died in The Netherlands, 
compared to 2,191 patients (37.6%) in Ireland.























figure 1c. Chemotherapy by stage
Five-year relative survival was 88.8% in The Netherlands and 82.9% in Ireland, for 
all stages combined (Figure 2). This survival difference was statistically significant, 
also after adjustment for age, grade, stage, ER, PR and morphology (relative ex-
cess risk [RER] for Ireland, with The Netherlands as reference category: 1.22; 95% 
confidence interval (CI) 1.10-1.36). Grouped by stage, no survival difference was 
demonstrated in stage I patients (adjusted RER 1.00, 95% CI 0.59-1.70), but worse 
survival was confirmed for Irish patients in stage II (adjusted RER 1.20, 95% CI 




























figure 2. Relative survival by stage
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DIsCUssIon
The current study, comparing treatment and relative survival of older breast 
cancer patients between two Western European countries with similar treatment 
guidelines, showed large differences in treatment approach for older breast cancer 
patients. A higher proportion of patients in The Netherlands received guideline-
adherent locoregional treatment than in Ireland in all stages, but in Ireland the 
receipt of systemic treatments was higher in all stages of disease. Relative survival 
of patients in Ireland was significantly poorer than in The Netherlands, but ad-
justed models suggested the difference most marked for stage II and III patients. 
The observed discrepancies in breast cancer treatment are consistent with find-
ings of earlier international comparisons of older and other breast cancer patients 
across Europe and the US.9,17–19 However, although international survival and 
treatment variations among breast cancer patients have recently been assessed on 
a global scale20, no clear evidence was published on the potential role of different 
treatment strategies in influencing survival discrepancies among early-stage cases. 
However, it is interesting to speculate on reasons for the differences in patterns of 
care for the specific treatment modalities. Some differences could be explained by 
discrepancies in guideline recommendations between the two countries. There are 
differences (Appendix S1) especially for postmastectomy radiotherapy and chemo-
therapy and for both of these, indications are broader in the Irish guidelines. These 
differences are reflected in our results, where we observed more patients from 
Ireland receiving these treatments, as compared to the patients from Netherlands, 
also stratified by stage of disease. Secondly, physicians from the Netherlands may 
also be more likely to deviate from the guidelines when treating older breast cancer 
patients. Unfortunately, in our study it was also not possible to draw any reliable 
conclusion about the impact of differences in any of the specific treatment modali-
ties, because of a potential bias due to confounding by indication when comparing 
the outcomes of patients with different treatments directly. 
In a large population-based study in The Netherlands, guideline adherence 
of breast cancer treatment among younger and older breast cancer patients was 
compared between different regions, and although differences in adherence were 
observed, there were no significant survival differences between regions.21 In the 
current study we found less guideline-adherence on locoregional treatment in Ire-
land, and this was accompanied by a worse survival in Ireland. On the other hand, 
patients in Ireland received more systemic therapies (both endocrine therapy and 
chemotherapy), so no conclusion can be drawn based on the locoregional treat-
ment only, because of a probably counterbalanced effect by adjuvant treatments. 
Treatment strategies and survival of older breast cancer patients - an international comparison 43
To obtain the highest level of evidence on treatment benefits, the effect of each 
treatment modality should be investigated based on randomized assignment of 
treatment. However, randomized clinical trials (RCTs) tend to be slow, expen-
sive, and insensitive to the heterogeneous contexts of the general population.22 
The disadvantages of RCTs are probably even stronger in the older population, 
because of their limited mobility and large heterogeneity. Observational studies, 
using population-based registry data, are considered to be a better reflection of the 
“real world”. 5,23 However, although large study populations can be derived from 
registries, the observational design means that confounding by indication must be 
considered when studying treatment effects.
A limitation of our study was that the selected populations differed in some 
respects.  Advanced stage and higher grade cases were more frequently observed 
in Ireland. Although the analyses included patients aged 65 and older, this finding 
might be explained partly by differences in screening24,25 and possibly methods of 
grading between countries. To overcome the difference in stage distribution, we 
grouped all analyses by stage. Slight under-ascertainment of radiotherapy treat-
ments is known to have occurred among Irish patients who had breast surgery 
in private hospitals. However, only about 17% of surgical patients in the age 65+ 
group falls into this category, and we estimate that the percentages of Irish patients 
reported as having radiotherapy in Ireland may about 2% too low, not enough to 
affect our conclusions. 
To achieve best practice for older breast cancer patients, possibly, attention 
should be shifted to other outcomes rather than survival to improve quality of 
care for older breast cancer patients. However, we could draw no conclusions on 
aspects such as quality of life, risk of recurrence or complications, as we did not 
have data on these aspects. In addition, because of full anonymization of the data-
sets used for our analysis, characteristics of hospitals, such as the type (academic/
teaching hospital, private/public clinic), but also the presence of radiotherapy 
facilities were not available. Therefore, we were unfortunately not able to see if 
guideline-adherence was associated with hospital characteristics.
The retrospective design of the current study, despite the positive arguments 
mentioned previously, remains a limitation. However, because of the availability 
of comprehensive cancer registry data, it was possible to create a large database of 
population-based, generalizable data.
In the future, study designs in which countries are compared on treatment 
strategy and breast cancer outcome are likely to be applied more frequently. By 
including many countries in analyses, specific populations that differ on only 
one treatment modality could be identified. Consequently, more evidence can 
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be obtained from observational studies, by comparing patient outcomes between 
countries using an instrumental variable study design.26 
The European Registration of Cancer Care, or in short European Cancer Audit 
(EURECCA)27 aims to create a population-based audit structure that covers all 
breast cancer patients across Europe: anonymous patient and tumor data, includ-
ing treatment and outcome information will be registered in a uniform way across 
countries. The aim is to develop an extensive data source with the ultimate goal 
to define high-quality care and monitor the quality of care of all European cancer 
patients and so improving outcome of cancer care. EURECCA aims to investigate 
best practices and learn from them, as well as perform analysis on patient groups 
that deviate from guidelines such as the young and elderly. The availability of 
comprehensive cancer registry data, (like that used in the current study)  facilitates 
the identification  of  large cohorts  of population-based, generalizable data.
In conclusion, in this population-based study comparing patterns of care and 
survival of older breast cancer patients on a national scale in The Netherlands and 
Ireland, we found large differences in treatment approach, with more guideline-
adherence on locoregional treatment in The Netherlands, and more prescription 
of systemic therapy in Ireland. Patients in Ireland had a worse relative survival as 
compared with the Dutch patients, although it was not possible to link this survival 
difference directly to differences in one or more of the specific treatment modali-
ties. However, our finding should be a strong recommendation to perform more 
research on an international scale, with the ultimate goal to equalize the survival 
rates for breast cancer patients across Europe.
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absTRaCT
objective. The aim of this study is to assess age-specific compliance to quality in-
dicators (QIs) regarding the treatment of breast cancer as defined by the European 
Society of Breast Cancer Specialists (EUSOMA) for patients across Europe.
Methods. All patients entered into this study were affected by in situ or invasive 
breast cancer, diagnosed and treated between 2003 and 2012 at 27 Breast Units 
across Europe, who were entered into the EUSOMA database. Patients were catego-
rized according to age; compliance to thirteen QIs was assessed for each age group 
and per time period (2003-2007 and 2008-2012). Compliance to QIs was tested by 
multivariable logistic regression models adjusted for breast unit, incidence year, 
and tumour characteristics.
Results. Overall, 41,871 patients with a mean age of 59.6 years were available for 
analysis. The highest compliance was reached for patients aged 55-64 years and in 
the time period 2008-2012, while the lowest compliance was observed for women 
aged over 74 or under 40 years and in the earlier time period. In multivariable 
logistic regression models, a significant difference between age categories was 
shown for 12 out of 13 QIs (P<0.001). Compliance to the QIs for patients aged ≥75 
years was significantly lower when compared to patients aged 55-64 years for ten 
QIs, while for patients in the youngest age group this was true for seven QIs. 
Conclusion. In conclusion, we found that among the 27 included breast units 
across Europe, compliance to QIs for breast cancer treatment is often lower in the 
youngest and oldest breast cancer patients, with a tendency to overtreatment in the 
youngest patients, and to under-treatment in the elderly.
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InTRoDUCTIon
Numerous national and international guidelines and recommendations are avail-
able to physicians treating breast cancer patients. However, a significant variation 
in patterns for breast cancer care has been reported throughout Europe.1,2 This 
variation in treatment is accompanied by variation in breast cancer survival rates.3
The European Society of Breast Cancer Specialists (EUSOMA) aims to improve 
and standardize the level of patients care throughout Europe. To accomplish this, 
the measurement of quality indicators in breast cancer care is essential, in order 
to monitor the effectiveness and to guide improving the healthcare.4  To identify 
the appropriate indicators for quality assurance in breast cancer care, EUSOMA 
organized a workshop in 2008 where 24 experts from different disciplines defined 
a set of quality indicators (QIs) on the whole process of breast cancer management 
based on the international literature, which was published in 2010. For each QI, the 
experts defined minimum and target standards.4 Breast centres certified in compli-
ance with the standards of the EUSOMA guidelines are required to hold a Breast 
Unit (BU) database for the purpose of auditing as well as for research purposes.5 
The QIs are defined without any age-specific comments, and also, the minimum 
standards are not age-specific. However, probably it is desired to take into account 
age-specific issues in treatment recommendations for breast cancer treatment. 
For instance, it is questionable if deviation from standard treatment has the same 
impact on patient outcomes across all age groups. Population-based data from Eu-
rope and North America have shown that among older women, large differences 
in locoregional treatment between countries have not led to survival differences .1,6-9 
This leads to the question if ‘non-inferior’ locoregional treatment strategies result 
in worsened outcomes among elderly. On the other hand, with regards to systemic 
therapy, a few randomized trials have shown that chemotherapy regimens which 
are considered inferior (but more patient-friendly, such as oral capecitabine), re-
sult in an inferior prognosis for both younger and older patients10,11, implying no 
age-specific impact on outcome. 
However, when interpreting trial results, it has to be taken into account that 
in contrast to the growing population of elderly with cancer, older patients are 
underrepresented in current clinical oncological studies.12  Moreover, it has been 
shown that the older subjects who are included in a clinical trial, are not always 
representative for the general older population.13 Therefore, the external validity of 
clinical trial results should be questioned when it concerns older patients.
With regards to younger breast cancer patients, it is opted that these patients 
probably deserve a different approach and management than older women, taking 
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into account their longer general life expectancy, but also, their other, more aggres-
sive tumour biology.14 
In summary, it is understandable to observe differences in treatment approach 
across age groups, accompanied by varying compliance to QIs by age. To test 
this hypothesis, the aim of this study is to assess age-specific compliance to the 
EUSOMA QIs regarding treatment for patients across Europe.
MeThoDs
The EUSOMA database (db) is a central data warehouse of prospectively collected 
information which includes individual records on primary breast cancer cases 
diagnosed and treated at European breast units (BUs) providing patients data in a 
standardized format. The database was started in 2006 and collects 108 variables 
for each patient record, including patient and tumour characteristics, information 
about preoperative work-up, multidisciplinary management, and follow-up data. 
Different BUs started entering patients in the db on different points in time, but 
it has been formally checked that the patients that were included in the database 
are consecutive patients. Records are anonymous but BUs can identify their own 
patients by the use of an ID code. The data transfer from each Unit database to 
the EUSOMA db occurs yearly through an online application and represents a 
requirement to obtain and to continue holding certification. BUs can access the 
EUSOMA db to check data quality, calculate QIs, perform data analysis and bench-
marking and agree to use it for certification purposes and for co-operative clinical 
research.15 For research purposes, the data are fully anonymized, as well on case 
record level, as on BU level. To assure the data quality, there have been several 
consistency checks built into the database, as is a report on missing values. In order 
to maintain EUSOMA certification, BUs are required to minimize inconsistencies 
an incompleteness and may send several data transfers in order to achieve this.
Patients
All patients with a diagnosis of in situ or invasive breast cancer diagnosed between 
2003 and 2012 from 27 certified BUs from Austria, Belgium, Germany, Italy, and 
Switzerland who provided their data to the EUSOMA db before August 2013 were 
included into this analysis. Patients with missing data on age or with non-epithelial 
tumours or other neoplasms were excluded. Age was categorized as <40 years, 
40-54 years, 55-64 years, 65-74 years, and ≥75 years. 
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outcome measures
Primary outcome measure was the compliance to EUSOMA QIs by age.4 We 
selected the thirteen QIs considering treatment (rather than diagnosis, staging, 
follow-up or counselling). QIs were divided into five groups: appropriate surgical 
approach, post-operative radiotherapy (RT), avoidance of overtreatment, appro-
priate hormonal therapy, appropriate chemotherapy, and other medical therapy. 
Data on trastuzumab were incomplete; therefore, QIs regarding this treatment 
modality were disregarded from the present investigation. 
statistical analyses
All analyses were performed using IBM SPSS Statistics 20 or R (v.3.0.0). All tests 
of significance were two-sided and P-values smaller than 0.05 were considered 
statistically significant. 
For each QI, the appropriate selection of patients was used (based on tumour 
stage or type of treatment). Patients with missing data on the treatment of inter-
est for a specific QI, were excluded from the analyses (per QI). The EUSOMA db 
datacentre considers outcomes of QIs with more than 25% missing values as highly 
unstable and therefore, QI compliance is not calculated when the proportion of 
missing values exceeds 25%. 
Proportions of compliance to each QI were stratified by age group and time 
period (2003-2007 and 2008-2012).
Primary outcome measure was the proportion of compliance to each QI. Multi-
variable logistic regression analyses were performed to calculate adjusted odd’s 
ratios (ORs) and 95% confidence intervals (CIs) by age group, with the middle age 
group (55-64 years) as reference category. The results were adjusted for BU, incident 
year, and, when appropriate, tumour characteristics (stage, grade, morphology, 
and hormone receptor expression). In case of missing data in one of the adjustment 
variables, these patients were not excluded from the multivariable models, but the 
missing data were taken into account as a separate value of the variable.
With the purpose of presenting the results into a more intuitive way, adjusted 
ORs were converted to risks using the formula: adjusted OR/ 1 - adjusted OR.16
ResUlTs
In total, 41,871 patients from the EUSOMA db were included into this study. The 
mean age was 59.6 years (Standard Deviation (SD) 13.0). The majority of patients 
were categorized into the middle three age groups, 5% were <40 years, and 13% were 
≥75 years. There was an increasing trend in the number of patients per year, from 
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2.6% in the year of initiation of the database (2003), to 18.8% in 2011. Most patients 
had stage I or II breast cancer (39.5% and 31.4%, respectively). Most cancers were 
hormone receptor positive (81.5%) and invasive ductal carcinoma (72.2%) (Table 1).
Table 1. Patient and tumour characteristics.
age categories
 
< 40 40-54 55-64 65-74 75+ all ages
N=2,260 N=13,701 N=10,706 N=10,323 N=5,475 N=41,871
 N % N % N % N % N % N %
Incidence year            
2003 69 3.1 380 2.9 335 3.1 205 2.0 97 1.8 1,086 2.6
2004 127 5.6 565 4.3 519 4.8 370 3.6 190 3.5 1,771 4.2
2005 157 6.9 779 5.9 713 6.7 531 5.1 281 5.1 2,461 5.9
2006 179 7.9 904 6.9 820 7.7 727 7.0 329 6.0 2,959 7.1
2007 210 9.3 1113 8.5 902 8.4 916 8.9 372 6.8 3,513 8.4
2008 238 10.5 1,471 11.2 1,227 11.5 1,266 12.3 570 10.4 4,772 11.4
2009 334 14.8 2,027 15.5 1,674 15.6 1,801 17.4 831 15.2 6,667 15.9
2010 360 15.9 2,221 16.9 1,827 17.1 1,870 18.1 1,023 18.7 7,301 17.4
2011 386 17.1 2,552 19.5 1,868 17.4 1,849 17.9 1,212 22.1 7,867 18.8
2012 200 8.8 1,095 8.4 821 7.7 788 7.6 570 10.4 3,474 8.3
stage
in situ 205 9.1 1,767 13.5 1,366 12.8 1,083 10.5 358 6.5 4,779 11.4
I 802 35.5 5,064 38.6 4,584 42.8 4,428 42.9 1,677 30.6 16,555 39.5
II 780 34.5 4,077 31.1 3,110 29.0 3,127 30.3 2,055 37.5 13,149 31.4
III 289 12.8 1,371 10.5 1,033 9.6 1,057 10.2 758 13.8 4,508 10.8
IV 40 1.8 216 1.6 184 1.7 202 2.0 132 2.4 774 1.8
missing 144 6.4 612 4.7 429 4.0 426 4.1 495 9.0 2,106 5.0
Grade
1 139 6.2 2,058 15.7 1,727 16.1 1,646 15.9 757 13.8 6,327 15.1
2 901 39.9 6,433 49.1 5,619 52.5 5,766 55.9 3,138 57.3 21,857 52.2
3 1054 46.6 3,902 29.8 2,897 27.1 2,538 24.6 1,447 26.4 11,838 28.3
missing 166 7.3 714 5.4 463 4.3 373 3.6 133 2.4 1,849 4.4
hormone receptor (eR and/or PR)       
negative 680 30.1 2,108 16.1 1,617 15.1 1,372 13.3 721 13.2 6,498 15.5
positive 1,483 65.6 1,0523 80.3 8,774 82.0 8,708 84.4 4,633 84.6 34,121 81.5
missing 97 4.3 476 3.6 315 2.9 243 2.4 121 2.2 1,252 3.0
Morphology
Ductal 1,851 81.9 9,422 71.9 7,611 71.1 7,294 70.7 4,043 73.8 30,221 72.2
Lobular 99 4.4 1,495 11.4 1,350 12.6 1,545 15.0 742 13.6 5,231 12.5
Combined/other 91 4.0 492 3.8 403 3.8 410 4.0 329 6.0 1,725 4.1
missing 219 9.7 1,698 13.0 1,342 12.5 1,074 10.4 361 6.6 4,694 11.2
Percentages indicate the proportion of patients within an age-group. ER=estrogen receptor. 
PR=progesterone receptor.
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The thirteen scrutinized QIs with definitions are listed in Table 2, which also dis-
plays the minimum standards as defined by EUSOMA4 and the absolute numbers 
of QI compliance by time period, including the number and proportion of missing 
values. The proportions of QI compliance by age and time-period are shown in 
Webtable 1. The highest compliance to QIs was reached in patients aged 55-64 
years, where the minimum standard was reached for ten QIs during 2008-2012 
and for six during 2003-2007. In patients aged ≥75 years, the minimum standard 
was reached in the two time periods for three and seven QIs respectively, while in 
women <40 for four and six QIs.
In multivariable logistic regression models (Webtable 2), a significant difference 
between age categories was shown for 12 of 13 QIs (P<0.001). No difference between 
age groups was shown for QI 13e (p=0.07). The adjusted  proportions of guideline 
adherence per age group are shown in Figure 1. Compliance to QIs for patients 
aged ≥75 years differed significantly from patients in the middle age group (55-64 
years) for almost all QIs, except QI 11b. For two indicators, 9a and 9b, the compli-
ance was higher among the oldest patients. However, for the remaining ten QIs, 
compliance of patients aged ≥75 years was significantly lower, when compared to 
patients aged 55-64 years.
Table 2. Definition of QIs and compliance by time period.
Definition Minimum 
standard
Time period Compliance  Missing
 N %  N %
















9a. % of patients with invasive cancer 
who received a single operation 
(excluding reconstruction)
80%
2003-2007 10254 75.0%  19 0.2%
2008-2012 25432 82.0%  45 0.2%
Total 35686 80.0%  64 0.2%
9b. % of patients with DCIS who 
received only one operation 70%
2003-2007 1218 53.9%  3 0.2%
2008-2012 3300 64.8%  1 0.0%
Total 4518 61.8%  4 0.1%
9c. % of patients with cN0 who had 
a SNB. 90%
2003-2007 9590 44.9%  173 1.8%
2008-2012 23376 81.1%  171 0.7%
Total 32966 70.5%  344 1.0%
9d. % if patients with ALND 
performed, with at least 10 LNs 
examined
95%
2003-2007 5896 84.7%  261 4.2%
2008-2012 8476 90.3%  333 3.8%









T 10a. % of patients with RT after BCS 
for M0 invasive cancer. 90%
2003-2007 4982 95.8%  1418 22.2%
2008-2012 15714 94.2%  1227 7.2%
Total 20696 94.6%  2645 11.3%
10b. % of patients with pN2a or more 
who received postmastectomy RT 90%
2003-2007 589 91.9%  190 24.4%
2008-2012 1225 85.2%  128 9.5%
Total 1814 87.4%  318 14.9%
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Furthermore, for eight QIs, compliance for the patients in the youngest age 
group differed significantly compared to those aged 55-64 years (Webtable 2). The 
compliance was lower, with the exception of QI 13a.
Table 2. Definition of QIs and compliance by time period. (continued)
Definition Minimum 
standard
Time period Compliance  Missing















11a. % of patients with invasive 
cancer not greater than 3 cm who 
underwent BCT
70%
2003-2007 7398 75.0%  158 2.1%
2008-2012 16967 82.3%  658 3.7%
Total 24365 80.1%  816 3.2%
11b. % of patients with non-invasive 
cancer not greater than 2 cm who 
underwent BCS
70%
2003-2007 801 77.8%  36 4.3%
2008-2012 1882 87.0%  149 7.3%
Total 2683 84.3%  185 6.5%
11c. % of patients with DCIS who do 
not undergo ALND 95%
2003-2007 1130 86.4%  18 1.6%
2008-2012 3236 96.0%  8 0.2%
Total 4366 93.5%  26 0.6%
11d. % of invasive breast cancer 
patients with pN0 who do not 
undergo ALND
80%
2003-2007 5818 48.7%  2 0.0%
2008-2012 15824 86.4%  4 0.0%
Total 21642 76.3%  6 0.0%















12a. % of patients with HR+ invasive 
cancer who received hormonotherapy 80%
2003-2007 5403 96.5%  3116 36.6%
2008-2012 18994 93.8%  3385 15.1%


























y 13a. % of patients with HR- (T>1 or 
N+) invasive cancer who received 
adjuvant chemotherapy
80%
2003-2007 1266 91.7%  324 20.4%
2008-2012 2806 90.6%  178 6.0%
Total 4072 90.9%  502 11.0%
13e. % of patients with inflammatory 
cancer or locally advanced 
irresectable cancer who had 
neoadjuvant chemotherapy
90%
2003-2007 27 11.1%  15 35.7%
2008-2012 111 78.4%  21 15.9%
Total 138 65.2%  36 20.7%
Numbers shown in bold type indicate that the minimum standard is reached. Patients with miss-
ing values were excluded for calculating the proportion of compliance per QI. The proportion of 
missing values indicate the missing values of the treatment of interest in the selection that was 
made for the specific QI.
DCIS=ductal carcinoma in situ. cN0=clinically node negative. SNB=sentinel node biopsy. 
ALND=axillary lymph node dissection. LN=lymph node. RT=radiotherapy. BCS=breast conserv-
ing surgery. M0=non-metastatic. HR=hormone receptor











































































































































































































































































































































































































































































































































































This observational study conducted on the largest European breast cancer data-
base demonstrates a low compliance to quality indicators among the youngest (<40 
years) and the oldest (≥75 years) patients. Below we will discuss compliance to the 
specific QIs per treatment category.
The category “Appropriate surgical approach” includes four QIs. Firstly, we 
observed that the proportion of patients receiving only one operation for invasive 
cancer (9a) increases with age. A possible explanation is that there is a more reluc-
tant approach to older patients with positive margins, whereas in younger breast 
cancer patients, positive margins are considered unacceptable, with regards to a 
higher risk on local recurrence.17 The same applies for QI 9b: the proportion of 
patients with ductal carcinoma in situ (DCIS) receiving only one operation; only 
patients aged ≥75 years met the minimum standard. For QI 9c; the proportion 
of clinically node negative patients receiving sentinel node biopsy was lower in 
the youngest and the oldest age group. Again, this is probably reflecting a more 
aggressive treatment approach in the youngest patients (axillary lymph node 
dissection), and a more reluctant approach to elderly. The time-period analyses 
showed almost twice as much compliance in the period 2008-2012 as compared to 
2003-2007, reflecting the increasing use of sentinel node procedures.18 For QI 9d; 
the proportion of patients with axillary clearance with at least ten lymph nodes 
examined, the compliance declined with increasing age. This is in keeping with 
previous studies.19,20
QIs for “Post-operative radiotherapy” are separated for radiotherapy after breast 
conserving surgery (BCS) for non-metastatic invasive cancer (10a), and after mas-
tectomy for pN2a or more (10b). The minimum standard for QI 10a was reached, 
except in the oldest group (≥75 years). Our observation is a confirmation of many 
population-based studies showing a decrease in the receipt of RT after BCS in older 
breast cancer patients, but still a proportion of 82% in the EUSOMA db is higher 
than previous observations.1,21,22 The compliance to QI10b was lower in patients 
aged ≥75 years, which again reflects a more reluctant treatment approach towards 
older patients.23  Interestingly, the compliance to QI 10b was higher in the time 
period 2003-2007. The decrease over time might be explained by the increasing 
use of aromatase inhibitors, which are considered more tolerable than other (che-
motherapeutic) systemic therapies, and moreover probably more effective than 
tamoxifen for advanced hormone receptor positive breast cancer.24 
The category “Avoidance of overtreatment” comprises four QIs. QI 11a and 11b 
consider the proportion of patients with small invasive and non-invasive breast 
cancers receiving BCS, respectively. We have found that compliance decreases with 
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increasing age, in line with previous studies which showed an increase in mastec-
tomies with increasing age.21,25  In contrast, for non-invasive cancer the compliance 
was lowest for the youngest age group, indicating more extensive surgery. For QIs 
11c and 11d, considering the avoidance of axillary lymph node dissection (ALND) 
for patients with non-invasive lesions or for pathologically confirmed N0 disease 
(pN0), the minimum standards were not reached in any of the age categories be-
fore 2008, which can be explained by the limited use of sentinel node procedures at 
that time.26 From 2008 onwards, this QI compliance increased dramatically, and the 
minimum standard for both QIs was reached in all age groups, except for patients 
aged <40 years. This indicates a possible overtreatment of the young patients, 
because there is no hard evidence and no guidelines that justify the use of ALND 
in non-invasive cancers.4
The relatively greater overtreatment in the youngest patients group is probably 
due to the attempt to assure the lowest risk of recurrence, although this practice 
should be challenged by considering the balance between benefits and harms.
The category “Appropriate hormonal therapy” comprises one QI (12a), which 
describes the proportion of patients with hormone receptor (HR) positive invasive 
breast cancer who received endocrine therapy. This is the only QI for which the 
minimum standard was achieved in all age categories, indicating good consensus 
on the provision of hormonal therapy for hormone receptor positive breast cancer. 
The last category is “Appropriate chemotherapy and other medical therapy”. 
The standard for QI 13e (chemotherapy for HR-, T>1 or N+) was reached for all 
patients, except for the oldest patients, where the compliance dropped to 53%. 
Reluctance to administer chemotherapy in the elderly has been described in previ-
ous studies. Reluctance is probably related to the expectation of as well physicians 
and patients that older patients have a lower treatment tolerability, but also to 
patient preferences.4,21,27 
For QI 13e (the proportion of patients with inflammatory cancer or locally ad-
vanced irresectable cancer who had neoadjuvant chemotherapy) we showed the 
same trend in reluctance with chemotherapy with increasing age; although the 
minimum standard was not reached in any age category, the compliance was by 
far the lowest in patients aged ≥75 years (44%). 
Summarizing our results, we found that treatment of breast cancer patients 
<40 years and ≥75 years was most often not compliant to the quality indicators as 
defined by EUSOMA. In the youngest age group, this non-compliance can most 
probably be explained by over-treatment rather than under-treatment. In 2012, 
EUSOMA published recommendations for the treatment of young women (<40 
years) with breast cancer.14 In 2007, the first recommendations for treatment of 
older patients with breast cancer were published by SIOG (International Society of 
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Geriatric Oncology), which were updated in 2012 in collaboration with EUSOMA 
(a summary of treatment recommendations is provided in Webtable 3).28,29 
The largest difference between these recommendations regards the use of sys-
temic therapy: EUSOMA advises to offer chemotherapy to all young patients with 
stage I-III breast cancers while EUSOMA/SIOG advises to restrict the provision of 
chemotherapy to older patients for node-positive, ER negative disease. 
With regards to the older patients, our findings raise the question whether a 
minimalistic attitude results into poorer outcomes. In the last decade, several stud-
ies have documented the omission of certain treatments. A small number of clinical 
trials omitting radiotherapy for selected groups of older, HR positive patients, have 
been performed30 none of them showing a deterred survival. However, the risk of 
locoregional recurrence was higher, as was also shown in the EBCTCG overview.31 
In addition, Martelli et al. published a two-armed trial in which axillary dissec-
tion versus no axillary dissection in elderly patients without clinically suspicious 
nodes.32 After a median follow-up of 15 years, no significant difference in breast 
cancer mortality was shown. More on, only a restricted number of randomized 
studies takes into account the omission of local surgery for older breast cancer 
patients. A meta-analysis of these trials showed that primary endocrine therapy 
with tamoxifen associates with inferior local disease control but non-inferior can-
cer specific survival after surgery.33 On the other hand, a few trials that studied 
the effectiveness of more tolerable chemotherapy regimens have shown that these 
regimens are, less effective in older patients, similar to the younger breast cancer 
population.10,11 However, the question is if the older patients that were included 
in these trials are comparable to the general older cancer patients in terms of, for 
example, tumour characteristics and comorbidity. Therefore, the generalizability 
of these trial results should be further explored.13 From these studies, among oth-
ers, it is clear that the treatment of breast cancer for older women should not be 
always the same as the treatment for their younger counterparts, at least not for all 
treatment modalities. Therefore, in quality of care research regarding breast cancer 
treatment, it is probably worth considering to  define age-specific QIs in the future, 
or at least to re-define the minimum standards by age category.
One limitation of our study rests on the voluntary certification of contributing 
breast centres, implying that enrolled patients are likely to be subjected to a selection 
of top performing breast units.5 A further limitation of the data is that hospitals did 
not start recruiting patients’ information at the same point in time. Furthermore, 
the QIs have been prepared in 2008 and published in 2010, whilst the patients in 
the database are included from 2003 onwards.4 The expected increasing trend in 
QI compliance due to the increasing awareness of these quality measurements has 
indeed been observed in our stratified analyses. Another limitation of our study 
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is one that often arises in observational studies, namely the existence of missing 
data. For the majority of treatment modalities, patients with missing values were 
limited to a proportion of lower than 10%, with the exception of data on systemic 
treatments, where the proportion was somewhat higher, but still not exceeding the 
preliminary defined limit of 25%. For our analyses regarding QI compliance, we 
excluded patients with missing data per QI. It is unknown if the missing data are 
‘missing at random’, therefore, it was not justified to use imputation techniques to 
fill in the missing data. Theoretically, in the case of ‘non-missing at random’ data, 
it is possible that our results slightly over- or underestimate the real compliance. 
However, we have no reason to believe that the missing data are related to the level 
of QI compliance, and therefore, we believe that the low proportion of missing data 
will not impact our results.
Further insight in patterns of care is mandatory to improve the quality of care and 
outcomes of cancer patients across Europe. The inclusion of follow up information 
in the EUSOMA db is on-going but not yet available, therefore we were not able 
to analyse the impact of QI compliance on patient outcome in our current study. 
The European Registration of Cancer Care, or in short European Cancer Audit 
(EURECCA) aims at improving outcome of cancer care through registration and 
auditing.34 The aim of EURECCA is to create a population-based audit structure 
that covers all breast cancer patients across Europe: anonymous patient and 
tumour data, including treatment and outcome information will be registered in 
an uniform way across countries. The aim is to develop an extensive data source 
with the ultimate goal to define high-quality care and monitor the quality of care 
of all European cancer patients. EURECCA aims to investigate best practices and 
learn from them, as well as perform analysis on patient groups that deviate from 
guidelines such as the young and elderly. 
In conclusion, we found that among twenty-seven BUs across Europe, compliance 
to quality indicators for breast cancer treatment is often lower for the youngest and 
oldest breast cancer patients, with a tendency to overtreatment in the youngest pa-
tients, and to under-treatment in the elderly. In the near future EURECCA, in close 
collaboration with EUSOMA, will map patterns of care and the clinical outcome of 
European breast cancer patients and will develop an international audit structure 
to improve quality of care.
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absTRaCT
Purpose. Older breast cancer patients often suffer from comorbid diseases, which 
may influence life expectancy. The aim of this study was to assess the impact 
of specific comorbidities on overall survival and distant recurrence free period 
(DRFP) of older breast cancer patients.
Methods. Patients were included from the population-based FOCUS cohort, 
which contains 3,672 breast cancer patients aged 65 years or older. The impact of 
comorbidity on overall survival and DRFP were analyzed using multivariable Cox 
proportional hazard models and Poisson regression models.
Results. Median follow-up time was 6.8 years (range 0-14.0). Irrespective of age, 
the number of comorbid diseases was significantly associated with worse overall 
survival (hazard ratio (HR) per increasing number of comorbid diseases: 1.20, 95% 
confidence interval (CI) 1.13-1.27 and HR 1.09, 95% CI 1.05-1.13 for age <75 and age 
≥75 respectively). Median follow-up time for DRFP was 5.7 years (range 0-14.0). 
An increasing number of comorbid diseases was associated with a decreasing risk 
of metastases among patients aged ≥75 (HR 0.94, 95% CI 0.87-1.02), whereas an 
increasing risk was shown for patients aged <75 (HR 1.09, 95% CI 1.01-1.19).
Conclusions. This study shows that in older breast cancer patients overall survival 
and DRFP are influenced by comorbidity. This reiterates that patient outcome is 
not only influenced by breast cancer, and non-cancer related factors should be 
taken into account.
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InTRoDUCTIon
Breast cancer among the elderly comprises 40% of all breast cancer cases in the 
Western society.1 Due to age and other restrictions to inclusion of older patients 
in clinical trials, there is a lack of evidence for the treatment of this specific and 
growing patient category.2 
One of the most important differences between older and younger patients is the 
heterogeneity of the former in terms of general fitness. Furthermore, older patients 
have a high competing risk of mortality, which is the risk of dying from another 
cause than cancer before developing a cancer-specific event, such as a recurrence or 
cancer-related death.3 This competing risk of death unsurprisingly increases with 
age, but is also affected by the presence and severity of comorbid diseases.4 With 
increasing age, the proportion of breast cancer deaths among all-cause mortality 
has been shown to decrease.5-7. In contrast, recently a higher cumulative incidence 
of distant recurrences and breast cancer mortality has been reported among the 
oldest patients (≥75 years).5-8
With the knowledge that competing risk of mortality increases with age and 
comorbidity4, and the number of prevalent comorbid diseases increase with age 
in general9, the competing risk of other cause-mortality should always be taken 
into account when studying breast cancer specific endpoints among older patients. 
When studying older patients included in clinical trials (with or without age re-
strictions), one should constantly be aware of the effect of selection, as only the 
fittest and most motivated patients will be included in trials.10,11 Therefore, to be 
able to get a reliable impression of the ‘real world’ patient, observational cohorts 
with detailed information on patient, disease, treatment and follow up, are pivotal 
when studying the older cancer patient.
The aim of the present study is to assess the impact of the extent of comorbid-
ity and specific comorbid diseases on overall survival and distant recurrence free 
period in two age strata of a large population-based cohort of older breast cancer 
patients in The Netherlands.
MeThoDs
Patients
The FOCUS cohort study (Female breast cancer in the elderly; Optimizing Clinical 
guidelines USing clinico-pathologocial & molecular data) is based on the National 
Cancer Registry in The Netherlands, which contains data of all newly diagnosed 
malignancies. The FOCUS database contains information on all consecutive female 
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patients aged 65 years and older with invasive and in situ breast cancer who were 
diagnosed between 1997 and 2004 in the South-West part of the Netherlands. 
Trained personnel reviewed the charts of these patients, and collected information 
on tumor characteristics, specific treatments, comorbidity, adverse events, geriatric 
parameters, and recurrence. 
All comorbidity, as present at the time of diagnosis, was recorded according to 
the categories in the ICD-10 classification12, on the basis of the case record forms 
and extracted from the medical charts by an experienced research nurse.
Follow up on survival status was available until January 1st 2011 through link-
age of cancer registry data with municipal population registries. For this study, 
all patients with breast cancer stage I–IV and in situ of all histological subtypes 
were included. Stage was described using the tumor-node-metastasis (TNM) 
classification, as valid in the year of diagnosis. If the data on T- or N- stage from 
pathological reports were missing (pT or pN), data from clinical reports (cT or 
cN) were used to complete the combined TNM stage. Hormone receptor status 
was analyzed in a combined dichotomized variable for estrogen receptor status 
and/or progesterone receptor status. If patients received breast-conserving surgery 
followed by mastectomy, the most extensive surgery was used for analyses. Axil-
lary surgery was defined as a sentinel node procedure or an axillary lymph node 
dissection, and dichotomized for analyses. Again, the most extensive surgery was 
used for the analyses. To compare different age groups, patients were categorized 
into two groups: 65–74 years and 75 years or older, as discussed at the meeting 
of the International Society of Geriatric Oncology (SIOG) in 200913 and in line 
with other publications.5,7 The number of comorbid diseases was categorized in 
three groups: 0 or 1 concomitant diseases, 2-4 concomitant diseases, and 5 or more 
concomitant diseases. Specific groups of comorbid disease were defined according 
to the ICD-10 classification.12 Endocrine diseases, psychiatric diseases, neurologic 
diseases, cardiovascular diseases, respiratory diseases, digestive diseases and mus-
culoskeletal diseases were considered as the clinically most important subgroups 
defined in the ICD-10 and were analyzed separately. The remaining comorbidities 
were defined as a category “other comorbidity”. 
statistical analyses
The primary study endpoints were overall survival and distant recurrence free 
period (DRFP), defined as time from breast cancer diagnosis to death of any cause 
and time to first distant recurrence respectively.
Overall survival and DRFP were calculated using univariable and multivariable 
Cox Regression models. All multivariable analyses were adjusted for age (continu-
ous), tumor stage (in situ, I, II, III, IV or missing), tumor grade (1, 2, 3 or missing), 
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hormone receptor status (negative, positive or missing), morphology (ductal, lobu-
lar or other/unknown), local surgical treatment (none, breast conserving surgery 
or mastectomy), axillary surgery (dichotomous), radiation therapy (dichotomous), 
endocrine therapy (dichotomous) and chemotherapy (dichotomous). Analyses of 
specific comorbid disease categories according to the ICD-10 were additionally ad-
justed for the number of additional comorbidities. In case of missing data, patients 
were not excluded from the analyses, but analyzed in a separate group. For DRFP 
analyses, patients with primary metastatic disease (stage IV) were excluded. Also 
for DRFP analyses, sensitivity analyses using Poisson regression models were per-
formed, comparing incidence rates of distant recurrences per 1000 person years, 
taking account of the actual follow-up time of each patient, to rule out the impact 
of short life expectancy of the oldest patients with more comorbidity.
In all statistical analyses, a p-value smaller than 0.05 was considered statistically 
significant. All statistical tests were performed two-sided. All statistical analyses 
were performed in IBM SPSS Statistics 20, except for Poisson regression analyses, 
which were performed in STATA SE 12.0. 
ResUlTs
Characteristics of patients
All 3,672 patients in the FOCUS cohort were included for the analyses. Of all 
patients, 1747 (48%) were aged 65-74 years at diagnosis, and 1925 (52%) patients 
were 75 years or older. Patient, tumor and treatment characteristics per age group 
are shown in Table 1A. Patients in the older age group (≥75) more frequently had 
advanced (stage III or IV) tumors, more missing data on grade and morphology, 
reflecting the fewer surgeries (and consequently less histology) performed among 
the ≥75 (no surgery: 6.1% among patients aged <75, 20.1% among patients aged 
≥75). Also, patients aged ≥75 years received radiotherapy and chemotherapy less 
often, and received endocrine monotherapy more often.
Comorbidity
Table 1B shows the distribution of comorbidity. The mean number of comorbidi-
ties was higher in the group aged ≥75 years (2.2 vs. 1.6 among the patients aged 
<75 years; p<0.001). The larger proportion of comorbidity in the older group can 
be explained by a significantly higher burden of psychiatric diseases, neurologic 
diseases, cardiovascular diseases, digestive diseases and musculoskeletal diseases.
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Table 1 - patient, tumor and treatment characteristics
 all patients  <75  ≥75  
 (N=3,672)  (N=1747)  (N=1925)  
Mean age in years (sD) 76.5 (7.4)  70.0 (2.9)  82.3 (4.9)   
 N %  N %  N %  P*
stage          <0.001
In situ 208 5.7  142 8.1  66 3.4   
I 1,130 30.8  704 40.3  426 22.1   
II 1,532 41.7  639 36.6  893 46.4   
III 368 10  121 6.9  247 12.8   
IV 212 5.8  72 4.1  140 7.3   
missing 222 6  69 3.9  153 7.9   
           
Tumor grade          <0.001
1 437 11.9  233 13.3  204 10.6   
2 1,005 27.4  507 29.0  498 25.9   
3 784 21.4  403 23.1  381 19.8   
missing 1,446 39.4  604 34.6  842 43.7   
           
hR status          0.215
ER and PR negative 540 14.7  274 15.7  266 13.8   
ER or PR positive 2,290 62.4  1,068 61.1  1,222 63.5   
missing 842 22.9  405 23.2  437 22.7   
           
Morphology          <0.001
Ductal 2,560 69.7  1,294 74.1  1,266 65.8   
Lobular 400 10.9  175 10  225 11.7   
other/unknown 712 19.4  278 15.9  434 22.5   
           
surgery          <0.001
None 493 13.4  107 6.1  386 20.1   
BCS 1,194 32.5  839 48  355 18.4   
Mastectomy 1,985 54.1  801 45.9  1,184 61.5   
           
axillary surgery 2,614 71.2  1,385 79.3  1,229 63.8  <0.001
           
adjuvant radiotherapy 1,532 41.7  981 56.2  551 28.6  <0.001
           
endocrine therapy 1,661 45.2  638 36.5  1023 53.1  <0.001
Endocrine monotherapy 371 10.1  74 4.2  297 15.4   
Adjuvant endocrine therapy 1,290 35.1  564 32.3  726 37.7   
           
Chemotherapy 306 8.3  184 10.5  122 6.3   
*p for difference between age categories (Chi square)        
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overall survival
As shown in Figure 1, in multivariable Cox regression models, overall survival 
was worse for patients with an increasing number of comorbidities in both age 
groups (multivariable Hazard Ratio (HR) for patients with 5 or more comorbidities 
compared to 0-1 comorbidities: 2.61 (95% Confidence Interval (CI) 1.92-3.56) and 
HR 1.51 (95% CI 1.24-1.83) respectively for the <75 and ≥75 group. In patients aged 
<75, specific categories of comorbidity that were associated with a worse overall 
survival were psychiatric diseases (HR 1.41, 95% CI 1.07-1.85), neurologic diseases 
(HR 1.94, 95% CI 1.50-2.52), cardiovascular diseases (HR 1.52, 95% CI 1.28-1.81) 
and other comorbidity (HR 1.47, 95% CI 1.03-1.30). Among the highest age group, 
only psychiatric diseases (HR 1.62, 95% CI 1.12-1.93) and cardiovascular diseases 
(HR 1.16, 95% CI 1.03-1.30) were associated with a worse overall survival. 
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figure 1. All-cause mortality, multivariable Cox regression analyses.
Distant recurrence free period
Overall, the proportion of patients who developed distant metastases among stage 
0 to III patients did not differ between the age categories (11% in both categories). 
Among the patients aged ≥75, the majority of breast cancer patients died without 
registered distant metastases (62%), in other words: they died due to a “compet-
ing event”, This proportion was almost three times smaller in the younger elderly 
(22%) (Figure 2).
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Results of the multivariable Cox regression analysis on Distant recurrence free pe-
riod (DRFP) are shown in Figure 3. In the patients aged <75, an association between 
the number of comorbidities and a higher risk of distant recurrences was found, 
the HR for each increase in number of comorbidities was 1.09 (95% CI 1.01-1.19). 
With the exception of neurologic diseases (HR 1.82, 95% CI 1.10-3.01, p=0.02) and 
cardiovascular diseases (HR 1.34, 95% CI 0.98-1.82), no association was observed 
between any of the specific comorbidities and DRFP. Among the patients aged 
≥75, there was also an association between the number of comorbidities and DRFP, 
multivariable Cox regression analyses showed a trend to decreased risk of distant 
metastases among the oldest group (HR per unit increase in number of comorbidi-
ties: 0.94, 95% CI 0.0.87-1.02, p=0.12). The finding that the number of comorbidities 
is associated with fewer distant metastases in older patients is endorsed by catego-
rizing the number of comorbidities, showing that patients aged 75 or older having 
5 or more comorbid diseases have a significantly lower HR for DRFP (HR 0.54, 95% 
CI 0.30-0.96, p=0.036). In addition, a lower risk on distant metastases was shown 
for patients with psychiatric comorbidity (HR 0.42, 95% CI 0.20-0.90, p=0.026).
Poisson regression analyses, adjusted for the same factors as the Cox regression 
analyses, and taking account with the actual time a patient was followed in the 
























figure 2. Distant recurrences and competing mortality.
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the <75 group with increasing number of comorbidities (Webtable 1) (multivariable 
Incidence Rate Ratio (IRR) 1.09 (95%CI 1.00-1.18; p=0.046); whereas a decreasing 
trend was shown in the patients aged ≥75 (IRR 0.93 (95% CI 0.86-1.01; p=0.094).
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figure 3. Distant recurrence free period, multivariable Cox regression analyses.
Table 2 - Comorbidity
 
 
all patients  <75  ≥75   
N %  N %  N %  p*
number of comorbidities - mean (sD) 1.9 (1.8) 1.6 (1.7) 2.2 (1.9)  <0.001**
endocrine diseases (ICD10-4) 983 26.8 447 25.6 536 27.8  0.13
hypercholesterolaemia 90 2.5 51 2.9 39 2.0  0.09
obesity 147 4.0 92 5.3 55 2.9  <0.001
diabetes 576 15.7 266 15.2 310 16.1  0.5
thyroid diseases 342 9.3 146 8.4 196 10.2 0.06
other endocrine diseases 13 0.4 4 0.2 9 0.5  0.3
Psychiatric diseases (ICD10-5) 354 9.6 127 7.3 230 11.9  <0.001
depression 109 3.0 49 2.8 60 3.1  0.6
severe psychiatric diseases 69 1.9 36 2.1 33 1.7  0.5
dementia/Alzheimer’s 170 4.6 27 1.5 143 7.4  <0.001
other psychiatric diseases 48 1.3 27 1.5 21 1.1  0.2
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Table 2 - Comorbidity (continued)
 
 
all patients  <75  ≥75   
N %  N %  N %  p*
neurologic diseases (ICD10-6) 414 11.3 138 7.9 276 14.3  <0.001
Parkinson’s disease 51 1.4 18 1.0 33 1.7  0.1
other neurologic diseases 366 10.0 120 6.9 246 12.8  <0.001
Cardiovascular diseases (ICD10-9) 1849 50.4 794 45.4 1055 54.8  <0.001
myocardial infarction 245 6.7 95 5.4 150 7.8  0.004
heart failure 190 5.2 37 2.1 153 7.9  <0.001
valve problems 159 4.3 52 3.0 107 5.6  <0.001
arrhythmia 426 11.6 137 7.8 289 15.0  <0.001
conduction disorder 60 1.6 13 0.7 47 2.4  <0.001
peripheral arterial occlusive disease 86 2.3 34 1.9 52 2.7  0.2
deep venous thrombosis 110 3.0 46 2.6 64 3.3  0.2
stroke 284 7.7 86 4.9 198 10.3  <0.001
hypertension 1177 32.1 561 32.1 616 32.0  0.9
other venous diseases 17 0.5 8 0.5 9 0.5  1.0
other cardiovascular diseases 79 2.2 33 1.9 46 2.4  0.6
Respiratory diseases (ICD10-10) 392 10.7 184 10.5 208 10.8  0.8
asthma 49 1.3 28 1.6 21 1.1  0.2
COPD 328 8.9 149 8.5 179 9.3  0.4
other respiratory diseases 23 0.6 11 0.6 12 0.6  1.0
Digestive diseases (ICD10-11) 469 12.8 194 11.1 275 14.3  0.004
ulcerative disease 142 3.9 50 2.9 92 4.8  0.003
diverticulosis 178 4.8 75 4.3 103 5.4  0.1
other digestive diseases 171 4.7 76 4.4 95 4.9  0.4
Musculoskeletal diseases (ICD10-13) 849 23.1 325 18.6 524 27.2  <0.001
arthrosis 564 15.4 206 11.8 358 18.6  <0.001
Sjogren’s disease 6 0.2 3 0.2 3 0.2  1.0
rheumatoid arthritis 126 3.4 60 3.4 66 3.4  1.0
osteoporosis 175 4.8 65 3.7 110 5.7  0.005
other musculoskeletal diseases 101 2.8 44 2.5 57 3.0  0.4
other diseases 306 8.3 133 7.6 173 9.0  0.1
blood/immune disease (ICD10-3) 37 1.0 20 1.1 17 0.9  0.5
ear/mastoid disease (ICD10-8) 18 0.5 9 0.5 9 0.5  1.0
genitourinary disease (ICD10-14) 226 6.2 95 5.4 131 6.8  0.06
other diseases not otherwise specified 
(ICD10-18) 30 0.8 13 0.7 17 0.9
 0.7
*P for difference between age categories (Chi-square test). **unpaired T-test
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DIsCUssIon
The main finding of our present study is that comorbidity in older breast cancer 
patients has a major impact on all-cause mortality. This association is most pro-
nounced among patients aged <75 years, but is also present in patients aged 75 
years or older. Regarding breast cancer specific outcome, the risk to be diagnosed 
with distant breast cancer metastases decreases with an increasing number of 
comorbidities among patients aged ≥75, whereas comorbidity in patients <75 years 
is associated with a higher incidence of distant recurrences.
Several previous studies have shown that both younger and older breast cancer 
patients with comorbidity have increased all-cause mortality.14-16 With the knowl-
edge that there is a significant increase in the number and severity of comorbidities 
with increasing age7,9,16, several studies reported on age-specific effects of comor-
bidity on outcome of older breast cancer patients.7,14,17-24 But those results were not 
consistent across studies.
In the present study we found that although the presence and number of comor-
bidity is predictive for mortality irrespective of age, the impact of comorbidity on 
overall mortality  decreases among the oldest old, although total mortality rates 
are almost three times higher in this oldest age group. A recent large population-
based study performed in the US showed that the presence of comorbid condi-
tions among older breast cancer patients is substantially associated with more 
all-cause mortality. Moreover, they showed that the impact of the investigated 
specific comorbidities decreased with increasing age.14 Hence, our findings are 
fully consistent with these previous results, showing that the majority of specific 
comorbidities did not have a significant impact on all-cause mortality among the 
patients  aged ≥75.14 This finding indicates that there is an additional role of age 
(or age related factors) in the life expectancy, irrespective of the number or type 
of comorbidity. Probably, this can be explained by other factors that are associ-
ated with ageing, such as decreased physiologic reserves, functional status and 
cognition. The combination of these factors makes a patient more vulnerable to 
institutionalization and mortality.25
A remarkable outcome of our study that supports our hypothesis about the vul-
nerability of the oldest breast cancer patients, is the impact of psychiatric comorbid-
ity on all-cause mortality. This probably reflects the effect of cognitive disorders, 
that are usually included in tools used in measuring frailty scores.26 Unlike other 
specific comorbidities, psychiatric comorbidity is associated with higher hazards 
of all-cause mortality in the oldest group compared to their younger counterparts. 
In previous studies, dementia was shown to be associated with an increased risk 
of all-cause mortality in breast cancer patients14,24,27-29, although the higher impact 
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among the oldest old found in our study was not previously described. Addition-
ally, psychiatric diseases were associated with a lower risk on distant recurrences 
among the patients aged ≥75 in our study. This finding might reflect underreport-
ing of recurrent disease in the oldest and most vulnerable patients rather than a 
true decrease in the incidence of distant recurrences. A recent study by Hamaker 
et al., showed that a substantial part of elderly care physicians working in nursing 
homes, do not refer patients with suspected (recurrent) breast cancer. The most 
important reason (accounting for 57% of all non-referrals) was end-stage dementia. 
By non-referral the patients will remain unregistered and will not be included in 
the cancer registry.30 Nonetheless, our finding warrants further exploration. 
In addition, we showed that an increasing number of comorbidities is associated 
with a lower risk on distant recurrences among patients aged ≥75, irrespective of 
tumor or treatment factors. To our knowledge, there are no previous studies as-
sessing age-specific impact of comorbidity on breast cancer recurrence risk. The 
few studies assessing the impact of comorbidity on cancer-specific outcome use 
combined outcome measures like disease free survival or progression free survival, 
endpoints that in addition to recurrent disease, also include all-cause mortality in 
the endpoint.31 This results in worse outcomes for patients with more comorbidity, 
but for the oldest patients, this is probably due to a higher risk on mortality and not 
on cancer recurrence. However, in the patients aged <75, after adjusting for breast 
cancer treatment, we found an increasing trend for distant recurrence incidence 
with an increasing number of comorbidities. 
To our knowledge, the FOCUS cohort is the largest available cohort comprising 
detailed information about almost 3,700 older breast cancer patients. Additionally, 
the registration of all specific comorbidities, instead of the use of a comorbidity 
index or a predefined selection of specific comorbidities is a major strength of this 
paper. The volume of the cohort and the detailed registration of comorbidities 
makes this a robust analysis. A limitation of our study is the retrospective design, 
which only allowed us to assess qualitative comorbidity diagnoses and their 
predictive value on outcome. Future prospective studies should also assess other 
age-related factors that can influence patient related outcomes such as functional 
status and cognition. Furthermore, future prospective studies are needed in order 
to register the severity and treatment of comorbidity, and to study interactions of 
breast cancer itself and the cancer treatment with (the treatment of) comorbidity.
In conclusion, in our present study we showed an important negative impact of 
an increasing number of comorbid diseases and several specific comorbidities on 
the overall survival of older breast cancer patients, that cannot be explained by 
worse breast cancer specific outcome. However, the relative impact of the number 
of comorbidities on survival decreases with increasing age, indicating that clini-
Impact of comorbidity on outcome of older breast cancer patients: a FOCUS cohort study 81
cians should be aware of other factors that influence prognosis when treating older 
breast cancer patients.
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absTRaCT
background. In developed countries, 40% of breast cancer patients is older than 65 
years of age at diagnosis, of whom 16% additionally suffer from diabetes. The aim 
of this study was to assess the impact of diabetes on relapse free period and overall 
mortality in elderly breast cancer patients. 
Patients and Methods. Patients were selected from the retrospective FOCUS co-
hort, which contains detailed information of elderly breast cancer patients. Relapse 
free period was calculated using Fine & Gray competing risk regression models 
for patients with diabetes versus patients without diabetes. Overall survival was 
calculated by Cox regression models, in which patients were divided into four 
groups: no comorbidity, diabetes only, diabetes and other comorbidity or other 
comorbidity without diabetes. 
Results. Overall, 3,124 patients with non-metastasized breast cancer were includ-
ed. Relapse free period was better for patients with diabetes compared to patients 
without diabetes (multivariable HR 0.77, 95% CI 0.59-1.01), irrespective of other 
comorbidity and most evident in patients aged 75 years and older (HR 0.67, 95% 
CI 0.45-0.98).  In overall survival analyses, patients with diabetes only had a similar 
outcomes patients without comorbidity (HR 0.86, 95% CI 0.55-1.33), while patients 
with diabetes and other comorbidity had the worst overall survival (HR 1.70, 95% 
CI 1.44-2.01). 
Conclusion. When taking competing mortality into account, relapse free period 
was better in elderly breast cancer patients with diabetes compared to patients 
without diabetes. Moreover, patients with diabetes without other comorbidity had 
a similar overall survival as patients without any comorbidity.   Possibly, unfavour-
able effects of (complications of) diabetes on overall survival are counterbalanced 
by beneficial effects of metformin on the occurrence of breast cancer recurrences. 
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InTRoDUCTIon
With the aging of Western Societies, elderly will account for an increasing percent-
age of breast cancer patients in developed countries.1 High age is predictive for 
comorbidity and decreased functioning2,3 both associated with decreased overall 
survival in elderly breast cancer patients.4 The incidence of diabetes is increasing 
worldwide. Importantly, diabetes mellitus type 2 has been shown to increase breast 
cancer risk in postmenopausal women.5 High levels of insulin may have a direct 
effect on breast tissue, or indirect effects through increase in sex steroids due to 
inhibition of sex hormone-binding globulin (SHBG), disruption of adipokines and 
increased insulin-like growth factor-I (IGF-I) production.6 Additionally, diabetes is 
associated with obesity and excess body weight is related to increased cancer risk 
in postmenopausal women.7 
At present, up to 16% of elderly breast cancer patients additionally suffer from 
diabetes.8 In several cohort studies, it has been shown that diabetes increases 
both overall and cancer-specific mortality in the general population and in cancer 
patients.9-12 Also, the presence of diabetes and its complications can influence the 
allocation of treatment, leading to possible negative effects on patient outcome.8 
Furthermore, diabetes may accentuate side-effects and complications of chemo-
therapy.8 Few studies have studied diabetes in combination with other comorbid 
diseases on the prognosis of elderly breast cancer patients, even though the inci-
dence of both diabetes mellitus type 2 and breast cancer increases with age. 
The aim of this study was to assess the impact of diabetes on relapse free period, 
and the impact of diabetes in combination with other comorbidities on overall 
survival in elderly breast cancer patients. 
MaTeRIals anD MeThoDs
Patients
Patients were selected from the FOCUS cohort study (Female breast cancer in the 
elderly; Optimizing Clinical guidelines USing clinico-pathologocial & molecular 
data). The FOCUS-database contains information of all consecutive female patients 
aged 65 years and older with invasive and in situ breast cancer who were diagnosed 
between 1997 and 2004 in the South-West part of the Netherlands. Trained person-
nel reviewed the medical charts of these patients between 2009 and 2011, and col-
lected information on treatment characteristics, specific treatments, comorbidity, 
adverse events, geriatric parameters and recurrences. Follow-up on survival status 
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was available until January 1st 2011 through linkage of cancer registry data with 
municipal population registries. 
Comorbidity was registered according to the ICD-10 classification, and analysed 
in  subgroups. Respectively, endocrine diseases (ICD10-4), psychiatric disorders 
(ICD10-5), neurologic diseases (ICD10-6), cardiovascular diseases (ICD10-9), re-
spiratory diseases (ICD10-10), digestive diseases (ICD10-11) and musculoskeletal 
diseases (ICD10-13) were used for analyses. Due to a low incidence in the studied 
population, diseases of the blood/immune diseases (ICD10-3), ear and mastoid 
(ICD10-8), the genitourinary system (ICD10-14) and other symptomatic diseases 
(ICD-10-18) were grouped together in one category “other”. The remaining disease 
groups in the ICD10 were not considered of importance and were not registered. 
Additionally, a category was created for patients who had no comorbid disease 
registered at the time of breast cancer diagnosis.
Recurrences were defined as any first registered relapse of breast cancer, this 
could either be a local recurrence (in the ipsilateral breast), regional recurrence (in 
the ipsilateral axilla or supraclavicular) or distant recurrence.  
For this study, patients with in situ and stage I-III breast cancer who were treated 
with any breast surgery were selected. Stage was described using the pathologi-
cal tumor-node-metastasis (TNM) classification, as valid in the year of diagnosis. 
Receptor positive disease was defined as either estrogen receptor positive disease, 
progesterone receptor positive disease, or both. Adequate locoregional treatment 
was defined as breast conserving surgery followed by radiotherapy or mastectomy, 
both followed by any axillary surgery.13
statistical analyses
All analyses were performed in IBM SPSS Statistics version 20.0 and STATA SE 
12.0. 
The primary outcome measure was relapse free period (RFP), defined as time of 
diagnosis to any first locoregional or distant recurrence. Uni- and multivariable 
competing risk regression analyses according to the method of Fine & Gray were 
performed for RFP, taking the risk of competing mortality into account. Under 
the assumption that additional comorbidity next to diabetes does not affect breast 
cancer relapse risk, patients with diabetes were compared to patients without 
diabetes. Multivariable analyses were adjusted for clinically relevant patient (age), 
tumour, (stage, grade, histological subtype, hormone receptor) and treatment 
characteristics (breast and axillary surgery, radiotherapy, endocrine therapy and 
chemotherapy). We also adjusted for the number of comorbidities next to diabetes 
to assure negligibility of other comorbidity than diabetes.
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Secondary outcome was overall survival, defined as the time of diagnosis to 
death of any cause. Because additional comorbidity next to diabetes is assumed 
to play a major role in overall prognosis, patients were analysed in 4 groups no 
comorbidity, diabetes only, diabetes and other comorbidity, and other comorbid-
ity without diabetes, and overall survival was compared between groups by the 
Log rank test and uni- and multivariable Cox regression models (adjusted for the 
same factors as RFP analyses).
Patient and tumour characteristics, even as the provision of adequate locore-
gional treatment, endocrine therapy and chemotherapy, were compared between 
the groups using Chi-square tests. 
In case of missing data, patients were not excluded from the analyses, except for 
patients with missing stage in multivariable models. Missing data were analysed 
as separate groups in the analyses. Additionally, stratified sensitivity analyses 
were performed in two age groups, based on the median age of the cohort.
ResUlTs
Patient characteristics
Overall, 3,124 patients were included. Median age was 74.6 years (range 65.0-98.3). 
Of all patients, 505 (16.2%) were diagnosed with diabetes mellitus, of whom 444 
patients (87.9%) also had other comorbidity (Table 1). Tumour stage, histological 
grade, morphology and hormone receptor status did not significantly differ be-
tween groups. Patients with other and additional comorbidity besides diabetes 
were generally older than patients without comorbidity or diabetes only (P<0.001). 
In the groups with other or additional comorbidity, patients with diabetes also had 
more endocrine diseases (obesity) and neurologic diseases (TIA), but the largest 
difference was observed in the coexistence of cardiovascular diseases; 85.6% of pa-
tients with diabetes and other comorbidity suffered from additional cardiovascular 
diseases, compared to 67% in the group with other comorbidity without diabetes 
(P<0.001).
Treatment
Similar proportions of adequate locoregional treatment, endocrine therapy and 
chemotherapy were allocated to the four groups (P=0.7, P=0.1 and P=0.9, respec-
tively; Supplementary Table 1). 
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Table 1. Patient and tumour characteristics
  















  N % N % N % N %  
Age (years)
<74,6 472 60,1 37 60,7 199 44,8 853 46,5
<0.001≥74,6 314 39,9 24 39,3 245 55,2 980 53,5
           
Stage
0 52 6,6 2 3,3 27 6,1 117 6,4
0,202
I 272 34,6 20 32,8 131 29,5 635 34,6
II 347 44,1 28 45,9 219 49,3 836 45,6
III 75 9,5 9 14,8 56 12,6 177 9,7
 Missing 40 5,1 2 3,3 11 2,5 68 3,7  
           
Grade
1 104 13,2 7 11,5 57 12,8 253 13,8
0,637
2 220 28,0 23 37,7 146 32,9 571 31,2
3 203 25,8 12 19,7 108 24,3 426 23,2
missing 259 33,0 19 31,1 133 30,0 583 31,8
           
Morphology
ductal 567 72,1 46 75,4 337 75,9 1366 74,5
0,128lobular 108 13,7 4 6,6 40 9,0 192 10,5
other 111 14,1 11 18,0 67 15,1 275 15,0
           
HR status
ER/PR- 135 17,2 12 19,7 52 11,7 289 15,8
0,084ER/PR+ 510 64,9 44 72,1 306 68,9 1203 65,6
Missing 141 17,9 5 8,2 86 19,4 341 18,6




Endocrine diseases*    127 28,6 364 19,9 <0.001**
Psychiatric diseases    48 10,8 235 12,8 0.3**
Neurologic disesaes    88 19,8 253 13,8 0.002**
Cardiovascular diseases    380 85,6 1228 67,0 <0.001**
Respiratory diseases    57 12,8 280 15,3 0.2**
Digestive diseases    88 19,8 327 17,8 0.3**
Muscoloskeletal diseases  145 32,7 605 33,0 0.9**
Other     55 12,4 208 11,3 0.6**
*excluding diabetes          
** Patients without additional comorbidity were excluded for this analysis 
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Relapse free period
Median follow-up time for RFP was 6.0 years. Overall, 474 patients developed a 
recurrence during the total follow up, 66 (13.1%) among patients with diabetes, 
408 (15.6%) among patients without diabetes (Table 2). Multivariable hazard ratio 
(HR) was 0.77 (95% confidence interval (CI) 0.59-1.01) for patients with diabetes 
compared to patients without diabetes. This effect was even stronger in patients 
in the oldest age group (HR 0.67, 95% CI 0.45-0.98). The cumulative incidence of 
recurrences and competing mortality for patients with and without diabetes in 
different age groups are shown in Figure 1.
Table 2. RFP analyses, stratified for age
 Recurrences  Competing Mortality   95% CI   
 N (%)  N (%)  HR Lower Upper  P
all patients          
Fine and Gray          
No diabetes 408 (15.6)  916 (35.0)  1 (ref)     
Diabetes 66 (13.1)  227 (45.0)  0.82 0.63 1.07  0.14
Fine and Gray-adjusteda          
No diabetes 408 (15.6)  916 (35.0)  1 (ref)     
Diabetes 66 (13.1)  227 (45.0)  0.77 0.59 1.01  0.06
          
age < 74,6 (years)          
Fine and Gray          
No diabetes 194 (14.6)  233 (17.6)  1 (ref)     
Diabetes 34 (14.4)  68 (28.8)  0.96 0.67 1.37  0.8
Fine and Gray-adjusteda          
No diabetes 194 (14.6)  233 (17.6)  1 (ref)     
Diabetes 34 (14.4)  68 (28.8)  0.88 0.61 1.27  0.5
          
age ≥ 74,6 (years)          
Fine and Gray          
No diabetes 214 (16.5)  683 (52.8)  1 (ref)     
Diabetes 32 (11.9)  159 (59.1)  0.71 0.49 1.03  0.07
Fine and Gray-adjusteda          
No diabetes 214 (16.5)  683 (52.8)  1 (ref)     
Diabetes 32 (11.9)  159 (59.1)  0.67 0.45 0.98  0.04
aAdjusted for age, stage, grade, histology, hormone receptor, breast and axillary surgery, radio-
therapy, endocrine therapy, chemotherapy, number of comorbidities excluding diabetes
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overall survival
Median follow-up time was 7.3 years (interquartile range (IQR) 4.2-9.7). In log rank 
analyses, there was a significant overall survival difference between the four groups 
(P<0.001), patients without comorbidity or diabetes only had the most favourable 
prognosis (Figure 2). This effect was even more evident in patients in the oldest age 
group (Supplementary Figure 1a and 1b). In uni- and multivariable Cox regression 
analysis, patients with diabetes only had a similar overall survival compared to 
patients without comorbidity (multivariable HR 0.85, 95% CI 0.55-1.33). Contrary, 
patients with diabetes and other comorbidity (HR 1.70, 95% CI 1.44-2.01), and pa-
tients without diabetes but with other comorbidity (HR 1.37, 95% CI 1.20-1.56) had 


































Cumulative incidence of recurrences and competing events
no event recurrence death without recurrence
HR 0.88 (95% CI 0.61-1.27)            HR 0.67 (95% CI 0.45-0.98)
- HRs for diabetics compared to non-diabetics
- adjusted for age, stage, grade, histology, hormone receptor, breast and axillary surgery,    
radiotherapy, endocrine therapy, chemotherapy, number of comorbidities excluding diabetes
figure 1. Cumulative incidence of recurrences and competing mortality.
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DIsCUssIon
The main finding of our study is that elderly breast cancer patients with diabetes, 
irrespective of other comorbidity, had a better relapse free period than patients 
without diabetes. In addition, overall survival of elderly breast cancer patients 
with diabetes without other comorbidity was similar to overall survival in patients 
without comorbidity. These differences were most evident in patients aged 75 
years and older.
In contrast to our present study, a recently published review and meta-analysis 
about diabetes mellitus and breast cancer outcomes concluded that patients with 
diabetes and breast cancer had a greater risk of all-cause mortality compared to 
patients without diabetes.14 In addition, a large cohort study in the US general 
population showed a multivariable adjusted relative risk of death of 1.90 (95% CI 
1.87-1.93) among breast cancer patients with diabetes, compared to their counter-
parts without diabetes.9 However, none of the reported studies investigated the 
effect of diabetes on mortality in combination with other comorbidities. Based on 
the literature, we expected to find a worse prognosis for all patients with diabetes 
in our study as well. By separating the patients with diabetes only, we discovered 
a novelty in the breast cancer and diabetes research field. 
 
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figure 2. Overall survival.
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In elderly breast cancer patients, the risk of death due to causes other than cancer 
is high, and this increases with age.15 Obviously, patients with multiple comorbid-
ity are at higher risk of competing death than patients without comorbidity.4,16 
In our study, the majority of patients with diabetes and other comorbidity suf-
fered from additional cardiovascular disease, most likely as a coexisting disease 
caused by shared risk factors, or as a diabetic complication.  We found that overall 
mortality of this group was higher than patients suffering from comorbidity 
without diabetes, independent of the type of comorbidity. This suggests that the 
additional comorbidity in patients with diabetes has a larger impact on survival 
than in patients with the same comorbidity without diabetes. Since patients with 
the worst overall survival are more likely to die before experiencing a breast cancer 
recurrence, it is very important to take this risk into account when studying breast 
cancer outcomes in this population. Therefore, we used Fine & Gray competing 
risk analysis to analyse the relapse free period.17
Interestingly, our data suggest that patients with diabetes in our cohort are at 
lower risk to develop a breast cancer relapse. The relation between diabetes and 
RFP appeared to be even stronger in the oldest patients in the cohort. Unfortu-
nately, we were not able to compare these findings with previous studies, since the 
association between diabetes and recurrence risk has not been described before.
How is it possible that patients with diabetes had a better relapse free period 
than patients without diabetes (when taking competing mortality into account)? 
A possible explanation might be the frequent use of metformin in patients with 
diabetes.  In the Dutch diabetes guidelines, metformin is the primary advised drug 
treatment in type 2 diabetes.18 Consequently, we can assume that the majority of 
patients with diabetes used metformin. Previous observational studies showed 
that the daily use of metformin in cancer patients is related to a survival benefit10 
and a higher pathologic complete response after neoadjuvant chemotherapy.19
The mechanism behind these findings has been thoroughly debated. Metformin, 
an insulin sensitizer from the family of the biguanides is widely used in the treat-
ment of diabetes but potentially also has modulator effects on the enhancement 
of cell cycle arrest, induced apoptosis, reduced growth factor signalling, the 
inflammatory response and on sex-steroid production.20-22 The suggested positive 
effect of metformin on the clinical course of breast cancer could be through its 
insulin-independent stimulation of the adenosine monophosphate-activated pro-
tein kinase (AMPK) and the subsequent inhibition of the mTOR pathway.22 In most 
cancer entities, increased mTOR signalling is associated with malignant tumour 
progression and resistance to chemotherapy. Inhibition of the mTOR pathway 
has a cellular growth inhibitory effect resulting in inhibited pathologic cell cycle 
progression, cell growth and angiogenesis.22 Currently, a large multicentre ran-
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domized placebo-controlled trial in Canada is recruiting early stage breast cancer 
patients to assess the impact of the addition of metformin to standard therapy on 
disease-free survival; results are expected not earlier than 2016.23 Unfortunately, 
this trial has an upper age limit of 74 years, which means that the findings cannot be 
extrapolated to the oldest patients. Especially in the elderly breast cancer patient, 
metformin might be a good adjuvant therapy, since our study showed that relapse 
free survival was best in the eldest breast cancer patients with  diabetes. Addition-
ally, metformin is relatively well-tolerated and new treatment strategies for the 
elderly population are highly desired. Therefore, we propose that future studies 
should focus on the benefit of metformin in the elderly breast cancer population.
strengths and limitations
To our knowledge, this is the largest and most detailed cohort of elderly breast 
cancer patients. Elderly patients are rarely included in clinical trials because of 
age restrictions, comorbidity or poor physical function.24 Therefore, observational 
studies can be considered an appropriate alternative for studying patient outcome 
in this patient group, since data are not conflicted by selective inclusion in clinical 
trials, and studies generally contain more patients.25 
However, there are some limitations in our study. First, medication was not reg-
istered. Therefore, our hypothesis about the effect of metformin on breast cancer 
outcome could not be confirmed. Second, one could state that the absence of data 
about causes of death in the cohort is a limitation. However, patients with non-
metastasized breast cancer who are primary surgically treated are unlikely to die 
of breast cancer without developing distant metastases. Additionally, causes of 
death extracted from death certificates of cancer patients have been shown not al-
ways to be accurate and can be overestimated.26,27 This issue is of large importance 
in elderly patients, as the risk of competing mortality strongly increases with age28, 
which can lead to an even larger overestimation of breast cancer mortality in elderly 
when death certificates are used. Therefore, in our opinion relapse free period is 
a more reliable breast cancer specific endpoint than breast cancer specific survival 
in elderly breast cancer patients. A possible drawback of relapse free period is that 
it does not include breast cancer therapy related deaths due to cancer therapies.
In conclusion, this study shows that diabetes in itself does not lead to a worse 
overall survival in elderly breast cancer patients. Diabetes might even lead to a 
lower relapse risk, especially in the oldest elderly, possibly through the effect of 
the use of metformin. Future studies should evaluate the effect of new adjuvant 
therapies such as metformin especially in elderly breast cancer patients, in order to 
improve the treatment for this vulnerable patient group.
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webfigure 1a. Overall survival, patients aged <74.6 years.
     












       

















webfigure 1b. Overall survival, patients aged ≥74.6 years.
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background. It has been suggested that the use of non-cancer drugs may improve 
breast cancer specific prognosis. Due to the low risk of toxicity, this may be espe-
cially of interest for older patients who potentially cannot tolerate all conventional 
systemic therapies. The objective of the current analysis was to assess the impact of 
three commonly used non-cancer medications on breast cancer prognosis of women 
participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) study.
Patients and Methods. Patients were selected from the TEAM study, enrolling 
postmenopausal, hormone receptor positive, early breast cancer patients. The 
primary endpoint was distant metastasis free period (DMFP).  Secondary endpoint 
was breast cancer specific survival (BCSS). Medications of interest comprised met-
formin, statins and beta blockers. These co-medications were incorporated in Cox 
regression analyses as time-varying covariates. All analyses were repeated in three 
age strata (<65, 65-74 and ≥ 75 years).
Results. Overall, 8,137 patients were included. Among them, 470 (5.8%) patients 
used metformin, 1,361 (16.7%) a statin, and 1,481 (18.2%) a beta blocker during the 
study period. No significantly beneficial effect of either of the three co-medications 
on DMFP was observed. Among the youngest patients, statin use was associated 
with a small but significantly better DMFP (HR 0.64, 95% CI 0.45-0.91). Regarding 
BCSS, there was a significant benefit for statin (HR 0.80, 95% CI 0.66-0.98) and beta 
blocker users (HR 0.80, 95% CI 0.67-0.96). No significant effect was observed for 
metformin users. No effect of age was observed.
Conclusion. In postmenopausal breast cancer patients, we found no significant 
impact of the use of metformin, statins and/or beta blockers on DMFP. A small but 
significant association was observed between the use of statins and beta blockers 
and better BCSS.
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InTRoDUCTIon
In recent years, interest about the potential anti-cancer effect of commonly used 
drugs that are not primarily registered as anti-cancer medication has been increas-
ing due to reports from  several studies suggesting a beneficial effect of different 
non-cancer medications on cancer prognosis. However, the results of studies 
hereon for breast cancer are scarce and inconsistent. The most described non-cancer 
medications in association with breast cancer (BC) prognosis include metformin, 
statins, beta blockers, and aspirin and other non-steroidal anti-inflammatory drugs 
(NSAIDs).1
Breast cancer patients with type 2 diabetes using metformin were observed to 
have an improved overall survival compared to patients using other or no anti-
diabetic medications.1 Also, for older breast cancer patients with diabetes, without 
other comorbidities, a lower risk of breast cancer recurrence has been reported.2 
Both observations are suggestive for an improved breast cancer prognosis in dia-
betic patients, potentially due to the use of metformin. It has been hypothesized 
that this possible beneficial effect may be caused by a combination of various 
potential anti-cancer mechanisms. Metformin inhibits cancer cell growth by the 
activation of AMP activated protein kinase (AMPK), which results in reduced 
levels of insulin and insulin like growth factor 1 (IGF-1). Activation of AMPK also 
results in blockage of the mammalian target of rapamycin (mTOR) pathway, which 
has shown to be an important player in tumor growth of most common human 
cancers. Furthermore, metformin can suppress HER-2 protein expression. Also, 
metformin lowers levels of VEGF, which inhibits angiogenesis, and  it can induce 
apoptosis and block cell cycle arrest via reduced cyclin D1 expression3. All these 
mechanisms potentially impact tumor growth.
The use of statins has similarly been associated with an improved cancer-specific 
survival in several types of cancer. This effect is possibly due to the lower availabil-
ity of free cholesterol, which can lead to a decreased proliferation and migration of 
cancer cells.4 Previous studies demonstrated that statins induce apoptosis, but also 
reduce cell invasiveness in various tumor types, including breast cancer.5
Regarding aspirin or NSAIDs, it is thought that these drugs may improve cancer 
survival due to the inhibition of prostaglandins and cyclooxygenase (COX-1 and 
COX-2). Herewith, NSAIDs can inhibit tumor growth and decrease invasiveness 
of cancer cells. Through blockage of COX-2, which has shown to be increased in 
patients with metastatic breast cancer, aspirin can reduce the risk of metastases.1,6 
Finally, a small number of observational studies indicate a positive effect of beta 
blockers on the breast cancer specific prognosis, potentially due to the blockage 
of the beta-adrenergic receptor, which mediates the stress response by binding 
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catecholamines.1 A preclinical study in mice showed that chronic stress increased 
the risk of breast cancer metastases.7 
These types of medications (without relevant toxicity) and their potential 
anti-cancer effect are especially of interest for older cancer patients, as the risk of 
adverse events due to chemotherapy, which is an option for breast cancer therapy 
especially in some subtypes and in case of metastatic disease, strongly increases 
with age. Improving outcome as of diagnosis might be welcomed in the older 
patient group in order to avoid the necessity of chemotherapy. 
The international Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial 
provides a unique opportunity to study the effect of non-cancer medication on 
breast cancer prognosis, as the use of co-medication was well registered. Further-
more, a relatively large number of older patients were included, enabling to study 
this effect in older patients specifically. 
Hence, the objectives of this study were to assess the impact of commonly used 
non-cancer medications on breast cancer prognosis in terms of distant metastasis 
free period (DMFP) and breast cancer specific survival (BCSS) in a large cohort of 
postmenopausal women with hormone receptor positive early breast cancer, and 
stratified by age (<65, 65-75 and >75 years).
MeThoDs
Participants
The TEAM trial is an international randomized controlled trial in postmenopausal 
patients with hormone-receptor positive early breast cancer. A detailed descrip-
tion of inclusion criteria and the study design and results, has been previously 
published.8 In short, patients were randomized to 5 years of exemestane versus 
2,5 years of tamoxifen followed by 2,5 years of exemestane. Patients were assessed 
every 3 months during the first year of endocrine treatment and at least once every 
year in the years thereafter. Patients with a survival time of zero (or less), probably 
indicating withdrawal before the study started, were excluded from all analyses 
(N=9). For the current analyses, all participants of the original TEAM trial from 
countries that registered co-medications were included (all countries, except for 
Japan, Greece and France).
statistical analysis
Data from the original TEAM database were completed with co-medication data 
as was registered on the Case Report Forms (CRFs) at baseline and during follow-
up, including name, start- and end dates of drug use. The database was locked for 
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follow-up at July 14th, 2015. The primary endpoint of the current analyses was distant 
metastasis free period (DMFP), defined as the time from randomization to the diag-
nosis of distant metastasi(e)s. A secondary endpoint was breast cancer specific sur-
vival (BCSS), defined as the time from randomization to death due to breast cancer. 
Cumulative incidences of distant metastases and breast cancer specific deaths 
were calculated for patients using metformin, statins and/or beta blockers (users), 
respectively, and compared to non-users. Both DMFP and BCSS were analyzed 
using Cox regression analysis using the medicine of interest as a time dependent 
covariate, to take the actual time that patients were using the medicine of interest 
into account. For the time dependent analyses, only the medication use during the 
study follow-up period (since date of randomization) was taken into consideration. 
Patients who were non users throughout the whole study period, but started the 
medicine of interest after randomization, were split in two episodes: one for the 
period they were non-user, and one for the period they were user. We handled the 
co-medication data according to the ‘intention to treat’ principle. When a patient 
had started metformin, a statin or beta blocker, she was considered a user since the 
recorded start date until the end of the study period. The NSAIDs were not taken 
into account in the analyses, because, due to different indications (i.e. shorter pain 
medication prescriptions) for the use of NSAIDs, the intention to treat assumption 
does not hold for this medication group. 
Analyses were performed both univariable and multivariable. According to the 
method of Hernan, a list of possible confounders was assessed, including patient, 
tumor and treatment characteristics, which resulted in a multivariable model in-
cluding age at diagnosis only.9 The proportional hazards assumptions were tested 
using Schoenfeld residuals.
All survival analyses were additionally stratified by age at diagnosis (<65, 65-74 
and ≥75), similar to the age-group categorization previously used for other analy-
ses within the TEAM trial.10 
All analyses were performed using IBM SPSS Statistics 20.0, or STATA SE 12.0. 
All P values are two-sided and a P value <0.05 was considered as statistically sig-
nificant.
ResUlTs
Overall, 8,137 TEAM patients were included in our present study (Webfigure 1 – 
flowchart). Patients had a mean age of 64.6 years (Standard Deviation (SD) 9.1). 
Patient and tumor characteristics, and cancer treatment types are summarized in 
Table 1. 
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Table 1. Patient characteristics and treatment.
age in years (mean-SD) 64.6 9.1
  N %
Country of origin   
 Netherlands 2,752 33.8%
 Germany 1,467 18.0%
 UK/Ireland 1,275 15.7%
 US 2,230 27.4%
 Belgium/Luxembourg 413 5.1%
T stage   
 Tis 4 0.0%
 T1 4,585 56.3%
 T2 3,124 38.4%
 T3 288 3.5%
 T4 120 1.5%
 TX 16 0.2%
n stage   
 N0 4,169 51.2%
 N1 3,529 43.4%
 N2 325 4.0%
 N3 88 1.1%
 NX 26 0.3%
histological grade   
 well 1,205 14.8%
 moderate 4,049 49.8%
 poor 2,126 26.1%
 Unknown 757 9.3%
Most extensive breast surgery   
 Mastectomy 3,910 48.1%
 Wide local excision 4,218 51.8%
 None 3 0.0%
 Unknown 6 0.1%
axillary dissection   
 No 1,232 15.1%
 Yes 5,436 66.8%
 Unknown 1,469 18.1%
Radiotherapy   
 No 2,793 34.3%
 Yes 5,262 64.7%
 Unknown 82 1.0%
endocrine therapy (randomisation scheme)
 Exemestane 4,082 50.2%
 Tamoxifen -> Exemestane 4,055 49.8%
Chemotherapy   
 No 5,237 64.4%
 Yes 2,900 35.6%
Total number of patients 8,137 100.0%
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Among all patients, 470 (5.8%) used metformin, 1,361 (16.7%) a statin, and 1,481 
(18.2%) a beta blocker during any point of the study follow-up period. For all three 
co-medications, the proportional hazard assumptions were not violated, accord-
ing to the Schoenfeld residuals (P=0.42, P=0.92 and P=0.96 for the multivariable 
analyses).
Median time to distant metastasi(e)s or end of study follow up was 6.1 years 
(interquartile range (IQR) 5.0-9.6). Among metformin users, 42 (8.9%) patients 
developed distant metastases during follow-up, as compared to 818 (12.7%) among 
non-users. Cox proportional hazard models did not show a statistically significant 
benefit for metformin users (adjusted Hazard Ratio (HR) (users/non-users) 0.77, 
95% Confidence Interval (CI) 0.57-1.05). Statin users had a lower proportion of dis-
tant metastases during follow-up than non-users (9.4% versus 13.1%), which was 
not statistically significant (adjusted HR 0.84, 95% CI 0.70-1.01). Among patients 
using a beta blocker, 165 (11.1%) developed distant metastasi(e)s, compared to 850 
(12.8%) in the non-user group, which was not statistically significant (HR 0.93, 95% 
CI 0.78-1.10) (Table 2).  
Table 2. Distant metastasis free period - Cox regression with time-varying covariate
 
N of events 
user group (%)













Metformin 42 (8.9) 973 (12.7) 0.78 0.57 1.06 0.77 0.57 1.05
Statin 128 (9.4) 887 (13.1) 0.86 0.71 1.04 0.84 0.70 1.01
Beta blocker 165 (11.1) 850 (12.8) 0.94 0.80 1.12 0.93 0.78 1.10
*reference category is patients not using the specific drug. **adjusted for age.
Age-stratified analyses yielded no significant benefit in terms of DMFP in all three 
age strata, except for statin users in the youngest age group (HR 0.64, 95% CI 0.45-
0.91) (Appendix A1-A3). 
For the analyses regarding BCSS, the median time to breast cancer death or end 
of follow up was 6.5 years (IQR 5.0-9.8). Among metformin users, statin and beta 
blocker users, 39 (8.3%), 117 (8.6%) and 136 (9.2%) patients, respectively, died due 
to breast cancer. Among non-users, this concerned 801 (10.5%), 723 (10.7%) and 
704 (10.6%) patients, respectively. Age-adjusted Cox models, with the medicine 
of interest as time varying covariate, showed a significant benefit for statin (HR 
0.80, 95% CI 0.66-0.98) and beta blocker users (HR 0.80, 95% CI 0.67-0.96). In con-
trast, there was no significant BCSS benefit for metformin users (HR 0.73, 95% CI 
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0.53-1.01) (Table 3). For the analyses regarding metformin and beta blockers, the 
proportional hazard assumption was not violated (Schoenfeld p=0.59 and 0.72). 
For the analysis regarding statins, there was a violation of the proportional hazard 
assumption (Schoenfeld P=0.04).
Table 3. Breast cancer specific survival - Cox regression with time-varying covariate
 
N of events 
user group 
(%)













Metformin 39 (8.3) 801 (10.5) 0.75 0.55 1.04 0.73 0.53 1.01
Statin 117 (8.6) 723 (10.7) 0.84 0.69 1.02 0.80 0.66 0.98
Beta blocker 136 (9.2) 704 (10.6) 0.83 0.69 1.00 0.80 0.67 0.96
*reference category is patients not using the specific drug. **adjusted for age.
Age-stratified analyses of BCSS yielded no significant benefit for any of the co-
medications in all three age strata (Appendix B1-B3). 
DIsCUssIon
The current analyses in postmenopausal hormone receptor positive early breast 
cancer patients, enrolled in the TEAM study, found less distant metastasi(e)s in 
metformin, statin or beta blocker users, although not statistically significant. How-
ever, we found a statistically significant association between the use of statins and 
beta blockers and an improved breast cancer specific survival. No differences were 
observed between age groups. 
Our results could not confirm the positive results of observational studies re-
porting a positive impact of metformin on breast cancer recurrence or BCSS,11,12 
although a trend toward a beneficial effect was observed. It should be noted that 
all positive studies on this topic analyzed metformin use as a time-fixed variable, 
based on the use of metformin at the time of diagnosis. It has been shown, how-
ever, that the use of co-medications in association with cancer prognosis always 
should be analyzed as a time-varying covariate, to avoid overestimation of the 
effect due to various biases.13 Therefore, we consider the results of our present 
analysis as more reliable. On the other hand, in view of the heterogeneity of breast 
cancer (different molecular subtypes) it is possible that the impact of metformin 
on cancer outcome might be different for the various subtypes, and prospectively 
planned sub analyses are warranted therefore. The impact of metformin on breast 
cancer prognosis is currently studied in a Canadian phase III randomized trial 
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of metformin vs. placebo in early stage non-diabetic breast cancer patients.14 This 
study is expected to close in 2017, and results are not to be expected before 2023, 
because the primary endpoint is invasive disease free survival at 6 years.
In our analyses, we found a trend for a positive effect of statins on the develop-
ment of distant metastases, but only in patients aged younger than 65 years. This 
may be due to the lower number of statin users and events in the older age group. 
Moreover, the significantly BCSS benefit we observed for statin users should be in-
terpreted with caution, because the proportional hazard assumption was violated. 
Still, our results are in line with the findings of two observational studies showing 
a positive impact of statins on breast cancer specific prognosis, also analyzing the 
medication data as time-varying covariate.15,16
With regards to the use of beta blockers, we found no impact on DMFP, but a 
significant BCSS benefit for users. This finding is partly in concordance with previ-
ous studies showing a beneficial impact on different breast cancer specific end-
points.17-19 It should be taken into account that, at least part of the previous studies 
reporting on the association between beta blockers and breast cancer prognosis, 
did not analyze the usage as a time-varying covariate17,18. Furthermore,  a number 
of recently published observational studies, including one very large (N=18.733) 
Danish population-based study, and a very recent study that pooled data from 
eight European countries, resulting in a sample size of 55.252 patients, did not 
show an association between the use of beta-blockers and BCSS.20-23 Considering 
these findings, combined with the data of our present study, it is questionable 
whether it is worthwhile to initiate a clinical trial on this issue.
We did not find a beneficial effect of either one of the medications in older pa-
tients specifically. This may be due to the lower number of events in these groups, 
since the risk estimates did not strongly differ between the three age-groups. 
strengths & limitations
A major strength of our study is that we used a very large cohort of postmeno-
pausal early BC patients enrolled in the TEAM study including patients from the 
U.S. and Europe, with robust and well-registered data. 
We chose distant metastasis free period as the primary endpoint of our current 
study to avoid that the endpoint might be contaminated with non-breast cancer 
specific events, as would be the case if we considered all-cause mortality. As sec-
ondary endpoint, we considered BCSS. This endpoint should be interpreted with 
caution, because it has been shown that the cause of death of breast cancer patients 
is often misclassified.24,25
Ideally, we would have preferred to adjust our analyses for comorbidity, as this 
can act as a possible confounder influencing both the determinant (co-medication 
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use) and the endpoint. However, data on comorbidity were not completely avail-
able for all countries. Most probably, additionally adjusting the data for comorbid-
ity would have nuanced the Hazard Ratio’s even more towards one.
Another limitation is that we only had one start date, and one stop date for a 
specific co-medication per patient available in the database. Therefore, we chose 
to use the recorded start date in our intention-to-treat analyses. This should not 
be a major problem regarding the co-medications which normally are prescribed 
for chronic conditions, which is the case for metformin, statins and/or beta block-
ers. However, several studies report about the association of NSAIDs and (breast) 
cancer prognosis, but due to unreliable data, we were not able to analyze the effect 
of NSAIDs in our study. NSAIDs are generally prescribed on an “as need” base for 
pain. We chose to not use the NSAIDs as intention-to-treat data. 
Although we were not able to use the full cohort of TEAM study participants 
(N=9,766), because of lack of data on co-medication from three countries, we were 
able to use the great majority of the patients (>80%) from six full countries. There-
fore, we consider the chance of inducing selection bias small.
Finally, we have previously shown that the TEAM trial comprises a selected 
population. It was shown that the trial included patients with fewer comorbidity, 
more favorable tumor characteristics and a better prognosis than the general popu-
lation of the same age, which limits external validity, especially in older patients.26
Conclusion
Among 8,137 patients from the TEAM study, we found no statistically significant 
impact of the use of metformin, statins and/or beta blockers on the development 
of distant metastasis, although all risk estimates were all below one. However, 
we did find a small but significant association between the use of statins and beta 
blockers, and breast cancer specific survival. No differences in age-groups were 
found. Eventually, the results of randomized clinical trials investigating these 
medications have to be awaited before to conclude on the real value of metformin, 
statins and beta blockers as adjuvant therapies for breast cancer.
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aPPenDIx
appendix a1. Distant metastasis free period - Cox regression with time-varying covariate. Age<65
 
N of events 
user group 
(%)













Metformin 17 (7.7) 525 (12.2) 0.72 0.44 1.16 0.81 0.61 1.09
Statin 50 (8.1) 492 (12.0) 0.81 0.60 1.08 0.64 0.45 0.91
Beta blocker 67 (10.1) 475 (12.0) 0.85 0.66 1.10 0.85 0.66 1.10
*reference category is patients not using the specific drug. **adjusted for age. 
appendix a2. Distant metastasis free period - Cox regression with time-varying covariate. Age 65-74
 
N of events 
user group 
(%)













Metformin 20 (10.8) 301 (12.5) 0.88 0.56 1.38 0.87 0.55 1.37
Statin 53 (10.2) 268 (12.4) 0.83 0.62 1.12 0.82 0.61 1.11
Beta blocker 61 (11.3) 260 (12.1) 0.93 0.70 1.23 0.91 0.69 1.21
*reference category is patients not using the specific drug. **adjusted for age.
appendix a3. Distant metastasis free period - Cox regression with time-varying covariate. Age ≥ 75
 
N of events 
in exposed 
group (%)













Metformin 5 (8.1) 147 (12.6) 0.62 0.26 1.52 0.61 0.25 1.48
Statin 25 (11.4) 127 (12.2) 0.84 0.52 1.35 0.96 0.62 1.46
Beta blocker 37 (13.5) 115 (11.6) 1.13 0.78 1.64 1.14 0.79 1.66
*reference category is patients not using the specific drug. **adjusted for age.
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appendix b1. Breast cancer specific survival - Cox regression with time-varying covariate. Age<65
 
N of events 
user group 
(%)













Metformin 16 (7.2) 407 (9.7) 0.74 0.45 1.21 0.74 0.45 1.22
Statin 45 (7.3) 378 (10.0) 0.79 0.58 1.08 0.80 0.58 1.09
Beta blocker 52 (7.8) 371 (9.9) 0.75 0.56 1.00 0.75 0.56 1.00
*reference category is patients not using the specific drug. **adjusted for age.
appendix b2. Breast cancer specific survival - Cox regression with time-varying covariate. Age 65-74
 
N of events 
user group 
(%)













Metformin 18 (9.7) 250 (10.7) 0.81 0.50 1.30 0.80 0.50 1.29
Statin 44 (8.5) 224 (11.2) 0.73 0.53 1.01 0.72 0.52 1.00
Beta blocker 50 (9.2) 218 (11.0) 0.80 0.58 1.08 0.78 0.57 1.06
*reference category is patients not using the specific drug. **adjusted for age.
appendix b3. Breast cancer specific survival - Cox regression with time-varying covariate. Age ≥ 75
 
N of events 
user group 
(%)













Metformin 5 (8.1) 144 (12.6) 0.58 0.23 1.41 0.57 0.23 1.39
Statin 28 (12.8) 121 (28) 1.03 0.68 1.55 1.02 0.68 1.54
Beta blocker 34 (12.4) 115 (12.3) 0.94 0.64 1.38 0.95 0.65 1.39
*reference category is patients not using the specific drug. **adjusted for age.
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absTRaCT
background. Inclusion in trials is selective and thus results may not be generaliz-
able to the general population. The aim of this study was to investigate the external 
validity of randomized clinical trial outcomes for elderly breast cancer patients.
Methods. We compared characteristics and outcome of breast cancer patients (n 
= 1325) who participated in a randomized clinical trial (Tamoxifen Exemestane 
Adjuvant Multinational trial) with unselected breast cancer patients of correspond-
ing age from the general population (n = 1056). Dutch patients aged ≥65 years at 
diagnosis of hormone-receptor positive breast cancer without distant metastases, 
with either nodal involvement, a tumor >3cm, or a 1-3cm histological grade III 
tumor, who completed local therapy were included. Analyses were stratified by 
age (65-75; ≥75 years). Primary outcome was overall mortality. Multivariable Cox 
proportional hazards models were used to assess the association between covari-
ates and overall mortality.  All statistical tests were two-sided.
Results. Irrespective of age, patients who participated in the trial had fewer co-
morbid diseases, a higher socio-economic status, and smaller tumors (all p-values 
<0.001). In patients aged 65-75 years, those who participated in the trial had a 
similar overall mortality to patients from the general population (multivariable 
hazard ratio (HR) = 1.08 (95%CI 0.73-1.60)). Alternatively, in patients aged ≥75y, 
those who participated in the trial had a lower overall mortality (multivariable HR 
= 0.72 (95%CI 0.55-0.95)) than patients in the general population.  
Conclusion. Breast cancer trial participants aged ≥75 years do not represent elderly 
breast cancer patients of corresponding age from the general population, which 
hampers the external validity of a trial. 
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InTRoDUCTIon
In developed countries, over 40% of all newly diagnosed breast cancer patients are 
65 years or older.1,2 Different factors may play a role in the evaluation of breast cancer 
treatment in elderly as compared to younger patients. Elderly patients suffer from 
a higher risk of competing mortality3 and have a lower remaining life expectancy. 
Consequently, the absolute benefit of anticancer therapy may be smaller, while 
long term adverse events may be less relevant. Moreover, concurrent disease and 
medication use may directly affect tolerability of treatment and increase toxicity.4,5 
Therefore, it is important to evaluate treatment efficacy and outcomes specifically 
in elderly patients and not to extrapolate results obtained in younger patients.
Despite comprising a large proportion of all breast cancer patients, the elderly 
are frequently underrepresented in clinical trials.6-8 This underrepresentation 
might not be problematic. As long as the included elderly are representative of the 
general population of elderly breast cancer patients, age specific subgroup analyses 
can be extrapolated. However, inclusion of elderly patients is likely to be selective.7 
The aim of the current study was to evaluate characteristics and outcomes of 
elderly breast cancer patients included in a large trial without upper age limit com-
pared with breast cancer patients of corresponding age from the general population. 
MeThoDs
We included elderly patients who participated in a clinical trial, and elderly breast 
cancer patients from the general population. To ensure a valid comparison, similar 
inclusion criteria with regards to tumor and treatment characteristics were applied 
to all patients. 
Patients who participated in a trial
Patients who participated in the Tamoxifen Exemestane Adjuvant Multinational 
trial9,10 were eligible for inclusion in the current study. Because five-year results of 
the TEAM trial showed no statistically significant differences in efficacy endpoints 
between the two treatment arms9, we were able to conduct the current study re-
gardless of randomized treatment. Between January 2001 and January  2006, 9,766 
postmenopausal women with hormone-receptor positive breast cancer without 
distant metastases, who completed local therapy with curative intent, were ran-
domized to either exemestane for 5 years or to a sequential regimen consisting 
of tamoxifen followed by exemestane for a total of 5 years. Inclusion for patients 
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in The Netherlands was restricted to those who either had nodal involvement, a 
tumor >3cm, or a histological grade III tumor of 1-3cm.10 
Patients from the general population
From the Netherlands Cancer Registry we identified all incident breast cancer 
patients aged 65 years or older, who were diagnosed in the geographically defined 
Comprehensive Cancer Center Region West in The Netherlands between January 
1997 and December 2004. By means of chart review by trained personnel, additional 
information on patient characteristics, tumor characteristics, treatment, follow-up 
and outcome were recorded.11 
Inclusion criteria
For a proper comparison between patients who participate in a trial and patients 
from the general population, similar inclusion criteria were applied to all patients. 
Hence, we restricted inclusion of patients who participated in a trial to patients 
from The Netherlands, who were 65 years and older at diagnosis. Likewise, the 
inclusion criteria that were used in the trial were applied to patients from the gen-
eral population; those who had hormone-receptor positive disease without distant 
metastases, and either one of the following; a tumor size >3cm, a histological grade 
III tumor of 1-3cm, or nodal involvement, were eligible. In addition, they had to 
have received breast surgery with curative intent.  
In all patients, pre-specified forms including free text fields were used for data 
collection. Comorbidity was defined as presence of comorbidity at time of diag-
nosis. Comorbid diseases were categorized into presence or absence of the main 
categories included in the 10th edition of the International Statistical Classification 
of Diseases and Related Health Problems (ICD-10), namely endocrine, nutritional 
and metabolic diseases (chapter IV); mental and behavioural disorders (chapter 
V); diseases of the nervous system (chapter VI); diseases of the circulatory system 
(chapter IX); diseases of the respiratory system (chapter X); diseases of the diges-
tive system (chapter XI); and diseases of the musculoskeletal and connective tissue 
(chapter XIII).12 In addition, comorbid diseases were categorized by number (0-1; 
2-4; 5 or more comorbid diseases). Socio-economic status (SES) was assigned using 
an area-based measure according to place of residence at the time of diagnosis. The 
area-based SES was provided by the Netherlands Institute for Social Research, and 
is based on data concerning income, employment, and education.13 In the current 
study, SES was categorized in tertiles (low, intermediate and high SES respectively). 
For the patients included in the TEAM trial, appropriate approvals from the ethical 
committee were obtained. All patients provided written informed consent. 
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statistical analyses
Statistical analyses were performed using SPSS 20.0 (SPSS, Chicago, IL) and Stata 
SE 12.0 (StataCorp LP, College station, TX). In line with previous publications 
and in line with SIOG recommendations14,15, the analyses were stratified by age at 
diagnosis (65-75 years; 75 years or older). To compare proportional differences in 
patient, tumor and treatment characteristics between patients who participated in 
a trial and patients from the general population, the Pearson χ2 test was used.  
Primary outcome was overall mortality, defined as death from any cause. Vital 
status was established either directly from the patient’s medical record or through 
linkage with the municipal population registries (follow-up until January 1st 2011). 
Follow-up was truncated at five years to accommodate differences in total follow-
up duration. Cumulative incidence of death was estimated by 1 — Ŝ(t) where Ŝ(t) 
is the Kaplan–Meier estimator for the probability of survival at time (t), based on 
the life tables.16 Corresponding 95% confidence intervals were calculated as the cu-
mulative incidence at t(x) ± 1.96 * standard error. Cox proportional hazard models 
were used to evaluate the association between covariates and overall mortality. 
For both age groups, the proportional hazard assumption was evaluated by the 
link test (p=0.45; p=0.89 respectively) and based on the analysis of the Schoenfeld 
residuals17 (p=0.20; p=0.75 respectively). 
As breast cancer mortality contributes to overall mortality, disparities in breast 
cancer outcome may affect the primary endpoint. Therefore we evaluated distant 
breast cancer recurrence as secondary endpoint, which was defined as recurrence 
in skeleton, skin, liver, lung, brain, or other distant localization. We focused on 
distant recurrence because cause of death is more difficult to attribute to a certain 
cause with increasing age18,19, and distant recurrence is a valid proxy for death due 
to breast cancer.20 Detection method of a breast cancer recurrence was similar for all 
patients. Cause-specific outcomes may be influenced by the risk of competing end-
points; for example, an individual who dies is no longer at risk for a distant breast 
cancer recurrence. This risk of competing endpoints may be particularly present 
in older populations.3 Therefore, distant breast cancer recurrence was estimated 
by regression analyses according to Fine and Gray.21,22 A Fine and Gray analysis 
is used to assess the risk of a distant breast cancer recurrence while taking into 
account the risks of reaching other, competing endpoints. Competing endpoints 
were a locoregional recurrence (recurrence in the ipsilateral breast or chest wall, 
ipsilateral axillary or supraclavicular lymph node(s)), contralateral breast cancer, 
and death due to any cause. 
Covariates were included in the multivariable model if they were judged to 
be clinically relevant, regardless of statistical significance. The fully adjusted 
multivariable model included tumor characteristics (histological grade [Bloom 
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Richardson grade I, II, III, unknown], T stage [T1/T2, T3/T4, unknown], nodal stage 
[negative, positive, unknown]), treatment characteristics (most extensive surgery 
[breast conserving surgery, mastectomy], radiotherapy [yes, no, unknown], 
endocrine therapy [yes, no], and chemotherapy [yes, no, unknown]), and patient 
characteristics (age [continuous], year of diagnosis [continuous], socio-economic 
status [in tertiles, unknown], and number of comorbidities [0-1, 2-4, ≥5]). Sensitiv-
ity analyses were performed excluding missing values.  All statistical tests were 
two-sided; p values <.05 were considered to be statistically significant.
ResUlTs
Overall, we included 1,325 breast cancer patients who participated in a trial, and 
1,056 unselected breast cancer patients from the general population. Mean age of 
patients who participated in a trial was 73.5 years, (standard deviation (SD) 5.7 
years), versus 76.7 years (SD 7.1 years) in patients from the general population 
(p<0.001). First, we investigated whether the phenotype of patients who par-
ticipated in a clinical trial differs from the phenotype of patients from the general 
population (Table 1). In both age groups, patients who participated in a trial had 
Table 1. Patient and tumor characteristics of elderly breast cancer patients who participated in a trial, 
as compared to those of elderly breast cancer patients from the general population.
Age 65-75 years Age ≥75 years
















n % N % n % n %
Socio-economic status (tertiles) <0.001 <0.001
1 (lowest) 200 23.5 205 43.9 108 22.8 250 42.4
2 177 20.8 96 20.6 106 22.4 122 20.7
3 419 49.2 165 35.3 238 50.3 217 36.8
Unknown 56 6.6 1 0.2 21 4.4 0 0
Number of comorbidities <0.001 <0.001
0-1 655 76.9 273 58.5 306 64.7 262 44.5
2-4 193 22.7 171 36.6 165 34.9 263 44.7
≥5 4 0.5 23 4.9 2 0.4 64 10.9
Presence of comorbidity
Endocrine 178 20.9 130 27.8 0.005 105 22.2 188 31.9 <0.001
Psychiatric 4 0.5 41 8.8 <0.001 7 1.5 72 12.5 <0.001
Neurological 31 3.6 38 8.1 <0.001 38 8.0 79 13.4 <0.001
Circulatory 334 39.2 225 48.2 0.002 220 46.5 334 39.2 <0.001
Respiratory 54 6.3 48 10.3 0.013 30 6.3 67 11.4 0.005
Gastro-intestinal 24 2.8 54 11.6 <0.001 16 3.4 83 14.1 <0.001
Musculoskeletal 104 12.2 86 18.4 0.002 100 21.1 167 28.4 0.008
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fewer comorbid diseases and more often had a high socio-economic status. More-
over, patients who participated in a trial had smaller tumors (all p <.001). 
Second, we investigated whether treatment of patients who participated in a 
clinical trial differs from treatment of patients from the general population (Table 
2). Needless to say, all patients who participated in the trial received endocrine 
therapy, whereas in both age groups 82% of patients from the general population 
received endocrine therapy, despite having hormone receptor-positive disease and 
an indication for endocrine therapy. In patients aged 75 years or older, patients 
who participated in a trial more often had breast conserving surgery as the most 
extended type of breast surgery (p<.001). 
Table 2. Treatment characteristics of elderly breast cancer patients who participated in a trial, as 
compared to elderly breast cancer patients from the general population.















n % n % n % n %
Most extended 
surgery 0.164 <0.001
BCS 383 45.0 191 40.9 114 24.1 75 12.7
Mastectomy 469 55.0 276 59.1 359 75.9 514 87.3
Radiotherapy 0.446 0.052
Yes 500 58.7 288 61.7 211 44.6 227 38.5
No 351 41.2 179 38.3 262 55.4 362 61.5
Unknown 1 0.1 0 0 0 0 0 0
Endocrine therapy <0.001 <0.001
Yes 852 100 384 82.2 473 100 480 81.5
No 0 0 83 17.8 0 0 109 18.5
Chemotherapy 0.054 <0.001
Yes 63 7.4 52 11.1 0 0 19 3.2
No 788 92.5 415 88.9 473 100 570 98.6
Unknown 1 0.1 0 0 0 0 0 0
BCS: breast conserving surgery.  To test for statistical differences in proportions, the Pearson χ2 
test was used.  All statistical tests were two-sided; p values <.05 were considered to be statistically 
significant.
Figure 1A and B show the unadjusted cumulative incidence of death for patients 
who participated in a trial and for patients from the general population, by age at 
diagnosis. In patients aged 65-75 years, five year cumulative incidence of death 
was 14% (95%CI 9-16) for patients who participated in a trial and 19% (95%CI 
16-23) for patients from the general population. For patients aged 75 years or older, 
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five years cumulative incidence of death was 28% (95%CI 23-32) and 48% (95%CI 
44-52), respectively. 
figure 1.  Univariate and multivariable cumulative incidence of death in elderly patients who 
participated in the TeaM trial compared with those in the general population. 
a.  Unadjusted cumulative incidence of death of elderly breast cancer patients aged 65-75 years who 
participated in a trial, as compared to elderly breast cancer patient from the general population. 
Cumulative incidence of death was estimated by 1 — Ŝ(t) where Ŝ(t) is the Kaplan–Meier estima-
tor for the probability of survival at time (t), based on the life tables.
b.  Unadjusted cumulative incidence of death of elderly breast cancer patients aged 75 years or older 
who participated in a trial, as compared to elderly breast cancer patient from the general popula-
tion. Cumulative incidence of death was estimated by 1 — Ŝ(t) where Ŝ(t) is the Kaplan–Meier 
estimator for the probability of survival at time (t), based on the life tables.
C.  Adjusted cumulative incidence of death of elderly breast cancer patients aged 65-75 years partici-
pated in a trial, as compared to elderly breast cancer patient from the general population, based 
on multivariable Cox regression analysis.   
D.  Adjusted cumulative incidence of death of elderly breast cancer patients aged 75 years or older 
who participated in a trial, as compared to elderly breast cancer patient from the general popula-
tion, based on multivariable Cox regression analysis.  All statistical tests were two-sided.   TEAM 
= Tamoxifen Exemestane Adjuvant Multinational trial. 
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Overall mortality of patients aged 65-75 years was lower for patients who par-
ticipated in a trial (univariate HR 0.65 (95%CI 0.50-0.86)). To explore whether this 
difference in mortality could be explained by unequal distributions in patient, 
tumor and treatment characteristics, multivariable analyses were performed. The 
fully adjusted model (Table 3), showed that after adjustment for tumor, treatment 
and patient characteristics, the hazard ratio attenuated towards 1 (HR 1.08 (95%CI 
0.73-1.60)).  The adjusted cumulative incidence of death is depicted in Figure 1C.
Table 3. Overall mortality for elderly breast cancer patients who participated in a trial, as compared 
to elderly patients from the general population, fully adjusted model.
Patients and 








HR (95% CI) p 
Patients 0.693 0.019
General population 91 1 (reference) 281 1 (reference)
Trial participants 110 1.08 (0.73-1.60) 124 0.72 (0.55-0.95)
Socio-economic status 0.935 0.102
Low 58 1 (reference) 112 1 (reference)
Intermediate 65 0.97 (0.65-1.43) 124 1.03 (0.78-1.36)
High 69 0.90 (0.65-1.43) 162 1.27 (1.01-1.60)
Missing 9 0.87 (0.42-1.80) 7 1.74 (0.80-3.82)
Number of comorbidities 0.010 0.122
0-1 121 1 (reference) 199 1 (reference)
2-4 75 1.58 (1.18-2.11) 171 1.13 (0.92-1.40)
≥5 5 1.18 (0.47-2.93) 35 1.46 (1.00-2.12)
Histological grade (BR) <0.001 0.007
Grade 1 18 1 (reference) 50 1 (reference)
Grade 2 55 0.97 (0.57-1.65) 126 0.90 (0.65-1.26)
Grade 3 92 2.19 (1.30-3.69) 143 1.32 (0.95-1.84)
Unknown 36 1.81 (0.99-3.31) 86 0.89 (0.61-1.29)
T stage 0.656 0.002
T1, T2 169 1 (reference) 313 1 (reference)
T3, T4 31 1.22 (0.80-1.87) 91 1.56 (1.22-2.00)
Unknown - Too low numbers 1 0.70 (0.10-5.09)
Nodal stage 0.007 0.058
Negative 44 1 (reference) 112 1 (reference)
Positive 156 1.82 (1.26-2.63) 288 1.32 (1.05-1.66)
Unknown - Too low numbers 5 1.25 (0.50-3.16)
Most extensive surgery 0.001 0.518
BCS 58 1 (reference) 49 1 (reference)
Mastectomy 143 2.03 (1.35-3.04) 356 1.12 (0.80-1.57)
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Patients aged 75 years or older who participated in a trial also had a lower 
overall mortality as compared to patients of corresponding age from the general 
population (univariate HR 0.49 (95%CI 0.39-0.60)). These differences could not be 
explained by unequal distributions in patient, tumor and treatment characteristics; 
multivariable analysis consistently showed a lower overall mortality (HR = 0.72; 
95%CI = 0.55-0.95; p = .019). The adjusted cumulative incidence of death is depicted 
in Figure 1D.
To explore whether differences in overall mortality could be explained by differ-
ences in breast cancer outcome, we evaluated the risk of a distant recurrence (Table 
4). Irrespective of age, multivariable analyses did not reveal any differences. Of 
note, in both age groups, the absolute number of patients who developed a distant 
recurrence was exceeded by the number of patients who died. Among patients 
aged 75 years or older, the number of patients who died during 5 years of follow 
up was 124 for trial participants and 281 for the general population. Alternatively, 
the number of patients who developed a distant recurrence was 54 and 74, respec-
tively, for the two groups. These data confirm that in those aged 75 years or older, 
the observed difference in overall mortality between patients who participated in 
Table 3. Overall mortality for elderly breast cancer patients who participated in a trial, as compared 
to elderly patients from the general population, fully adjusted model. (continued)
Patients and 








HR (95% CI) p 
Radiotherapy 0.448 0.333
Yes 115 1 (reference) 148 1 (reference)
No 86 1.27 (0.88-1.84) 257 0.89 (0.70-1.13)
Unknown - Too low numbers - NA
Endocrine therapy 0.048 0.232
Yes 182 1 (reference) 347 1 (reference)
No 19 0.59 (0.35-1.00) 58 0.83 (0.61-1.13)
Chemotherapy 0.568 0.993
Yes 22 1 (reference) 10 1 (reference)
No 179 1.15 (0.71-1.88) 395 1.00 (0.52-1.91)
Unknown - Too low numbers - NA
* Hazard ratios adjusted for all other covariates mentioned in the Table, and age (continuous) and 
year of diagnosis (continuous). BR: Bloom Richardson; BCS: breast conserving surgery. Cox pro-
portional hazard models were used to evaluate the association between covariates and overall 
mortality. All statistical tests were two-sided; p values <.05 were considered to be statistically sig-
nificant.
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a trial and patients from the general population is likely to resemble a non-breast 
cancer driven difference in overall fitness.
Table 4.   Risk of distant breast cancer recurrence for elderly breast cancer patients who participated 
















65-75 years 0.05 0.514
General population 
(n=467) 
61 59 1 (reference) 1 (reference)
Trial participants (n=852) 84 62 0.72 (0.52-1.00) 1.17 (0.73-1.87)
≥75 years 0.447 0.277
General population 
(n=589)
74 228 1 (reference) 1 (reference)
Trial participants (n=473) 54 95 0.87 (0.66-1.24) 1.33 (0.79-2.34)
HR: Hazard ratio. * Competing events comprise intercurrent death; locoregional recurrence as first 
site of recurrence; contralateral breast cancer. 
† Multivariable HRs were adjusted for histological grade, T stage, nodal stage, most extensive 
surgery, radiotherapy, endocrine therapy, chemotherapy, socio-economic status, comorbidity, age, 
year of diagnosis. Fine and Gray regression models were used to evaluate the association between 
covariates and distant breast cancer recurrence. All statistical tests were two-sided; p values <.05 
were considered to be statistically significant.
DIsCUssIon
To warrant the internal validity of a clinical trial, inclusion of patients into a 
trial is often selective, though this may compromise the external validity of the 
trial.23 Indeed we showed that patients who participated in a clinical trial had 
more favourable patient and tumor characteristics as compared to patients from 
the general population. In patients aged 65-75 years, those who participated in 
the trial had a similar overall mortality as patients from the general population 
after adjustment. Thus, selective inclusion can be overcome by taking into account 
patient, tumor and treatment characteristics. Selection of patients into a trial may 
be more pronounced with increasing age, given the larger heterogeneity of pa-
tients with increasing age. This hypothesis was confirmed in the current study; 
we showed that in patients aged 75 years or older, differences in overall mortality 
could not be explained by patient, tumor and treatment characteristics. Therefore 
other, unmeasured mechanisms may have played a role in the selection of elderly 
patients into a trial. 
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A selective inclusion of patients into a trial is multifactorial. First, eligibility cri-
teria may hamper inclusion of elderly patients in general and inclusion of certain 
elderly in particular. Patients were ineligible for the TEAM trial if they had a ma-
lignancy within 5 years preceding breast cancer diagnosis, an Eastern Cooperative 
Oncology Group performance status of >2, substantial cardiac disease, or other 
illness interfering with study participation and follow-up.10 Others have published 
about the impact of eligibility criteria on the inclusion in trials.24 Of all clinical tri-
als published in 2008 in five major medical journals, 20% excluded patients based 
on age.7 In the remaining trials, almost half of the studies excluded patients with 
age-related diseases, which could disproportionally impact inclusion of certain 
elderly patients. Next to eligibility criteria hampering inclusion of elderly patients, 
physician factors25-27, patient factors25, and factors related to trial logistics may af-
fect participation.25. From a patient point of view, age has not been shown to be a 
statistically significant predictor as to whether a patient would participate, once 
they have been offered a trial.26,28 
To summarize, the lower overall mortality of patients aged 75 years or older who 
participated in a trial may be the result of selective inclusion of patients into a trial. 
As was shown, those who participated in a trial had, among other characteristics, 
fewer comorbid diseases. Additionally, participation in a trial in itself may result 
in lower overall mortality. One may argue that more attention is being paid to 
treatment of comorbid disease of elderly patients who participate in a trial, as com-
pared to those from the general population, which may decrease overall mortality. 
Others have published on the external validity of clinical trials.23 The novelty of 
the current study is that we were able to perform a head-to-head comparison of 
patients participating in a clinical trial and patients from the general population. 
This way we could pinpoint that external validity is compromised for patients 
aged 75 years or older in particular. Our study has some limitations. By applying 
identical inclusion criteria, we aimed to construct similar groups of patients. How-
ever, differences in design and data collection may have influenced our results, 
by misclassification of baseline characteristics and follow-up data. Although pre-
specified forms including free text fields were used for all patients, and baseline 
characteristics were reported extensively in the medical files of patients from the 
general population, we cannot exclude possible differences due to the prospective 
and retrospective nature of data collection. A strength of this study is that system-
atic misclassification of the primary endpoint of overall mortality is unlikely; vital 
status was established through linkage with the municipal population registries 
for all patients. Regarding the secondary endpoint, the method of detection of a 
breast cancer recurrence was similar for all patients. Of note, those who partici-
pated in the trial had strict follow-up schemes, whereas this may not always be 
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accomplished in general practice. Therefore, we cannot exclude the possibility of 
underdiagnosis of breast cancer recurrence among patients from the general popu-
lation. Regarding overall mortality, sample size was sufficient to detect a difference 
among patients aged 75 years or older. Among patients aged 65-75 years, given 
the confidence interval of the multivariable analysis (95%CI 0.73-1.60), we cannot 
exclude that those who participate in a trial do have a different overall mortality 
as compared to patients from the general population. Regarding the secondary 
endpoint, sample size may have been insufficient. However, it was also shown 
that the absolute number of patients who developed a distant recurrence was 
greatly exceeded by the absolute number of patients who died, especially in pa-
tients aged 75 years or older. Therefore, although the direct comparison of distant 
breast cancer recurrence between patients who participated in a trial and patients 
from the general population is possibly underpowered, the secondary endpoint 
does strengthen the main conclusion that the observed higher overall mortality in 
patients aged 75 years or older from the general population is likely to resemble a 
non-breast cancer driven difference in overall fitness.
Clinical implications
As compared with other randomized clinical trials, the TEAM trial had relatively 
few eligibility criteria, without an upper age limitation, enabling enrollment of 
many elderly patients.9 Therefore it is expected that the discrepancy between trial 
patients and patients from the general population will be present in other breast 
cancer trials including elderly patients. Investigators and clinicians may need to 
pay more attention to actively including a representative sample of patients aged 
75 years or older into clinical trials. 
Since treatment guidelines are mainly based on clinical trial results, the evidence 
base for treatment in patients aged 75 years or older may be limited. However, it 
is unlikely that clinical trials are sufficient to fill this ‘evidence gap’. Even in the 
absence of eligibility criteria it is expected that elderly included in a trial will be 
selected.26;27;29 Moreover, the large heterogeneity in the elderly population makes it 
difficult to conduct clinical trials including a representative sample of the general 
population; even with inclusion of large numbers, it remains a challenge to cre-
ate comparable study arms. Therefore different study designs may be warranted. 
Restriction in research topics, design, and analysis may give observational research 
the chance to be as credible as randomized evidence.30 Moreover, observational, 
population-based data reflect the heterogeneity of the general population. Among 
others, international comparisons of treatment strategies, using country as an 
instrumental variable, may increase insight in adequate treatment for different 
groups of elderly breast cancer patients.  
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ConClUsIons
Inclusion in a breast cancer trial is more selective with increasing age. Breast cancer 
patients aged 75 years or older who participate in a trial are not representative of 
breast cancer patients of corresponding age from the general population, which 
may hamper the external validity of a trial; breast cancer trial results may not nec-
essarily be extrapolated to the general breast cancer patient with corresponding 
age.
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absTRaCT
An important consideration in studies that use cause-specific endpoints such as 
cancer-specific survival or disease recurrence is that risk of dying from another 
cause before experiencing the event of interest is generally much higher in older 
patients. Such competing events are of major importance in the design and analysis 
of studies with older patients, as a patient who dies from another cause before 
the event of interest cannot reach the endpoint. In this Commentary, we present 
several clinical examples of research questions in a population-based cohort of 
older breast cancer patients with a high frequency of competing events and dis-
cuss implications of choosing models that deal with competing risks in different 
ways. We show that in populations with high frequency of competing events, it is 
important to consider which method is most appropriate to estimate cause-specific 
endpoints. We demonstrate that when calculating absolute cause-specific risks 
the Kaplan-Meier method overestimates risk of the event of interest and that the 
cumulative incidence competing risks (CICR) method, which takes competing 
risks into account, should be used instead. Two approaches are commonly used to 
model the association between prognostic factors and cause-specific survival: the 
Cox proportional hazards model and the Fine and Gray model. We discuss both 
models and show that in etiologic research the Cox Proportional Hazards model is 
recommended, while in predictive research the Fine and Gray model is often more 
appropriate. In conclusion, in studies with cause-specific endpoints in populations 
with a high frequency of competing events, researchers should carefully choose the 
most appropriate statistical method to prevent incorrect interpretation of results.
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InTRoDUCTIon
In order to study treatment efficacy or other outcomes in clinical research, large 
cohorts of patients are often followed during a certain period of time. Frequently, 
cause-specific endpoints are used in these  studies, such as recurrence, cancer-
specific mortality, or cardiovascular mortality.1 For these endpoints, statistical 
methods that assess the time to an event such as the Kaplan-Meier method or the 
Cox Proportional Hazards model are frequently used.2,3 
An important consideration in studies that use these cause-specific endpoints is 
that the risk of dying from a cause other than reaching the endpoint of interest is 
generally much higher in older patients than in younger patients.4,5 These so-called 
competing events are of major importance in the design and analyses of studies 
with older patients5 because a patient who dies from another cause can obviously 
not reach the endpoint of interest anymore. This topic is especially important in ge-
riatric oncology research as a large proportion of older cancer patients will die from 
non-cancer-related causes before reaching the endpoint of interest.5 For example, 
around 70% of breast cancer patients age 75 years or older who die do not die 
from breast cancer but from another cause.6  There are several statistical methods 
that are frequently used for time-to-event analyses such as the Cox Proportional 
Hazards Model and the Fine and Gray model. These methods deal with competing 
events in different ways.2 It is likely that the choice of model can strongly influence 
the interpretation of the outcome, especially in populations with a high frequency 
of competing events.3,4 Several studies have described the methodology of dealing 
with competing risks in detail, but these methodological papers may be difficult to 
interpret in clinical research. Therefore, the aim of this study is to present clinical 
examples of research questions in a population-based cohort of older breast cancer 
patients with a high frequency of competing events and to discuss the implications 
of choosing different methods for the interpretation of the results. In addition, 
this paper will give recommendations for choosing specific statistical methods for 
specific research questions.
TheoReTICal fRaMewoRk
First, we will provide some background information on methods that can be used 
to calculate absolute risks (ie, cumulative incidences), and models that can be used 
to model the effect of variables on the outcome.
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estimating absolute Risks
The Kaplan-Meier method is a commonly used method to estimate survival prob-
abilities over time. It can deal with censored follow-up times; ie, it can handle 
situations where the exact time of death is not known because patients drop out 
of the study or are still alive at the end of follow-up. One important assumption 
of the Kaplan-Meier method is independent censoring: at any time patients with 
censored survival times have the same survival prognosis as patients who are still 
in the study.7 Kaplan-Meier curves are often used to calculate survival probabilities 
for a specific cause of death. Patients who die of other causes are censored. Clearly, 
the assumption that censored patients have the same prognosis as those who are 
still followed is invalid because patients who die of other causes have a probability
of zero to reach the cause of interest. This means that estimated survival proba-
bilities of the Kaplan-Meier method are no longer correct. Hence, the Kaplan-Meier 
method does not estimate the actual survival probability but estimates what would 
have been observed if dying from other causes would not have been possible.
Alternatively, the Cumulative Incidence Competing Risks (CICR) method2,3 
assumes that patients who experienced a competing event are no longer at risk 
for the endpoint of interest.8 This approach estimates the actual probabilities of 
reaching different endpoints (cumulative incidences). At each time point, the sum 
of all the cumulative incidences will be equal to the total probability to reach an 
endpoint before that time. 
To illustrate the difference between the two methods, consider a very simple 
example in which three women with breast cancer are followed. One woman dies 
after one month of a myocardial infarct (MI), the second woman dies after two 
months of breast cancer, and the third woman is still alive after three months. 
The Kaplan-Meier method will estimate the probability to die of a MI within three 
months as 1/3. However, when considering death because of breast cancer, the 
Kaplan-Meier method treats the women who died in the first month of MI as 
censored after month 1, meaning that there are only two women at risk at month 
2. The risk of dying of breast cancer in month 2 is therefore estimated as being 
1/2. The three-month probability to die of breast cancer is then estimated as being 
1/2, the probability to die of MI as 1/3, and the probability to be alive after three 
months as only 1/6. This clearly shows that the Kaplan-Meier method yields incor-
rect results. The CICR method accounts for the woman with the competing event 
by adding her to the denominator of the probability to die of breast cancer. This 
yields a three-month probability to die of breast cancer of 1/3, the probability to die 
of MI is 1/3, and the probability to be alive is 1/3.
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hazard functions
There are different ways to assess the association between certain variables and the 
outcome with the possibility to adjust for confounding factors. The most commonly 
used methods are Cox proportional hazards models and Fine and Gray models. In 
order to understand the difference between these two models, we first have to 
introduce the concept of the hazard function. Roughly speaking, hazard functions 
are event rates that vary over time. An intuitive explanation of the hazard can 
be given in the situation when time is discrete. In this instance, the hazard at a 
certain time is the probability to die at that time point in those patients who are still 
alive.2 In absence of competing risk, there is a 1:1 mathematical relation between 
the hazard function and the survival function.
Cox Proportional hazards Model
The Cox proportional hazards model assesses the effects of variables on the hazard 
function. In the Cox proportional hazards model, hazard functions for different 
values of the prognostic variable are assumed to be proportional over time, and 
the parameters of the models can be interpreted as hazard ratios (HRs). In absence 
of competing risk, a hazard ratio above 1 implies smaller survival probabilities for 
the exposed group compared with the unexposed group. 
In a similar way, cause-specific hazard functions can be defined. Cause-specific 
hazards are similar to cause-specific mortality rates over small time periods. Ef-
fects of prognostic factors on cause-specific hazards can be assessed using the Cox 
proportional hazards model, where subjects who die of other causes are censored. 
However, a hazard ratio above 1 no longer implies that subjects with the risk factor 
are truly more likely to experience the specific event because subjects can die of 
other causes before they are able to reach this event. If the hazards for dying from 
other causes are much larger and the prognostic factor also affects these hazards, it 
could happen that actually fewer people reach the cause of interest. For example, 
smoking increases the hazard to develop dementia, but only few smokers will 
actually develop dementia because of the competing effects of death because of 
cancer or cardiovascular diseases. As a result, it could happen that actually fewer 
smokers than nonsmokers will experience dementia (ie, the cumulative incidence 
of dementia is lower in the smoking group), even though the cause-specific hazard 
ratio for the effect of smoking on dementia may actually be larger than 1. Assum-
ing that there is a biological relation between smoking and dementia, this relation 
can be found by the Cox regression model (ie, the HR is higher than 1 for smokers) 
while the cumulative incidence of dementia is in fact lower in smokers because of 
competing causes of death.
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fine and Gray Model
The Fine and Gray model9 links the effect of risk factors directly to the cause-specific 
cumulative incidences of death. In our smoking/dementia example, the Fine and 
Gray model considers the direct effect of smoking on the cumulative incidence 
of dementia (which was lower for smokers because of the competing risks). The 
effects of risk factors are expressed in subdistribution hazard ratios (SHR), where 
the subdistribution hazard function has a 1:1 relation with the cause-specific cu-
mulative distribution function. An intuitive interpretation of this SHR is difficult, 
but readers should be reminded that an SHR above 1 corresponds to higher cause-
specific event probabilities. In our dementia example, the Fine and Gray model will 
yield an SHR below 1 as it directly models the cumulative incidence of developing 
dementia in both subgroups, resulting in a lower risk of dementia for smokers. For 
a more detailed theoretical background of these models, we refer to Putter et al.3
ClInICal exaMPles
For the examples in this Commentary, we used data from the population-based 
Female breast cancer in the elderly; Optimizing Clinical guidelines USing clinico-
pathological & molecular data (FOCUS) cohort. This cohort comprises all incident 
breast cancer patients age 65 years or older who were diagnosed in the geographi-
cally defined Comprehensive Cancer Center Region West in the Netherlands 
between January 1997 and December 2004 (n = 3672). Trained personnel reviewed 
the charts of these patients and collected information on specific treatments, co-
morbidity according to the ICD-10 classification10, adverse events, recurrences, and 
geriatric parameters including polypharmacy, difficulties walking, poor vision and 
hearing, and living in a nursing home.11 
For the examples that are used below, only patients with nonmetastatic invasive 
breast cancer who received primary surgery were included. The endpoint of inter-
est was breast cancer recurrence, defined as any local recurrence (skin or in-breast), 
regional recurrence (axillary or supraclavicular lymph nodes), or distant metas-
tasis. The competing event was defined as death because of any cause without 
breast cancer recurrence. Censoring only occurred because of end of follow-up or 
emigration, the latter being very rare in our cohort. 
Overall, 2805 patients were included in the analyses. Patient and tumor char-
acteristics are briefly described in Table 1. Median follow-up time was 5.6 years, 
ranging from 0 to 14.2 years. Overall, 478 (17%) developed a breast cancer recur-
rence. The prevalence of competing events (death without recurrence) was 36% 
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(n = 1015). The risk of competing events increased with age, from 19% in patients 
younger than age 75 years to 54% in patients age 75 years or older.
Table 1. Patient and tumor charachteristic of patients in the FOCUS cohort
Characteristics  N (%)
Age, y   
65-74  1425 (50.8)
≥75  1380 (49.2)
Stage   
I  1058 (37.7)
II  1430 (51.0)
III  317 (11.3)
Grade   
1  385 (13.7)
2  906 (32.3)
3  670 (23.9)
Missing  844 (30.1)
Morphology   
Ductal  2074 (73.9)
Lobular  328 (11.7)
Mixed/other  403 (14.4)
Number of comorbid 
diseases   
0  694 (24.7)
1  656 (23.4)
2 or more  1455 (51.9)
   
Total  2805 (100)
example 1: Psychiatric Disorders in association with breast Cancer 
Recurrence
Recently, we assessed the association between concomitant disease and breast 
cancer recurrence11 as it has been suggested that concomitant diseases can interact 
with tumor growth and treatment.12 Hence, the research question that we aimed 
to study was of an etiological nature. One of the concomitant diseases that we 
assessed was psychiatric disorders, defined according to the ICD10-classification.10 
We will now discuss several models that can be used to study the association 
between psychiatric disease and breast cancer recurrence. For simplicity, we will 
present univariate analyses only.
Overall, 256 patients in the FOCUS cohort had a psychiatric disorder. Of all 
patients with a psychiatric disorder, 29 (11%) developed a breast cancer recur-
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rence during follow-up. Among the 2549 patients without psychiatric disorders, 
449 (18%) developed a recurrence. Among patients with psychiatric disorders, 150 
(59%) competing events occurred, as compared with 865 (34%) among patients 
without psychiatric disorders.
First, we assessed the association of psychiatric disease with breast cancer recur-
rence using the Kaplan-Meier method. The 10-year cumulative incidence of breast 
cancer recurrence as calculated by the Kaplan-Meier method in patients without 
a psychiatric disorder was 24%, compared with 18% among patients with a psy-
chiatric disorder (Table 2). Second, we used the CICR method to assess cumulative 
incidence of recurrence, which resulted in a 10-year cumulative incidence of recur-
rence of 20% and 12%, respectively, for patients without and with a psychiatric 
disorder. This shows that the Kaplan-Meier method overestimates the cumulative 
incidences.
As shown in Table 2, the hazard ratio for having a recurrence for patients with 
a psychiatric disorder was 0.78 (95% confidence interval [CI] = 0.53 to 1.13) com-
pared with patients without a psychiatric disorder, calculated by unadjusted Cox 
regression analysis. This implies that there is no statistical difference in the hazard 
on recurrences between patients with and without psychiatric disorders. The 
hazards were proportional over time (tested using Schoenfeld residuals, P = .27). 
Patients with a psychiatric disorder had a higher probability to die of any cause 
(HR = 1.6, 95% CI = 1.4 to 1.8, P < .001, compared with patients without psychiatric 
diseases). In Fine and Gray regression analysis, the SHR was 0.61 (95% CI = 0.42 to 
0.90) for patients with a psychiatric disorder, as compared with patients without 
psychiatric disorders. This implies that the probability of recurrence was estimated 
to be lower for patients with psychiatric disease when the Fine and Gray model 
was used compared with the Cox Regression Model. In this example, the Fine and 
Gray model, in contrast with the Cox model, even yielded a statistically significant 
result.
Table 2. 10-year cumulative incidence of recurrence for patients with and without psychiatric dis-
orders
       Cox regression  
Fine and Gray Competing 
risks regression
Psychiatric 
disorder  KM  CICR  HR (95% CI) P  SHR (95% CI) P
No   24%  20%  1 (referent)   1 (referent)  
Yes   18%  12%  0.78 (0.53 -1.13) 0.188  0.61 (0.42-0.90) 0.012
*CI = confidence interval; CICR = cumulative incidence competing risks; HR = Hazard ratio; KM = 
Kaplan Meier; SHR = subdistribution hazard ratio
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example 2: Prediction of breast Cancer Recurrence in older Patients
Currently, interest is in the prediction of the risk of breast cancer recurrence 
and breast cancer mortality in order to estimate which patients are at high risk 
and should receive additional treatments. Most currently available models were 
developed in generally young populations and were not validated in older popula-
tions.13 We recently showed that the online Adjuvant! program, which is widely 
implemented in daily clinical practice, does not accurately predict breast cancer 
recurrence in older patients.13  Therefore, one of the aims of the FOCUS study was 
to develop a new prediction tool that can be used to estimate breast cancer recur-
rence in older patients. Hence, for this study, we were interested in predictors of 
breast cancer recurrence and in calculating the absolute risk of recurrence.
Ten-year cumulative incidences of recurrence and competing events, calculated 
by the Kaplan-Meier method and the CICR function, are presented in Figure 1, A 
and B, respectively. As shown in Figure 1A, towards the end of follow-up the prob-
ability of dying without breast cancer recurrence and the cumulative incidence 
of recurrence as calculated by the Kaplan-Meier method added up to an estimate 
higher than the cumulative incidence of death or recurrence combined. In contrast, 
the sum of the estimates of mortality and recurrence was equal to the cumulative 
incidence of death or recurrence combined when the CICR method was used (Fig-
ure 1B). Clearly, the Kaplan-Meier method overestimated the cumulative incidence 
of recurrence and the cumulative incidence of competing events.
figure 1a. Cumulative incidences based on Kaplan-Meier estimates
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figure 1b. Cumulative incidences based on cumulative incidence competing risk estimates. 
In a recent review, it was shown that both tumor size and nodal status are the most 
incorporated variables in prediction models for breast cancer prognosis.13 There-
fore, for this example we assessed the predictive value of tumor stage according to 
the Tumor-Node-Metastasis (TNM) classification.15 In order to further demonstrate 
the impact of competing events, we stratified patients into two age groups: younger 
than age 75 years and age 75 years or older (Table 3). In both age groups, tumor 
stage was predictive for breast cancer recurrence, as can be expected. However, in 
patients younger than age 75 years, the prevalence of competing events was 19% 
during follow-up, which is much lower than in patients age 75 years or older, of 
whom 54% of all patients died without a recurrence. Among patients younger than 
age 75 years, the lower incidence of competing events, as compared with patients 
age 75 years or older, resulted in relatively small differences in outcomes between 
the Kaplan-Meier method and the CICR method, while in the patients age 75 years 
or older the Kaplan-Meier method more strongly overestimated the risk of recur-
rence. Cox Regression analyses resulted in a strongly increased risk of recurrence 
with increasing tumor stage (HR = 5.42, 95% CI = 4.08 to 7.21 for stage III vs stage I) 
(Table 3). Although the difference between the tumor stages remained statistically 
significant in the Fine and Gray analysis, the Fine and Gray analysis attenuated the 
effect estimates. For predictive research, we are interested in the direct effect on the 
cumulative incidence, and therefore Fine and Gray analyses provide more valid 
effect estimates. As shown in Table 3, the differences between estimates that are 
calculated in Cox Regression analyses and Fine and Gray analyses become larger 
when the frequency of competing events increases.
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Table 3. 10-year cumulative incidence of recurrence by stage
Stage  KM  CICR  HR* (95% CI)  SHR† (95% CI)
Overall         
Stage I  12%  10%  1 (referent)  1 (referent)
Stage II  28%  22%  2.72 (2.15-3.44)  2.43 (1.93-3.07)
Stage III  45%  33%  5.42 (4.08-7.21)  4.10 (3.08-5.46)
Patients age <75 y         
Stage I  12%  11%  1 (referent)  1 (referent)
Stage II  27%  24%  2.68 (1.98-3.63)  2.59 (1.91-3.50)
Stage III  55%  46%  6.62 (4.51-9.72)  5.72 (3.89-8.41)
Patients age ≥ 75 y         
Stage I  12%  9%  1 (referent)  1 (referent)
Stage II  29%  20%  2.56 (1.75-3.75)  2.32 (1.59-3.40)
Stage III  35%  26%  4.31 (2.77-6.71)  3.35 (2.15-5.23)
*Derived from univariate Cox regression analysis. †Derived from Fine and Gray analyses. CI = 
confidence interval; CICR = cumulative incidence competing risks; HR = hazard ratio; KM = Kaplan 
Meier; SHR = subdistribution hazard ratio.
DIsCUssIon
Our results show that in populations with a high frequency of competing events, 
it is important to consider which methods are the most appropriate to deal with 
cause-specific endpoints. The Kaplan-Meier method should never be used to esti-
mate cause-specific survival curves because it overestimates the absolute risk of 
the event of interest. The CICR method appropriately deals with competing risks. 
When assessing relative effect sizes in etiologic research, the Cox proportional 
hazards model is most appropriate. In contrast, to estimate effects on the absolute 
risk in predictive research, the Fine & Gray Model should be used in populations 
with a high frequency of competing events. 
The main strength of this Commentary is that the examples were performed us-
ing a real cohort of patients with a high prevalence of competing risk. By present-
ing the results of several methods in different research questions, we were able to 
demonstrate the effects of the choice of a certain method in different settings. Of 
course, this study also has its limitations. First, it must be noted that the recur-
rence rate that was registered in the cohort may have been underestimated as older 
patients may be less adherent to follow-up schemes. This may have influenced our 
analyses, especially if there was selective nonadherence to follow-up schemes. In 
addition, 10-year follow-up for recurrence was not complete for the whole cohort, 
but this mostly applied to the most recent years of the cohort, and it is unlikely that 
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this has influenced our results as it has been shown that outcome of older patients 
has not changed in recent years.16
With the results of our current study, we want to highlight the difference be-
tween etiological and predictive research questions in the comparison between the 
Cox proportional hazards model and the Fine and Gray model. In Example 1, the 
Fine and Gray model yielded rather strange results from an etiologic point of view 
as it suggests that psychiatric disorders are protective for recurrence. It is very 
unlikely that there is some biological mechanism in which psychiatric disorders 
are protective for breast cancer recurrence. More likely, our finding can be ex-
plained by the fact that the Fine and Gray analysis incorporates the competing risk 
of death, which influences the cumulative incidences of recurrence. This makes 
sense because patients with psychiatric disorders (especially dementia) have an 
increased risk of dying compared with patients without psychiatric disorders and 
patients who have died cannot get a breast cancer recurrence anymore. In contrast, 
the Cox regression model considers the effect on the cause-specific hazards, ie, on 
the instantaneous risk of recurrence for patients who are still at risk for the event at 
a certain time point, which is what interested us in this research question. 
Therefore, in etiologic research questions, the Cox regression model is often the 
most appropriate method. In contrast, for predictive studies, methods that incor-
porate competing events such as Fine and Gray competing risk regression are more 
appealing because they provide a single summary value for the association between 
a risk variable and the cumulative cause-specific risk. In this case, it is important 
to consider that patients with a large risk of experiencing a competing event are 
unlikely to develop a breast cancer recurrence. Note that in this Commentary we 
focused on the choice of the appropriate measures for the effect of risk factors on 
breast cancer recurrence. Estimates of absolute mortality probabilities for specific 
causes as functions of risk variables can be obtained from either of the two models. 
For the Cox model approach, this implies estimating the causespecific hazard ratios 
and using the Aalen-Johansen estimator to get the cumulative incidences, a direct 
extension of the CICR method, which can be carried out in, for example, the R 
packages mstate and survival3,17,18. A major advantage of this Cox model approach 
is that it ensures that the sum of the cause-specific cumulative incidence equals 
the total cumulative incidence of experiencing any of the endpoints. This is not 
guaranteed when calculating cumulative incidences using Fine and Gray models. 
Another statistical argument in favor of modeling the cause-specific hazards using 
Cox models is that the proportional hazard assumption is often not unreasonable 
and can straightforwardly be checked. The proportional sub distribution hazard 
assumption in the Fine and Gray model is unlikely to hold over longer time peri-
ods. Moreover, the proportional subdistribution hazard assumptions of the Fine 
Performing survival analyses in the presence of competing risks: a clinical example in older breast cancer patients 147
and Gray model will generally not hold for each of the different endpoints, and 
using Fine and Gray models to calculate absolute mortality probabilities could 
therefore yield impossible results .19,20  Hence, the Fine and Gray model does have 
some major limitations that should be taken into account.
These issues that we highlight are especially important for studies in older 
patients with indolent cancer types such as prostate cancer or hormone receptor–
positive breast cancer as the risk of competing mortality is generally large in these 
studies, especially in studies that require a long period of follow-up (eg, adjuvant 
studies). In addition, the issue of competing mortality should be considered in 
other populations with a large frequency of competing events as well, such as 
populations with many concomitant diseases or a limited performance status, 
even if these are not limited to older patients. In contrast, the issue of competing 
mortality does not play a major role in studies that investigate older populations 
with highly aggressive tumors such as pancreas cancer or lung cancer as the risk of 
dying from the cancer itself is high in these populations, such that cancer-specific 
mortality will be almost similar to overall survival. This also applies to studies in 
the metastatic setting as patients with metastatic disease have a large risk of dying 
from cancer and follow-up is generally short. 
In conclusion, in studies with cause-specific endpoints in populations with a 
high frequency of competing events, researchers should carefully choose the most 
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This thesis has three main conclusions:
1. There are large international differences in the treatment strategy of breast can-
cer among older women. These differences are not associated with a significant 
difference in prognosis.
2. The presence of comorbidity has an important impact on the general prognosis 
of older women with breast cancer. We did not show an important associa-
tion between specific comorbidities or the use of co-medications and the breast 
cancer specific prognosis.
3. Concerning older women with breast cancer for research, there are very im-
portant methodological issues to take into account, including to avoidance of 
selection bias and the proper methodologies to take in to account the chance of 
dying from another cause of cancer: the competing risk of mortality.
The foCUs sTUDy
A large part of this thesis is established using data from the FOCUS study. With the 
aim to develop guidelines for the treatment of older women with breast cancer, the 
FOCUS study was initiated in 2007: “Female breast cancer in the elderly: Optimiz-
ing Clinical guidelines USing clinico-pathological and molecular data”. The FOCUS 
database is the largest, most detailed population-based database of older women 
with breast cancer. Worldwide, no other database of this size included only older 
women, and gathered this detailed data about the patients, tumour characteristics, 
treatment and follow up. In addition to clinical data, tumour tissues of a very 
large part of the included patients, was collected. The database consists of 3,672 
consecutive breast cancer patients, aged 65 years or older at the time of diagnosis, 
diagnosed between 1997 and 2004 in the South West region of The Netherlands. In 
addition to the standard data included in the cancer registry, detailed information 
was gathered on the tumours’ treatment and the occurrence of a recurrence during 
follow-up. Also, patient-related information was registered, including comorbidity 
and social economic status. 
Within the FOCUS project,  also large datasets from (national) cancer registries 
were shared for research projects. In addition, data from the TEAM trial were used. 
The Tamoxifen Exemestane Adjuvant Multinational was a large multicentre phase 
III trial on endocrine therapy. This is one of the few trials without an upper age 
limit, which results in a relative large number of older participants.
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TReaTMenT of olDeR woMen wITh bReasT CanCeR
The FOCUS study group has been conducting a number of studies in the available 
observational data and the relevant literature was reviewed. Important to note is 
that, due to the observational nature of the data that were used, it was impossible to 
directly link the observed treatment strategies in our cohorts to survival outcomes. 
This is due to the likelihood of introducing bias due to confounding by indication. 
In observational studies, treatment allocation is not controlled. Therefore, there 
can be several other factors related to treatment allocation, which interfere with the 
prognosis of a patient. This is one of the most important reasons why observational 
data should be interpreted with caution, especially when the intention of the study 
is to answer a prognostic question. One of the suggested methodologies to study 
treatment effects in observational studies, is using an Instrumental Variable.1 This 
is a variable that is not directly related to the outcome, but which is related to the 
‘determinant’. In this thesis, two studies are included using country as an instru-
mental variable. 
In Chapter 2, a large population-based study is discussed, using data from 
cancer registries from five European countries and the US (SEER database). In this 
study, local treatment as provided to older women with early breast cancer was 
compared between the countries. Large international differences were observed in 
the provision of any surgery, the type of surgery (breast conserving or mastectomy) 
and radiotherapy after breast conserving surgery. Despite these large differences, 
a rough comparison of survival data, showed no large international differences in 
survival. Chapter 3 describes a follow-up study, in which all treatment modalities 
were assessed and compared between older women with breast cancer treated in 
Ireland and The Netherlands. This study also showed very large differences, in 
which the reluctance in local therapy seems to be compensated by providing more 
systemic (endocrine) therapy. Again, in this study, large treatment differences did 
not affect the outcome of the patients. These studies, in which treatment strategies 
are compared between countries, will be followed up by larger studies from the 
EURECCA group (EUropean REgistry of Cancer Care). In our opinion, these large 
population-based studies can provide us with a lot of knowledge. Especially for 
older patients, as stated before, there is a large gap in the literature, resulting in 
a lack of evidence for treatment. Probably, the answer to the questions that are 
still open for the treatment of older patients will not only come from randomized 
clinical trials, but also from observational studies, using proper methodology.
In Chapter 4, guideline adherence was shown to decline with increasing age at 
an international level. For this study, EUSOMA (European Society of Breast cancer 
specialists) provided their database, comprising data from 27 breast cancer units 
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across Europe associated to the society. In this study, the objective was to assess 
compliance to quality indicators, as defined by EUSOMA. The EUSOMA database 
consisted of 41.871 breast cancer patients across Europe. It was shown that among 
the oldest patients, aged 75 years and older, compliance to the indicators was sig-
nificantly lowest, as compared to the younger age groups, with a tendency to under 
treatment. Interestingly, patients from the youngest age category (<40 years), were 
also observed to have a low compliance to the quality indicators. However, in this 
age group, there was an intention to over treatment.
CoMoRbIDITy anD Co-MeDICaTIons
An important early finding from the FOCUS studies is that cancer-specific prog-
nosis of women with breast cancer declines with age, independent of tumour and 
treatment characteristics. This was studied both in the national cancer registry, 
as well as in the FOCUS cohort and the TEAM trial.2-5 One of the possible expla-
nations of the worse prognosis of older women with breast cancer is the impact 
of other diseases on prognosis, or the interaction of other diseases with breast 
cancer treatment. Therefore, in Chapter 5 of this thesis, the FOCUS database was 
used to study if the existence of comorbidity during diagnosis was associated 
with the breast cancer specific prognosis. It was demonstrated that the number 
of comorbidities, but also a number of specific diseases by itself were associated 
with a higher overall mortality, which we considered as an expected result. More 
interestingly, it was found that more comorbidity was associated with a higher 
recurrence risk among younger elderly (<75 years), but with a lower recurrence risk 
among the oldest elderly (75 years and older). Also, the co-existence of psychiatric 
comorbidity (mostly reflecting dementia), was associated with a lower recurrence 
risk. New insights, which are discussed in Chapter 9, suggest this is the case of 
competing mortality: these women probably died from another cause than cancer, 
before experiencing a breast cancer recurrence. In Chapter 6, the association of 
the coexistence of diabetes during diagnosis and breast cancer prognosis among 
elderly was studied. In this study, a trend towards a more favourable cancer prog-
nosis for diabetic women was observed, which was also most pronounced in the 
oldest patients. These findings are not thoroughly understood yet, but may also be 
explained by competing mortality: patients with more or severe comorbidity are 
at higher risk to die from another reason, before they can develop a cancer recur-
rence. Another possible explanation for the finding that breast cancer patients, 
with co-existing diabetes at the time of diagnosis, had a more favourable prognosis 
is the potential anti-cancer effect of metformin.6 This hypothesis has been studied 
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in several observational studies; a clinical trial has also been designed to assess the 
association between the use of metformin and prognosis of breast cancer7. Results 
of this trial are not to be expected before 2023. 
In Chapter 7, we present an observational study investigating the association 
of three different co-medications (including metformin, statins and beta blockers) 
and breast cancer specific prognosis. These analyses in postmenopausal hormone 
receptor positive early breast cancer patients, enrolled in the TEAM study, found 
less distant metastases in metformin, statin or beta blocker users, although not 
statistically significant. However, a statistically significant association between the 
use of statins and beta blockers and an improved breast cancer specific survival 
were demonstrated. These analyses are specifically important for the older patients. 
Conventional systemic adjuvant therapies, have shown to be associated with more 
adverse events and toxicity with increasing age. However, in our analyses no dif-
ferences were observed between age groups, indicating that these drugs cannot 
serve as a specific new treatment option for breast cancer, neither in the elderly.
PRoGnosIs
One of the problems to face in the lack of evidence for treatment for older women 
with breast cancer, is the underrepresentation of elderly in clinical cancer trials.8,9 
Furthermore, in Chapter 8, we describe a study showing that older patients who 
are included in a large breast cancer trial, are not representative for the patients in 
de general population. In this study, patients from the population-based FOCUS 
cohort, who met the inclusion criteria for the TEAM study, were compared with 
the participants from the TEAM study aged 65 years and older. This study showed 
first, regarding patient characteristics, that women included in the trial had fewer 
comorbid diseases and a higher socioeconomic status. Moreover, although the 
same inclusion criteria were applied, tumours from women in the trial appeared 
to be smaller. Finally, the oldest patients (≥75 years) who participated in the trial, 
had a lower overall mortality than women from the population based cohort. The 
results of this study show that results from a clinical trial, can often not be ex-
trapolated to the general population. The question is, if the current lack of evidence 
on the treatment of breast cancer among older women, can be filled with clinical 
trial results. Therefore, we suggest to use more observational study designs to fill 
the gap. Using the appropriate study designs, data obtained from observational 
studies can be of equivalent value as clinical trial results.1 Probably, considering 
the older patients and their heterogeneity, which is an almost unsolvable issue in 
clinical trials, observational studies can be even more valuable.
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In Chapter 9, we address one important issue to take into account using observa-
tional studies for prognostic research. In geriatric oncology, there are more goals to 
achieve than curing cancer, for instance, to preserve functional capabilities. More-
over, in older patients, the risk of competing mortality, i.e. dying of another cause 
than breast cancer, is a very important matter to take into account. The competing 
risk of mortality should be taken into account when making a treatment plan, 
but also in research. In this chapter, we show with an example study, using data 
from the FOCUS cohort, that not using the appropriate model in risk prediction 
in a population with a high risk on competing mortality, can result in an overes-
timation of the real risk on cancer-specific events. Therefore, when predicting the 
prognosis in a population with a high risk of  competing mortality, we advise to 
use specific models taking into account this risk of competing mortality, to make 
a more adequate estimation of the risk of interest. This risk of competing mortal-
ity should also be taken into account when making decisions about treatment. In 
clinical practice, this is a process taking place in the physician’s room, or in the 
multidisciplinary team, when the treatment plan is being discussed. Currently, 
physicians are forced to determine this risk by their ‘gut feeling’, to decide how 
aggressive or reluctant the patient sitting in front of them will be treated. 
fUTURe PeRsPeCTIves
Recently it was shown, that the most frequently used and recommended tool, 
‘Adjuvant! Online’ is not able to accurately predict the prognosis of breast cancer 
patients aged 65 years or older. Using data from the FOCUS cohort, the actual 
prognosis was compared with the predicted prognosis by Adjuvant! Online. Using 
the tool, overall survival appeared to be over-estimated by 9.8%. This overestima-
tion was even larger in patients aged 75-79 and 80-84, compared to younger elderly. 
Also, the degree of overestimation increased with increasing numbers of comor-
bidities. These findings can probably be explained by the fact that the Adjuvant! 
Online model is created using a cohort from which elderly patients were excluded: 
there was an upper age limit of 69 years.10 Therefore, this study implies that results 
derived from younger (and obviously healthier) patients, cannot be extrapolated 
directly to an older population of patients with the same disease. 
Another, increasingly used prediction tool is the PREDICT tool. This tool was also 
subject to a validation study, using the FOCUS data. In this validation study, the 
PREDICT tool was shown to be more accurate in the prediction of the prognosis of 
older patients, compared to the previously described Adjuvant! Online tool.11 The 
most reasonable explanation for the more accurate prediction is that de PREDICT 
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tool was designed in a cohort including a relatively large number of older women. 
Also, PREDICT added two extra markers to the model: HER-2 and Ki-67.
The available tools, have one thing in common: they predict the prognosis in 
terms of recurrence free survival or overall survival. Currently, the FOCUS study 
group is working on new studies among older women with breast cancer. In this 
novel study, a prediction model will be created using the data from the FOCUS 
cohort. In this model more patient characteristics will be added to the formerly 
used, conventional predictors. Suggested endpoints are: overall survival, treat-
ment toxicity, quality of life and functional decline.
The studies described in this thesis, along with the other studies performed 
by the FOCUS study group, have highlighted the urgent need for a new type of 
investigation to create a tool which might assist in identifying the individualised 
treatment strategy for older women with breast cancer. This will have to take into 
consideration patient’s and the tumour’s information as well as the endpoints for 
each individual patient.
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De drie belangrijkste conclusies van dit proefschrift zijn:
1. Er zijn grote internationale verschillen in de behandelstrategie van oudere 
vrouwen met borstkanker. Deze verschillen zijn echter niet geassocieerd met 
een verschil in prognose.
2. De aanwezigheid van comorbiditeit heeft een belangrijke invloed op de 
algemene prognose van oudere vrouwen met borstkanker. We hebben geen 
significante associatie aangetoond tussen specifieke comborbiditeiten óf van 
het gebruik van comedicatie en de borstkanker-specifieke prognose.
3. Bij onderzoek naar oudere vrouwen met borstkanker, zijn er verschillende be-
langrijke methodologische zaken die in acht zouden moeten worden genomen. 
Ten eerste het vermijden van selectieve inclusie, wat kan leiden tot “selection 
bias”. Ten tweede moet een adequate methodologie gebruikt worden om de 
kans om rekening te houden met de kans om te overlijden door een andere 
oorzaak dan borstkanker: “competing risk of mortality”. 
De foCUs sTUDIe
Een groot deel van dit proefschrift is tot stand gekomen met data uit de FOCUS 
studie: “Female breast cancer in the elderly: Optimizing Clinical guidelines USing 
clinico-pathological and molecular data”. Deze studie werd in 2007 opgezet, met 
initieel als doel om specifieke richtlijnen te formuleren voor de behandeling van 
oudere vrouwen met borstkanker. De FOCUS database is de grootste en meest 
gedetailleerde population-based database van oudere vrouwen met borstkanker. 
Wereldwijd bestaat er geen andere database van deze grootte die alleen oudere 
vrouwen met borstkanker bevat, of die zodanig gedetailleerde data verzamelde 
over de patiënten, tumor karakteristieken, behandeling en follow-up. Bovendien 
zijn in de FOCUS database de klinische data aangevuld met data van een groot deel 
van de tumorweefsels van de patiënten, welke ook werden verzameld en geanaly-
seerd. De database bestaat uit 3672 opeenvolgende vrouwen met borstkanker, met 
de leeftijd van 65 jaar of ouder ten tijde van de diagnose, gediagnosticeerd tussen 
1997 en 2004 in de Zuid-West Nederland (Integraal Kanker Centrum Nederland 
(IKNL), regio Leiden). In aanvulling op de standaard data uit de kankerregistratie, 
werd gedetailleerde informatie verzameld over de behandeling en het optreden 
van een recidief tijdens de follow-up. Bovendien werden patient-gerelateerde 
variabelen toegevoegd, inclusief comorbiditeit en sociaal economische status.
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Binnen het FOCUS project werden ook grote datasets van nationale en interna-
tionale kankerregistraties gedeeld voor onderzoeksprojecten. Daarnaast werden 
data van de Tamoxifen Exemestane Adjuvant Multination (TEAM) trial gebruikt. 
De TEAM studie was een grote multicentre fase 3 trial naar endocriene therapie bij 
postmenopauzale vrouwen met borstkanker. Dit is één van de weinige borstkanker 
trials zonder een leeftijdsgrens. Dit resulteert in een relatief groot aantal oudere 
deelnemers. 
behanDelInG van oUDeRe vRoUwen MeT 
boRsTkankeR
De FOCUS studiegroep heeft een aantal ruim aantal studies verricht met beschik-
bare observationele data en waar nodig werd de relevante literatuur gereviewd. 
Belangrijk om op te merken is dat door de observationele aard van de data die 
werden gebruikt, het onmogelijk was om causale verbanden te leggen tussen de 
geobserveerde behandelstrategieën in de cohorten en de uitkomsten in termen van 
overleving. Dit komt door de grote kans op het introduceren van een bias door 
‘confounding by indication’. In observationele studies is de toewijzing van behan-
deling ongecontroleerd (anders dan in gerandomiseerd onderzoek). Daarom kun-
nen er verschillende factoren aanwezig zijn die gerelateerd zijn aan de toewijzing 
van een bepaalde behandeling, die interfereren met de prognose van de patiënt. 
Dit is een van de belangrijkste redenen waarom de uitkomsten van observationele 
studies voorzichtig moeten worden geïnterpreteerd, in het bijzonder als er sprake 
is van een prognostische vraagstelling. Eén van de gesuggereerde methodologieën 
om te gebruiken wanneer men het effect van een behandeling wil onderzoeken 
in observationele data, is een ‘Instrumentele Variabele’.1 Dit is een variabele die 
niet direct gerelateerd is aan de uitkomst, maar welke wel gerelateerd is aan de 
‘determinant’ van interesse. In dit proefschrift zijn twee studies opgenomen die 
een land als instrumentele variabele gebruiken.
In hoofstuk 2 is een grote observationele, “population-based” studie bes-
chreven. In deze studie werd gebruik gemaakt van data van kankerregistraties 
uit vijf verschillende Europese landen en de Verenigde Staten (SEER database). 
Dit onderzoek vergelijkt lokale behandeling van borstkanker bij oudere vrouwen 
tussen de landen. Er werden grote internationale verschillen geobserveerd, met 
name in het wel of niet toepassen van chirurgie, maar ook in het type chirurgie 
(borstsparend of ablatief), en radiotherapie na borstsparende chirurgie. Ondanks 
deze grote verschillen in behandeling, leverde een grove vergelijking van overlev-
ingsdata geen grote internationale verschillen in overleving op.
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hoofdstuk 3 beschrijft een vervolgstudie, waarin alle modaliteiten van de 
behandeling werden beschreven en vergeleken tussen oudere vrouwen met borst-
kanker in Ierland en Nederland. Deze studie liet eveneens grote internationale 
verschillen zien, waarbij terughoudendheid op het gebied van lokale therapie 
werd gecompenseerd door meer systemische (endocriene) therapie. Ook in deze 
studie leken grote verschillen in behandelstrategie geen effect op de overleving 
van de patiënten te hebben. 
Bovengenoemde studies, waarin behandelstrategieën internationaal werden 
vergeleken, zullen worden opgevolgd door grotere studies door de EURECCA 
groep (EUropean REgistry of Cancer CAre). Deze grote observationele, ‘population-
based’ studies kunnen volgens ons een grote hoeveelheid aan kennis verschaffen. 
In het bijzonder voor oudere patiënten met kanker is er een grote lacune in de 
literatuur, wat resulteert in een gebrek aan bewijs, ‘evidence’, voor behandeling. 
Meest waarschijnlijk zullen de antwoorden van openstaande vraagstukken voor 
oudere vrouwen met borstkanker niet komen vanuit gerandomiseerd onderzoek, 
maar mogelijk wel uit observationele onderzoeken, gebruik makend van de juiste 
methodologie.
In hoofdstuk 4 wordt aangetoond dat onder Europese vrouwen met borst-
kanker, het naleven van behandelrichtlijnen afneemt met het toenemen van de 
leeftijd. Voor deze studie heeft The European Society of Breast cancer specialists 
(EUSOMA) hun database gedeeld. Deze database bestond uit data uit 27 ‘breast 
cancer units’ verspreid door Europa, welke gelieerd zijn aan de society. Het doel 
van deze studie was het evalueren van het naleven van kwaliteitsindicatoren, die 
gedefinieerd zijn door EUSOMA. De EUSOMA database bevatte data van 41.871 
vrouwen met borstkanker in Europa. Aangetoond werd dat bij de oudste patiënten, 
75 jaar en ouder, naleving van de indicatoren proportioneel het laagst was. Er werd 
onder de oudste patiënten een neiging tot onder-behandeling geobserveerd. Inter-
essant genoeg, werd ook aangetoond dat in de jongste patiënten categorie, jonger 
dan 40 jaar, een lage proportie aan naleving van de indicatoren werd geobserveerd. 
In deze leeftijdscategorie was echter sprake van een neiging tot over-behandeling.
CoMoRbIDITeIT en CoMeDICaTIe
Een belangrijke bevinding uit een van de eerste FOCUS studies is dat de kank-
erspecifieke prognose van vrouwen met borstkanker afneemt met toenemende 
leeftijd, onafhankelijk van tumorkarakteristieken en behandeling. Dit is onderzocht 
in zowel de nationale kankerregistratie, als in het FOCUS cohort en de TEAM 
trial.2-5 Eén van de mogelijke verklaringen voor de slechtere prognose van oudere 
166 Appendices
vrouwen met borstkanker is de invloed van ander ziekten op de prognose, óf de 
interactie van andere ziekten (comorbiditeit) met de behandeling van borstkanker. 
Daarom werd in hoofdstuk 5 van dit proefschrift in het FOCUS cohort onderzocht 
of de aanwezigheid van comorbiditeit ten tijde van de diagnose, geassocieerd 
was met de borstkankerspecifieke prognose. Aangetoond werd dat het aantal co-
morbiditeiten, maar ook een aantal specifieke ziekten waren geassocieerd met de 
borstkankerspecifieke prognose. Dit resultaat werd beschouwd als een verwachte 
uitkomst. Een interessanter bevinding was dat meer comorbiditeit geassocieerd 
was met een hogere kans op een recidief onder jongere ouderen (<75 jaar), maar 
met een lagere kans op een recidief onder de oudste ouderen (75 jaar en ouder). 
Bovendien was de aanwezigheid van een psychiatrische ziekte (waarschijnlijk 
dementie) geassocieerd met een lagere kans op een recidief. Nieuwe inzichten, 
welke beschreven worden in hoofdstuk 9, suggereren dat dit is een geval van 
competing mortality: deze vrouwen zijn waarschijnlijk overladen door een andere 
oorzaak dan kanker, voordat zij überhaupt blootgesteld konden worden aan een 
recidief borstkanker. 
In hoofstuk 6 werd de associatie tussen de aanwezigheid van diabetes ten tijde 
van de diagnose en borstkankerspecifieke prognose onderzocht onder oudere 
vrouwen met borstkanker, eveneens in het FOCUS cohort. In deze studie werd 
een iets betere kankerspecifieke prognose geobserveerd voor vrouwen met borst-
kanker mét diabetes, dit was het meest uitgesproken onder de oudste vrouwen. 
Deze bevindingen worden nog niet volledig begrepen, maar zouden eveneens 
verklaard kunnen worden door het concept van competing mortality: patienten met 
meer of ernstiger comorbiditeit hebben een hoger risico om te sterven door een an-
dere oorzaak dan kanker, voordat zij een borstkankerrecidief kunnen krijgen. Een 
andere mogelijke verklaring voor de bevinding dat vrouwen met borstkanker en 
daarnaast diabetes een betere prognose hadden is het potentiele anti-kanker effect 
van metformine.6 Deze hypothese is eerder onderzocht in observationele studies, 
en ook loopt er een gerandomiseerde trial om de associatie tussen het gebruik van 
metformine en de borstkankerspecifieke prognose te onderzoeken.7 De resultaten 
van deze trial worden niet voor 2023 verwacht. 
In hoofdstuk 7 wordt een onderzoek beschreven dat kijkt naar de associatie tus-
sen  drie verschillende types comedicatie (metformine, statines en bètablokkers) 
en de borstkankerspecifieke prognose. De analyses werden gedaan in data van 
de TEAM studie, waar in alleen postmenopauzale vrouwen met hormoonreceptor 
positieve borstkanker in een vroeg stadium geïncludeerd zijn. De analyses toonden 
absoluut minder afstandsmetastasen onder gebruiksters van metformine, statines 
en bètablokkers, echter dit was niet statistisch significant. Er werd wel een statisch 
Nederlandse samenvatting 167
significante associatie gevonden tussen het gebruik van statines en bètablokkers 
en een betere borstkankerspecifieke overleving. Dit resultaat is wel moeilijk te 
verklaren gezien het ontbreken van een verband tussen het medicatiegebruik en 
het optreden van metastasen. Dit onderzoek is belangrijk voor oudere patiënten in 
het bijzonder. De conventionele systemische adjuvante behandelingen zijn geas-
socieerd met meer bijwerkingen en toxiciteit bij ouderen. Echter in onze analyses 
werden geen verschillen geobserveerd tussen leeftijdscategorieën. Deze studie 
geeft onvoldoende aanleiding om de onderzochte medicamenten in te zetten als 
een nieuwe behandelingsoptie voor borstkanker, ook niet bij ouderen.
PRoGnose
Eén van de problemen waarmee men geconfronteerd wordt bij het gebrek aan 
bewijs (evidence) voor de behandeling van oudere vrouwen met borstkanker, is de 
onder-representatie van ouderen in klinische trials.8,9 Bovendien, wordt in hoofstuk 
8 van dit proefschrift een onderzoek beschreven dat aantoont dat oudere patiënten 
die wel geïncludeerd zijn in een grote borstkanker trial, niet representatief zijn 
voor de patiënten uit de algemene bevolking. In deze studie werden de patiënten 
uit het population-based FOCUS cohort, die voldeden aan de inclusiecriteria voor 
de TEAM studie, vergeleken met de deelneemsters van de TEAM studie, die 65 
jaar en ouder waren. Dit onderzoek toonde, bij het vergelijk van patiëntkarakter-
istieken, dat de vrouwen uit de trial minder comorbiditeit hadden en een hogere 
sociaal economische status. Verder, ondanks dezelfde inclusiecriteria, waren de 
tumoren van de vrouwen in de trial toch kleiner dan in het FOCUS cohort. Tot slot 
werd aangetoond dat de oudste vrouwen uit de trial (75 jaar of ouder) een lagere 
mortaliteit (dus betere overleving) dan de vrouwen uit het FOCUS cohort. De re-
sultaten van dit onderzoek impliceren dat de resultaten van een klinische trial niet 
altijd geëxtrapoleerd kunnen worden naar patiënten in de algemene bevolking. De 
vraag is of het huidige gebrek aan evidence voor de behandeling van borstkanker 
bij ouderen aangevuld kan worden met data van gerandomiseerde klinische trials. 
Mits adequate studie methodiek wordt gebruikt, kunnen data uit observationele 
studies wellicht van gelijkwaardige waarde zijn als resultaten van gerandomiseerd 
onderzoek.1 Mogelijk, gezien de heterogeniteit van oudere patiënten, wat een ono-
plosbaar probleem is in klinische trials, zijn observationele studies misschien zelfs 
waardevoller in deze populatie.
In hoofdstuk 9 wordt een belangrijke kwestie aangehaald waar rekening mee 
gehouden moet worden bij prognostisch onderzoek met observationele data. Bij 
onderzoek naar ouderen met kanker zijn er meer doelen te bereiken dan alleen het 
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genezen van kanker. Een voorbeeld is het behouden van het functioneel vermo-
gen. Bovendien, bij oudere patienten is het risico van het sterven ten gevolge van 
een andere oorzaak dan borstkanker, “competing mortality”, zeer belangrijk om 
rekening mee te houden. Dit risico zou in acht moeten worden genomen op het 
moment dat een behandelplan gemaakt wordt, maar ook bij het doen van weten-
schappelijk onderzoek. In dit hoofdstuk wordt een voorbeeldstudie beschreven, 
waarin gebruik gemaakt werd van data uit het FOCUS cohort. Hiermee wordt 
aangetoond dat gebruik van het onjuiste model bij het voorspellen van risico’s in 
een populatie met een hoog risico op ‘competing mortality’, kan resulteren in een 
overschatting van het echte risico op kanker-specifieke events. Daarom, bij analyses 
met als doel het voorspellen van de prognose in een populatie met een hoog risico 
op ‘competing mortality’, wordt geadviseerd om gebruik te maken van specifieke 
modellen die rekening houden met dit risico, om zo een adequatere voorspelling 
te maken van het risico (bijvoorbeeld risico op recidief) waarin men daadwerkelijk 
geïnteresseerd is. 
Het risico op ‘competing mortality’ zou ook altijd in acht moeten worden genomen 
bij het maken van beslissingen over behandeling in de kliniek. In de praktijk is dit 
een proces dat plaatsvindt in de spreekkamer, of in het multidisciplair onverleg, 
waar het behandelplan wordt besproken. In de huidige situatie wordt van artsen 
verwacht om dit risico te bepalen op basis van een gevoel, om daarmee te bepalen 
hoe agressief, of juist terughoudend, de patiënte die voor hen zit behandeld zou 
moeten worden. 
ToekoMsTPeRsPeCTIeven
Uit recent onderzoek van onze groep blijkt dat het meest gebruikte en aangeraden 
hulpprogramma in het voorspellen van prognose van vrouwen met borstkanker, 
‘Adjuvant! Online’, niet in staat is om een accurate voorspelling van de prognose 
te geven van vrouwen met borstkanker die 65 jaar of ouder zijn. Met data uit 
het FOCUS cohort werd de werkelijke prognose van patienten vergeleken met 
de prognose zoals voorspeld door het programma ‘Adjuvant! Online’. Het pro-
gramma maakte een overschatting van de algemene overleving van 9.8%. Deze 
overschatting was zelfs groter onder nog oudere patiënten (75-79 jaar en 80-84 
jaar). Daarnaast nam de mate van overschatting ook toe met een toenemend aantal 
comorbiditeiten. Deze bevindingen kunnen waarschijnlijk worden verklaard door 
het feit dat ‘Adjuvant! Online’ is gecreëerd op basis van een cohort waar oudere 
patiënten warden geëxcludeerd: er was een leeftijdsgrens van maximaal 69 jaar.10 
Deze studie toont aan dat resultaten van studies onder jongere (en waarschijnlijk 
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gezondere) patiënten, niet zo maar kan worden geëxtrapoleerd naar een populatie 
van oudere patiënten met dezelfde ziekte.
Een ander hulpprogramma dat de prognose van patienten met borstkanker 
voorspelt is PREDICT. Dit programma werd eveneens gevalideerd in het FOCUS 
cohort. Uit deze studie blijkt dat PREDICT beter in staat is om de prognose van 
oudere patienten te bepalen, in vergelijking met ‘Adjuvant! Online’.11 De meest 
waarschijnlijke verklaring voor het de meer accurate voorspelling is dat het PRE-
DICT programma ontwikkeld werd in een cohort waar een relatief groot aantal 
ouderen in zat. Daarnaast heeft PREDICT twee extra markers toegevoegd aan het 
model: HER-2 en Ki-67.
De nu beschikbare digitale hulpprogramma’s hebben één ding gemeen: ze 
voorspellen de prognose in termen van recidief vrije overleving of overleving. De 
FOCUS groep is op dit moment bezig met nieuwe studies onder oudere vrouwen 
met borstkanker. Het doel van deze nieuwe studies is om een predictiemodel te 
creëren met data van alleen oudere vrouwen (het FOCUS cohort). In dit model 
worden meer voorspellende factoren onderzocht, met name patiënt-gerelateerde 
factoren zoals comorbiditeit. Ook zullen andere eindpunten worden onderzocht 
zoals bijvoorbeeld: toxiciteit van behandeling, kwaliteit van leven en functionele 
capaciteit.
De onderzoeken zoals beschreven in dit proefschrift, samen met de andere 
studies die verricht zijn door de FOCUS studiegroep, hebben het belang van een 
nieuw type onderzoek aangetoond. Dit onderzoek moet een model creëren dat 
kan helpen om een geïndividualiseerde behandelstrategie voor oudere vrouwen 
met borstkanker. Dit model zal rekening houden met zowel de patiënt- als de tu-
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